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ABSTRACT
Economic Evaluation of Three Preventive Drug Therapies for
Osteoporotic Fractures among Women at Different Risk levels
Xin Gao
Objective: To evaluate cost-effectiveness (CE) of three drug therapies for preventing
osteoporotic fractures in postmenopausal women from a state Medicaid Program perspective
using the estimated risk distribution in the study population. The three therapies are: hormone
replacement therapy (HRT), alendronate, and raloxifene. Methods: A hypothetical cohort of
white women aged 45-85 years, postmenopausal, and without past incidence of osteoporotic
fractures was treated with one of the three alternatives, and tracked over 3 years in a decision
model. The CE ratio was defined as the treatment costs [e.g., medications, monitoring, adverse
events (AE)] divided by the number of fractures averted. Treatment Willingness-To-Continue
(WTC) rate was also considered. Data were collected from literature, expert panel survey,
Medicaid claims data, and a risk survey in the study population. Monte Carlo simulations were
conducted (distributions used: background risk, cost, and risk reduction rate). Risk or probability
of osteoporotic fracture was also divided into three strata: low (risk<0.1), medium (0.1<risk<0.3),
and high (risk>0.3). Results: Compared to no therapy, the expected CE of HRT was $29,119 per
fracture averted, alendronate: $35,101, and raloxifene: $39,760. The incremental CE was $42,181
for alendronate (relative to HRT) and $85,509 for raloxifene (relative to alendronate). The
incremental CE of alendronate and raloxifene were $151,981 and $697,270 among women with
low risk (43% of the sample), compared to $11,099 and $34,017 respectively among high-risk
women (26% of the sample). CE was not sensitive to discount rate and AE probabilities.
Conclusions: HRT is the most cost-effective strategy even though it may have relatively high
monitoring and AE costs, and low WTC rate. The significant decrease in marginal costs of
Alendronate and Raloxifene in high-risk women indicates an economic condition to use these two
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Epidemiology and Costs of Osteoporosis and Osteoporotic Fracture
Osteoporosis is a systemic skeletal disease characterized by low bone mineral
density (BMD) and microarchitectural deterioration of bone tissue, leading to bone
fragility and increased susceptibility of fractures (Consensus Development Conference,
1991).  It is especially prevalent in older postmenopausal women (Consensus
Development Conference, 1991; Melton, 1995; Kanis et al., 1991).  Because the age of
onset of menopause is about 50, women can now expect to live one-third of their 80-year
life-span at risk for developing osteoporosis and fractures.  The National Osteoporosis
Foundation (NOF) has estimated that in 1996, approximately 29 million people aged 50
and over in the United States either had osteoporosis or were at risk of developing the
disease (WV Bureau for Public Health, 1998).  Incidence rate increases with age: 22%
among women 60 to 69 years old, 30% among women 70 to 79 years, and 70% among
women 80 years or older (Prestwood & Weksler, 1997).  As a major cause of morbidity
and mortality in postmenopausal women, osteoporosis induces a high burden of pain,
physical disability, and has a profound effect on the quality of life among these women.
Osteoporosis is only clinically important when fractures occur (Lindsay &
Cosman, 1990).  One of the most important clinical and economic implications of
osteoporosis to society is the increased risk of bone fracture resulting from decreased
BMD.  The mortality rate in women from osteoporotic fracture is greater than the




Faulds, 1994).  In the United States, approximately 250,000 hip fractures and 500,000
vertebral fractures are thought to occur each year in postmenopausal women (Prestwood
& Weksler, 1997; Lindsay & Cosman, 1990).  The cumulative lifetime fracture risks for a
50-year-old woman are 40% for any fracture, 18% for hip, and 16% for spine (Kanis et
al., 1994; Riggs & Melton, 1995).  Other studies indicated that the average lifetime risk
of fractures for white women includes a 16% risk of one or more painful vertebral
fracture, 15% risk of Colles’ (wrist) fracture, and 16% risk of hip fracture (Melton et al.,
1993; Lauritzen et al., 1993).  In addition, fracture rate increases by 30% for every
decade of life (Gallagher, 1992).  In 1995, $13.8 billion in direct medical costs were
spent on osteoporotic fractures (Ray et al., 1997).
The most common fractures consequent upon osteoporosis are fractures of hip,
vertebral, and wrist (Colles’ fracture) (Lindsay & Cosman, 1990; Meunier et al., 1999).
Although all of them are debilitating to patients, hip fracture is the most serious and
costly.  Women with hip fracture are 2 to 4 times more likely to die within 12 months of
the event as are women of the same age in the general population without hip fracture
(Schurch et al., 1996).  Hip fracture is reported to result in about 30,000 deaths each year
in the USA (Lindsay & Cosman, 1990).  The average mortality rate is 12% to 36% within
one year (Egol et al., 1997).  In women surviving one year after a hip fracture, high
morbidity rate is observed (Marotolli et al., 1992; Cummings et al., 1988; Magaziner et
al., 1990; Mossey et al., 1989; Jalovaara & Virkkunen, 1991).  Half of all hip fracture




did not recover the ability to independently walk, transfer from one place to another, and
climb stairs, respectively (Marotolli et al., 1992).
Although hip fractures represent only a small part (<10%) of the fractures, the
financial cost of hip fracture is enormous.  Hip fractures are responsible for more hospital
bed days among women after age 45 than are myocardial infarction, breast cancer,
chronic obstructive pulmonary disease, or diabetes (Kanis et al, 1997).  About 35% of
patients with limb fractures require hospital admission, including all patients with hip
fracture, who may require up to 33 days in an acute setting (Lindsay & Cosman, 1990).
The total costs (including direct and indirect costs) of hip fractures were estimated to be
$8.7 billion in the USA in 1988  (Melton, 1993).  Those costs can only be expected to
increase as the proportion of elderly increases in the population.
Vertebral fracture is the most common osteoporotic fracture and usually occurs
earlier in life than hip fracture.  The prevalence of vertebral fractures among the aging
population may exceed 75% for very aged women (Lindsay & Cosman, 1990).  Like hip
fracture, vertebral fracture is associated with considerable morbidity (Gold, 1996; Ross,
1997).  It may be painless and gradually progressive for years, or acute and accompanied
by severe back pain.  Among women with symptomatic vertebral fracture and chronic
pain, 60% to 87% reported problems with carrying, lifting, walking, doing housework,
and shopping (Cook et al., 1993).  Although about two thirds of all vertebral fractures are
not recognized clinically, both diagnosed and undiagnosed vertebral fractures are
associated with pain and impaired physical function (Huang et al., 1996; Nevitt et al.,




these fractures.  Estimates of incidence based on the prevalence data available show that
incidence begins to increase around the time of menopause and continues to rise
throughout life (Lindsay & Cosman, 1990; Melton et al., 1993).
Vertebral fractures, although causing pain and loss of height, tend to require a
relatively small proportion of healthcare resources.  Hospitalization, if required, is
generally brief.  Assuming that only 50% of fractures would require treatment and no
costs for the remaining 50%, the direct and indirect costs were estimated ranging from
$8,723 to $9,917 (1988 dollars) per vertebral fracture depending on patient age (Clark
and Schuttinga, 1992).  The total cost per vertebral fracture was approximately 25% of
the estimated cost of a hip fracture.
Wrist fracture may represent the earliest effect of osteoporosis.  The incidence of
wrist fracture increases rapidly around menopause (Melton, 1993).  Wrist fractures are
usually treated on an outpatient basis.  Only 8% to 10% of patients experiencing wrist
fracture are hospitalized, although this rate may increase to 76% after age 85 (Melton,
1993; Chrischilles et al., 1994).  A severe consequence of wrist fracture is algodystrophy
(reflex sympathetic dystrophy): less than 10% of patients were affected in most surveys,
but the number has been reported to be as high as 30% (Kanis &Pitt, 1992).  The costs of
wrist fractures are typically associated with a number of follow-up physician visits.  A
total cost of $250 per wrist fracture (1982 dollars) was estimated, but no detailed cost




Fracture of any bone can occur as part of the osteoporotic syndrome.  After the
commonest fractures mentioned above, other fractures encountered are of the proximal
humerus, pelvis, and proximal tibia (Riggs & Melton, 1986).
Factors Associated with the Development of Osteoporosis and Risk of Fracture
Various risk factors for osteoporosis and osteoporotic fractures have been
presented in literature, although some of them are debatable.  So far, studies in all
populations show that the incidence of osteoporotic fractures increases with age.  Bone
mass is found to decrease with age in all studies.  The relationship between low bone
mineral density (BMD) and fracture occurrence has been well established (e.g., Ross et
al., 19881,2; Lindsay & Cosman, 1990).  Women with very low BMD have much higher
risks than the average, and many of them will experience fractures if untreated.  Hence, it
is not surprising that the major risk factors are advanced age and low BMD.
Among women, postmenopausal hormonal changes are also related to their BMD
level and thus osteoporosis risk.  Women with menopause-related estrogen deficiency are
found to be at high risk for osteoporosis and fractures (Lindsay & Cosman, 1990;
Willhite, 1998).  Other factors that increase risk include being of Caucasian or Asian
race, thin body frame or underweight, early age at menopause (either natural or surgically
induced), family history, and inadequate calcium and vitamin D intake.  Sedentary
lifestyle, smoking, and excessive alcohol and caffeine consumption have also been linked
with bone loss, although the associations are not strong (Osteoporosis Task Force, 1996;




increased risk by hyperathyroidism, thyrotoxicosis, and long-acting psychotropic drugs is
controversial and needs further evaluation (Odell & Heath, 1993; Reid, 1998).
Furthermore, many studies show that women who have one osteoporotic fracture
are more likely to experience further fractures.  Consequently, prior fracture itself is an
important predictor for future fracture (Ross et al., 1991; Ross et al., 1993; Ensrud et al.,
1997).
Osteoporosis in West Virginia (WV)
Osteoporosis has become a serious public health issue in WV.  As mentioned
above, age, sex, and race all play an important role in the development of osteoporosis,
with older white women at high risk for the disease.  In 1996, WV had the oldest
population in the nation, with a median age of 38, and ranked fourth in the U.S. in the
proportion of its population that is elderly (>65).  Also, women compose a larger
percentage of the population in WV than in the nation as a whole: 53.1% vs. 51.3% in
1996.  Finally, WV has a very small minority population, with more than 96% of the
population classified as white.
In WV, a total of 183,962 women suffered from either low bone mass or
osteoporosis in 1996.  Additionally, 416 out of every 1,000 people aged 50 and older in
WV either already had osteoporosis or were at risk.  Approximately six out of every ten
women in this age group were at risk for osteoporosis or osteoporotic fractures (WV
Bureau for Public Health, 1998).  It is predicted that if no action is taken, a total of
227,246 women in WV will have osteoporosis or low bone mass by 2015 (National




incidence of all fractures will increase by 19% from 1995 through 2015, more than
41,000 women will experience hip fractures and result in about 5,200 deaths, as well as
approximately 100,000 and 38,500 will experience vertebral and wrist fractures
respectively (Abbott et al., 1996)
The estimated hospitalization costs related to osteoporotic fractures in 1996
exceeded $42 million, of which an estimated $36 million were billed to Medicare.
Women accounted for approximately four out of five (81%) osteoporotic fracture
hospitalizations, with an average stay of 8.83 days.  The average charge per osteoporotic
fracture among female patients was $10,219 of which two-thirds was for hip fractures.
Given the aging of West Virginia's population, the public health burden of this disease
will become worse if no effective action is taken (WV Bureau for Public Health, 1998).
Prevention Strategies
Osteoporosis is a complex chronic disease that may progress silently for many
years until a fracture occurs.  Patient management is difficult because many patients with
osteoporosis are asymptomatic.  Most patients are not diagnosed in time for effective
prevention or treatment.  If untreated, more than half of white women will experience at
least one osteoporotic fracture during their lifetimes (Jones et al., 1994; Ross, 1996;
Cooper, 1997).  Although effective treatment after the first fracture presents can
substantially reduce the risk of further fractures, the risk remains appreciable.  Also,
patients' quality of life is reduced irreversibly due to continuing pain and impaired




loss and thus reduce the risk of the first fracture.  As suggested earlier, preventing the
first fracture can dramatically decrease the risk of further fractures.
Preventive strategies are essential for reducing the incidence of osteoporosis and
consequent fractures.  Studies have shown that recommending preventive therapy for all
menopausal women is not appropriate (Lindsay & Cosman, 1990; Riggs & Melton, 1986;
JÖnsson, 1998).  Nevertheless menopause, because of its association with acceleration of
bone loss, is probably a useful time at which to evaluate women for their risk of
osteoporosis or osteoporotic fractures and to target treatment for high risk women.  Cost-
effectiveness analyses of the “high-risk approach” suggest economic benefits of policies
targeting pharmacological treatments to women at high risk (Jönsson, 1998).
Bone density is a good predictor of future fracture risk.  In clinical practice, BMD
testing plays an important role in the detection and management of osteoporosis and
fractures.  BMD test can be used to select individuals for osteoporosis/osteoporotic
fracture prevention and treatment and to monitor response to therapy.  In practice, T
scores (standard deviations below peak bone density) are often used to represent risk of
osteoporosis and osteoporotic fractures.  However, the bone mineral measurement
procedure is “too expensive and time-consuming for general use in the unselected
population” (Michaelsson et al., 1996).  There is a great need for simple means of
identifying osteoporosis/osteoporotic fractures risk in population-based studies.  Several
important risk factors have been used to evaluate patients' fracture risk through a BMD
prediction model.  Those include age, age at menopause (or years since menopause), and




patients’ fracture risk may not be accurate enough to replace the BMD test in clinical
practice, it may still be reliable and applicable for population-based studies (e.g.,
Michaelsson et al., 1996; Kroger et al.,1994; Ribot et al., 1992).
In brief, although treatment options exist, the most effective way of dealing with
osteoporosis is prevention aimed at high risk population.  For middle-aged and older
individuals, modification of risk factors (e.g., changing diet and lifestyle by taking
calcium supplementation and doing weight-bearing exercise) and drug therapies are the
major forms of prevention strategies for osteoporotic fractures.  Regarding preventive
drug therapy, there are three main intervention strategies available for preventing and
treating osteoporosis/osteoporotic fracture: Hormonal replacement therapy (HRT),
Alendronate therapy, and Raloxifene therapy.
Hormonal Replacement Therapy. HRT is the most commonly used method for
osteoporosis prevention and treatment, as well as the treatment of menopausal symptoms.
Studies have indicated that HRT substantially increases BMD and reduces fracture risk
(e.g., Weiss et al., 1980; Ettinger et al., 1985; Keil et al., 1987; Felson et al., 1993).  The
additional benefits associated with HRT include the reduced risk of cardiovascular
disease and Alzheimer’s disease, relief from the symptoms of estrogen deficiency such as
hot flashes, and a decrease in urogenital effects (Adis International Limited, 1998;
Cooper, 1997).
The major risk of unopposed estrogen therapy is endometrial cancer.  The
reported magnitude of relative risk has varied from 1.7 to 20 times (Heidrich &




women with an intact uterus minimizes the increased risk of endometrial cancer.  The
association between HRT and breast cancer has not been definitively established.  The
data are conflicting and the relative risk is between 1.0 and 2.0 (Collaborative Group on
Hormonal Factors in Breast Cancer, 1997; Tosteson, 1994; DeGregorio & Taras, 1998).
The use of estrogen is also reported to slightly increase risk of venous thromboembolic
events (DeGregorio & Taras, 1998; Meunier et al., 1999).  Other major adverse effects
include breast pain, vaginal bleeding, headache, fluid retention, and GI complaints (e.g.,
nausea, vomiting, and cramps).  Although side effects can sometimes be alleviated by
changing the treatment regimen, some women cannot tolerate estrogen or HRT.
Alendronate Therapy. Alendronate, a bisphosphonate, inhibits osteoclasic bone
resorption.  Alendronate binds preferentially to active sites of bone resorption and is not
biologically active; thus, unlike estrogen, its effect may last long after discontinuation.
Also, unlike early bisphosphonates such as etidronate, alendronate does not suppress
bone formation, and it can be given continuously.  It is the only FDA approved
bisphosphonate for the prevention and treatment of osteoporosis (Willhite, 1998).
Numerous studies have demonstrated that Alendronate treatment effectively increases
BMD in women aged 44 to 84 years.  It significantly prevents bone loss in early
postmenopausal women and reduces the risk of fracture at all sites (Karpf et al., 1997;





The most serious side effect of Alendronate is esophageal ulceration. Less
serious, but more common adverse effects are gastrointestinal: abdominal pain, nausea,
dyspepsia, constipation and diarrhea (Adis International Limited, 1998).
Raloxifene Therapy.  Raloxifene is the first selective estrogen receptor modulator
(SERM) to be approved for the prevention of osteoporosis in postmenopausal women.  It
prevents bone loss and significantly increases BMD at the lumbar spine, hip, femoral
neck, and overall in postmenopausal women with or without osteoporosis (Balfour &
Goa, 1998).  Although improvements in BMD may be greater with HRT than with
raloxifene therapy in elder postmenopausal women, unlike unopposed estrogen and
tamoxifen (the first SERM developed), raloxifene does not have endometrial stimulatory
effects and therefore does not increase the risk of endometrial cancer (van Leeuwen et al.,
1994).  In addition, daily therapy with raloxifene lowers serum levels of total and low-
density lipoprotein cholesterol.  However, it is unclear whether this effect on lipids will
translate into the clear cardiac benefit that HRT provides (Balfour & Goa, 1998; Kushner,
1998).
Compared with continuous HRT, raloxifene appeared to cause less breast pain,
vaginal bleeding, flatulence, and abdominal pain.  However, unlike estrogen, raloxifene
does not relieve menopausal symptoms such as hot flushes. Raloxifene’s potential for
causing leg cramps and venous thrombosis is similar to that of estrogen (Kushner, 1998;





The growth rate in health care spending has occurred at more than twice the
general inflation rate for two decades in the U.S. (ACCP, 1997).  Spending of both
private and government health insurance programs (i.e., Medicaid and Medicare) has
significantly increased.  In order to curtail growth in health care expenditures and
utilization, numerous nationwide policy interventions have been attempted over the past
two decades.  The major interventions include capitation, prospective payment system,
drug formularies, and physician payment reforms.  Those cost containment strategies
make third-party payers/insurers take both a financial risk and responsibility for health
service delivery.  Health care providers are also given strong incentives for cost-
conscious health care delivery under those policies.  Although constraining health care
cost has been driven largely by the private sector with employers seeking to slow the
growth rates in health care premiums paid for their employees, federal and state
governments that fund Medicaid and Medicare programs have also been playing very
important roles in promoting cost control.
The national trend in health care cost is also evident in West Virginia (WV).  The
average per member costs for WV Medicaid have gone up from about $675 in 1982 to
about $3,696 in 1999 (National Pharmaceutical Council, 1983; WV Medicaid HCFA
2082 Report, 1999).  The drug costs percentage of total medical costs also increased from
8.3% in 1993 to 15.4% in 1999, and the average drug cost per recipient rose from $335 to
$712 during the same time period (National Pharmaceutical Council, 1983; WV




costs is the implementation of several cost-containment policies such as requiring a drug
prior authorization process, increasing co-payment, reducing pharmacy reimbursements,
and imposing a 10-prescription limit per month per member.  For WV Medicaid, making
every effort to control costs while maintaining health care quality has become
increasingly important.
As mentioned before, osteoporosis/osteoporotic fractures is a serious problem in
WV.  Osteoporosis and its associated fractures are an important public health problem
that will worsen as the population ages.  The large number of postmenopausal women at
risk and the high toll of osteoporotic fractures in regard to functional status and health
care cost have motivated increased thirty-party payers' awareness.  Although most
hospitalization costs of fractures are born by Medicare, they also constitute significant
Medicaid expenditures for pharmaceuticals.  Since controlling costs is a priority of WV
Medicaid, how to control the costs associated with osteoporotic fractures has become a
major concern for Medicaid.
Under this circumstance, increased interest has been shown in detection and
prevention of osteoporosis/osteoporotic fractures and determination of optimal preventive
interventions.  Regarding the prevention of osteoporotic fractures, most researchers and
physicians recommend that treatment should be limited to those women at high risk of
developing osteoporosis/osteoporotic fractures (e.g., Willhite, 1998; Jönsson, 1998).
However, questions arise about how to identify women at different risk levels.
Controversies exist regarding the evaluation for fracture risk.  Although several studies




fractures, the results were not satisfactory (Lydick et al., 1998; Carroll et al., 1997;
Blalock et al., 1996; Franceschi et al., 1996).  The sensitivity and/or specificity were low
and most studies were limited by the relatively small sample size and the type of
fractures.  It is not clear which and how risk factor(s) should be measured to estimate and
quantify the risk levels of osteoporotic fractures in the WV Medicaid population.
With respect to preventive drug therapies, the implementation of new therapies
such as raloxifene and the existence of multiple drug therapy options have raised several
questions for WV Medicaid.  The raloxifene and alendronate therapies are much more
expensive than the traditional HRT.  In 1998, the average acquisition costs per year for
raloxifene, alendronate, and HRT were about $594, $642, and $223, respectively (Adis
International Limited, 1998).  In order to control the escalating drug expenditures,
Medicaid needs to decide who should be covered for drug therapies to prevent
osteoporotic fractures.  Preventive drug therapy for all women may be cost-prohibitive,
risky, and wasteful.  Also, considering the benefits of HRT and raloxifene as well as their
risks and side effects, the net economic and clinical consequences of these therapies are
vital issues.  In a cost conscious environment, the choice of a preventive strategy for any
disease is highly dependent upon cost-effectiveness or cost-benefit considerations.  In
other words, in order to use health care resources efficiently, it is critical to consider both
the costs and potential consequences of different prevention strategies.
Medication adherence is another key issue.  A cost-effective therapy proven in the
controlled settings of clinical trials may not be of the same effectiveness in the real world.




of adherence achievable with each therapeutic intervention.  Decisions regarding
medication adherence depend on an individual woman’s preferences, which may further
rely on her understanding of the risk-benefit equation of a specific therapy.  For example,
in the case of HRT, discontinuation and noncompliance are major problems.  Of women
who do receive a prescription for HRT, nearly 30% never have it filled, 20% stop taking
the medication within nine months (Ravnikar, 1987), and at least 25% stop treatment
within 2 years (Kushner, 1998).  Perceived lack of need for HRT and concern for adverse
effects (breast cancer and vaginal bleeding) are the main reasons for never using HRT or
noncompliance (Wysowski et al., 1995; Salamone et al., 1996).  Obviously, the
effectiveness of HRT for non-adherents would be reduced.  Therefore, the problem of
non-adherence in medication taking behaviors should be considered in cost-effectiveness
evaluations.  Currently, little information is available on how medication adherence will
influence the relative cost-effectiveness of HRT compared to alternative strategies.
Finally, the cost-effectiveness of an intervention may vary among women at
different risk levels.  For example, raloxifene may be cost-effective for women at high
risk for osteoporotic fractures, but not for women at average or low risk.  The usage of
each therapy among women with different risks will determine the total possible costs to
Medicaid for covering these preventive agents.  Medicaid programs must determine
which drug therapies are the most cost-effective at different risk levels to encourage their
risk-appropriate utilization.  Then the original question "who among Medicaid women
should be covered for preventive drug therapies?" becomes "what are the cost-




these questions, a decision model incorporating the costs and effectiveness of each
therapy needs to be established and the most risk-appropriate therapy needs to be
determined.
Currently, no comparisons of the three drug therapies have been reported that take
into consideration their costs, preventive effectiveness, and discontinuation rates.  Direct
comparative trials of the effects of the three treatment strategies on fracture prevention
have so far not been published.  In addition, no study has linked women's fracture risks to
the cost-effectiveness evaluation of the drug therapies.
Research Questions
Based on the need for the study and review of the literature, this study will try to
answer the following research questions with respect to the WV Medicaid female
population.  Since all of them are exploratory questions, no hypotheses are proposed.
1. What are the costs and risk reduction rates related to the three drug therapies for
preventing osteoporotic fractures?
2. What is the background fracture risk among women 45 year and older in the study
population?
3. What is the expected cost-effectiveness of the three drug therapies based upon the




Study Goal and Scope
The goal of this study is to evaluate the cost effectiveness of three drug therapies
for preventing osteoporotic fractures and to assess the economic impact of risk-based
utilization on Medicaid program costs.  The three intervention strategies that will be
evaluated are: Hormone Replacement Therapy (HRT), alendronate (Fosamax®, and
raloxifene (Evista®).  The study population will consist of postmenopausal women who
are enrolled in WV Medicaid and aged 45 to 85 years.  The perspective of the WV
Medicaid program will be taken for this study.
Conceptual Framework
To complete the study goals, different methodologies are required.  Hence the
study will be completed in three phases.  Phase I will construct a hypothetical decision
model to evaluate the cost effectiveness of the three drug therapies for preventing
osteoporotic fractures.  Phase II will assess the distribution of the background risk in the
study population.  And Phase III will combine the information obtained from the first two
phases and calculate the cost-effectiveness ratios of the three drug therapies.  The
economic impact of risk-based utilization on the Medicaid program expenditures will
also be evaluated.  The rationale and conceptual framework of the three phases are
described below.
Phase I.  Model Development
To substantially reduce the population rate of osteoporosis and fractures, a




acceptable for use.  Since each current drug intervention is associated with risks and
benefits, how to balance the costs and effectiveness becomes a critical issue.
A decision tree will be constructed to identify the relevant costs and consequences
of the three competing drug interventions.  A hypothetical treatment model for a white
postmenopausal woman aged 45 years or older and without past incidence of osteoporotic
fractures will be established.  The woman will be treated with one of the three treatment
alternatives, and tracked over a period of 3 years.  This length of intervention is chosen to
coincide with the time period for which relevant clinical data from studies are available
(Eli Lilly and Company, 1997; Carroll et al., 1997; Meunier et al., 1999; Rosner et al.,
1998).  The model follows the incidence of fracture and adverse events associated with
each therapy over a three-year period.  The woman’s compliance with each drug therapy
will also be incorporated in the model.
Treatment effectiveness will be measured in terms of the number of fractures
averted by each drug therapy.  Resource costs will include the direct medication costs of
each treatment strategy (CMedication), monitoring costs (CMonitoring), and the cost of the
adverse effects (CAE).  The cost-effectiveness ratios are thus defined as:
C/E = (CMedication + CMonitoring + CAE)/(Number of Fractures Averted)
       = (CMedication + CMonitoring + CAE)/( I0 * R)
The number of fracture prevented can be calculated as I0 * R, in which I0 was the
background risk; and R was the risk reduction rate by the treatment.
Phase I will identify the CMedication, CMonitoring, and CAE, as well as the risk reduction




risk used for “no therapy” (I0), a different approach is needed.  Therefore, Phase II study
is designed to obtain the background risk in the study population.
Phase II.  Analysis of Background Risk  
Literature shows that one way to achieve cost-effectiveness of preventive
interventions is to target interventions at the high-risk population (Jönsson, 1998).  The
effectiveness of a preventive drug therapy tends to be more obvious or stronger in high
risk population than that in low risk population.  Consequently, the ratio of costs to risk
reduction (effectiveness) of a drug therapy will be affected by the risk levels of the
population.  For example, a drug therapy unable to significantly reduce the number of
fractures (ineffective in prevention) may be only due to the originally low fracture rate
(“floor effect”).  Unless the drug therapy is very cheap and/or has extra benefits other
than preventing fractures, it is difficult for the small prevention effects to offset the costs
in low-risk population.  Therefore, uniform treatments prescribed for all postmenopausal
women are unrealistic.  The direct medical costs would increase dramatically, even
though some people may argue the savings in long-term costs are not clear.
On the other hand, physicians and patients may be reluctant to use drug therapies
in the absence of indications or symptoms.  Since osteoporosis can be developed
asymptomatically before a fracture occurs, this may lead to inadequate preventive care
for women at high risk.  To avoid the two situations in which women with low risk of the
disease are “over-treated” and women with high risk are “under-treated”, it is critical to




therapies based on their risk.  Then, an appropriate cost-effective drug therapy can be
chosen for each woman based upon the most cost-effective drug available for their risk
levels.
In Phase II, a regression model will be built by comparing the risk factors
between women without previous osteoporotic fractures (controls) and those who had
fracture experience after 45 (cases) to predict the risk of osteoporotic fractures.  The risk
factors examined in the model include: a) age; b) age at menopause; c) current Body
Mass Index (BMI) and BMI in the 20s to 30s of age; d) family history; e) calcium and
vitamin D intake; f) smoking behavior; g) alcohol consumption, and h) exercise.  Since
more than 96% of WV population are white, race will not be included in the model.
The established prediction model will then be applied to the sample which only
contains fracture-free women to estimate their fracture probability.  The predicted
probability (P) of fracture occurrence in the target fracture-free sample can be calculated
by the following formulas (Wright, 1995):
g = b0 +b1(x1) + b2(x2) + b3(x3)…
P = eg/(1 + eg)
For each woman in the fracture-free sample, her probability of developing a
osteoporotic fracture can be estimated by the model.  The fracture probability distribution





Phase III.  Cost-Effectiveness Analysis
Phase III of the study will evaluate the cost-effectiveness of the three drug
therapies for women with different risk levels, utilizing the information obtained from
Phase I and Phase II.  A cost-effectiveness analysis will be conducted to determine which
drug therapy is of the most value for the hypothetical woman in the decision-making
model established in Phase I.  As mentioned before, the effectiveness of treatments varies
with the risk levels in the study population.  This characteristic of uncertainty in the
effectiveness value should be considered and reflected in the calculation of cost-
effectiveness ratios.  To incorporate uncertainties in the effectiveness variable as well as
the most influential cost variables to the evaluation (detected by simple sensitivity
analyses), a probabilistic analysis (Monte Carlo simulations) will be conducted based on
the distribution of background fracture risk (I0), treatment cost, and fracture risk
reduction rate.  The expected values (expected costs per fracture averted per woman) will
be estimated for the three preventive drug therapies among fracture-free women in the
study population.
Using the hypothetical model and decision tree structure developed in Phase I, the
base formula to calculate CE ratio of the Monte Carlo simulations will be:
f[costs/(fracture averted)] = f(C)/ [(f(I0) x  f(R)]
in which f(C) is the distribution of treatment costs for the treatment, f(I0) is the
distribution of background fracture risks, and f(R) is the distribution of fracture risk
reduction rates. f(I0) will be estimated from the actual risk distribution in the study




reduction rates will be estimated by Triangle distribution using high, basic, and low
values.
Incremental cost-effectiveness ratio will be calculated for each treatment strategy
relative to the next most effective strategy.  Since it is well accepted that women who
have high risk of osteoporosis should be treated for preventing osteoporotic fractures, the
cost-effectiveness of each drug therapy relative to not using any intervention will be
obvious.  The question then turns to whether the additional benefit is worth the additional
cost among the competing alternatives.  Thus, it is important to compare incremental
cost-effectiveness of alternative interventions.
Finally, a matrix of expected CE ratios by risk levels and by preventive drug
strategies will be created to illustrate the potential economic and clinical outcomes.




To develop a decision model that identifies the costs and effectiveness of three
preventive drug therapies for osteoporotic fractures in postmenopausal women aged 45 to
85 years old.
Objective 2
To assess the relationship between various risk factors and the occurrence of first





To determine the distribution of women on the basis of their probabilities for
osteoporotic fractures in the study population.
Objective 4
To examine the expected cost-effectiveness of each of the three drug therapies
based on the fracture risk distribution in the study population.
Research Significance
One of the most important trends in health care is the increasing emphasis toward
disease prevention.  Besides the efforts aimed at adjusting behavioral factors, more drugs
aimed at both primary and secondary prevention have been developed.  However, the
health care system nationwide has been plagued by escalating drug product costs.  The
introduction of new chemo-preventive agents may further threaten drug budgets of third-
party payers, especially if this trend continues or escalates.  The question arises which
and how preventive medication(s) should be covered by third-party payers such as
Medicaid, managed care organizations, and other insurance payers among their members
with different risks for the disease.
A novel aspect of this study is the establishment of a risk-based approach to
evaluate preventive drug therapies and make appropriate coverage decision.  A drug
therapy may not be cost-effective among low risk women, even if it is cost-effective
among high risk women.  Consequently, an evaluation of the cost-effectiveness of three




the WV Medicaid program, information regarding the costs per fracture averted based on
the possible treatment costs and effectiveness as well as the fracture risk distribution can
provide decision makers a better understanding of the possible expenditures and risks
(uncertainty) associated with each prevention strategy.  Findings of this study will also
help policy makers assess the economic and clinical benefits of providing coverage for
the drug therapies in women with different risk levels.  Policy makers so informed can
determine what drugs should be covered and who can receive them to optimize outcomes
given the budget constraints.
The study will also have relevance to clinical decision-making.  In clinical
practice, physicians and other decision makers should consider the benefits, risks, and
costs of each drug therapy as it applies to the individual patient.  Information from a
thorough evaluation of alternative therapies is greatly needed.  This study will help
decision makers to determine whether the costs associated with each therapy are
reasonable or within accepted limits when both costs and benefits are taken into account.
By comparing incremental cost-effectiveness of three drug therapies based on the
women's risk, decision makers can choose the most cost-effective treatment for women at
different risk levels.  The established model can be used in the process of making
formulary decision and developing clinical practice guidelines to improve and
standardize preventive health care delivery.
Furthermore, the risk prediction model obtained in this study can be used to
develop a risk assessment algorithm that clinicians can utilize to estimate fracture risk for




costly advanced test (i.e., BMD test).  A clinical guideline can also be developed based
on the matrix of cost-effectiveness ratios by therapy and by fracture risk.
Finally, the methodology developed for assessing cost-effectiveness of preventive
drug therapy will be an addition to the literature that is currently lacking in this important
area of need.  The risk distribution-based evaluation method will not only be useful to
Medicaid programs but also to managed care organizations who also face similar cost






This chapter summarizes the results of an extensive review of the available
literature regarding osteoporosis/osteoporotic fracture and its prevention and treatment,
pharmacoeconomic evaluation of the three pharmacotherapies, fracture risk assessment,
and the West Virginia Medicaid program.
Postmenopausal Osteoporosis and Related Fractures
Burden of Illness
Osteoporosis is a systemic bone disease associated with altered bone architecture,
reduced bone mass, and an increased fracture rate.  The World Health Organization has
defined osteoporosis as a bone mineral-density measurement (T-score) of more than 2.5
standard deviations (SDs) below the mean for young adults.  Bone densitometry reports
refer to Z scores or T scores.  The Z score (age-matched control) compares the patient
with a population adjusted for age, sex, and weight; the T score (young, normal control)
compares the patient with a sex-adjusted population at peak bone mass (Consensus
Development Conference, 1991).  A bone will be considered to be osteoporotic if it has
sufficiently decreased density measured by a T or Z score, or if there has already been




Osteoporosis is a major health and economic problem.  The National Osteoporosis
Foundation estimated that in 1996 approximately 29 million people aged 50 and over in
the United States either had osteoporosis or were at risk of developing the disease; this
number is expected to rise to over 41 million by the year 2015 (WV Bureau for Public
Health, 1998).
Postmenopausal osteoporosis is the most common type of osteoporosis, compared
to senile and secondary osteoporosis (caused by certain medications and/or diseases).
Age-related bone loss commences in both men and women at about 40 years of age and
continues throughout life, with acceleration in the rate of loss in women during
menopause.  The average age of onset of menopause in the US is 52 years (Hormone
Replacement Therapy Technical Bulletin, 1992).  Postmenopausal osteoporosis is usually
diagnosed in women 51 to 75 years of age.  The reduction in estrogen levels associated
with menopause is an important contributory factor to bone mineral loss and the
development of osteoporosis.  Estrogen deficiency not only decreases protective effects
on serum lipid profiles and other cardiovascular parameters, causing an increased risk of
ischemic heart disease, but also results in increased bone resorption without change in
bone formation, particularly in trabecular bone (Whittington & Faulds, 1994).  This leads
postmenopausal women at high risk of fracture.  A report from National Institutes of
Health (NIH) shows that one in every two women will suffer an osteoporotic fracture at
some time in their lives.  A woman’s risk of a hip fracture is equal to her COMBINED
risk of having breast, uterine, or ovarian cancer (WV Bureau for Public Health, 1998).  It




women older than 50 years of age (Mosca et al., 1997).  This suggests a large number of
women who will be at risk of osteoporosis and would need appropriate preventive
treatment.  At present, most of the drugs used in the management of osteoporosis are
approved only for the prevention and treatment of postmenopausal osteoporosis; other
forms of the disease, such as corticosteroid-induced osteoporosis and osteoporosis in
men, have not been studied well due to their relatively low prevalence.
The most serious consequence of osteoporosis is fracture.  The National
Osteoporosis Foundation (NOF) estimates that approximately 1.5 million fractures per
year are osteoporosis related: 300,000 hip fractures, 700,000 vertebral fractures, 250,000
forearm fractures, and 250,000 fractures at other sites (National Osteoporosis Foundation,
1997). Osteoporotic fractures are a major cause of morbidity and mortality in elderly
population.  For instance, half of all hip fracture patients will be unable to live
independently, 12% to 36% will die within one year, and the mortality significantly
increases with age (Egol et al., 1997).  One-half of persons who have a hip fracture will
be unable to walk without assistance during their remaining lifetime, and 25% will
require long-term care (National Institute of Arthritis and Musculoskeletal and Skin
Diseases, 1997).  Osteoporosis can also cause kyphosis (dowager’s hump) which
contributes to the compression of internal organs and related consequences.  Other effects
of osteoporosis include decreased height, reduced lung capacity, and chronic pain
(Prestwood & Weksler, 1997).  Patients’ quality of life can also be decreased
significantly by a functional disability, restricted activities, fear of falling, and the pain




The economic costs of treating osteoporosis and related fractures are enormous,
both to individual patients and to society in general.  Ray et al. (1996) estimated the
direct costs to the health care system to be nearly $14 billion annually or $38 million each
day.  By 2040, the total annual cost of hip fractures alone is predicted to be $240 billion
(Cummings et al., 19901).  The total societal costs may be underestimated since some
indirect costs such as workday loss of care givers have not been considered.
As the number of elderly people in the US and the world increases, osteoporosis
and its related fractures have become a focus of attention to the public.  Considering the
high prevalence of osteoporosis and its impact on health care expenditure and patients’
quality of life, consideration of more vigorous prevention strategies is warranted.
Prevalence and Incidence in West Virginia
Because osteoporosis primarily affects older, white women, it becomes a
particular concern in West Virginia. According to the U.S. Census Bureau, West Virginia
ranks fourth in the nation in the proportion of its population that is elderly and has the
highest median age in the nation, 37.7 years.  White women also compose a larger
percentage of the population in West Virginia than in the nation as a whole (Hobbs,
1996).
Data from the 1997 Behavioral Risk Factor Surveillance System (BRFSS), a CDC
funded annual telephone survey of West Virginians aged 18 and older that monitors
health behaviors, provided information on the prevalence of eight risk factors for
osteoporosis: bone structure/body weight, menopause, heredity, thyroid or cortisone-like




alcohol abuse.  Specifically, 23.5% postmenopausal women smoked, 70.3% were
sedentary, 90.0% consumed fewer than three servings of dairy products per day, and
19.0% had a family history of osteoporosis.  Nearly nine out of every ten postmenopausal
women (87.7%) reported having three or more risk factors for osteoporosis (WV Bureau
for Public Health, 1998).
Prevalence of Osteoporosis. Based on research summaries from the National
Health and Nutrition Examination Survey III (NHANES III) conducted from 1988
through 1994, the National Osteoporosis Foundation (NOF) reported that in 1996
approximately 13%-14% of the men and women aged 50 and over in any given state had
osteoporosis.  The exceptions to this were the District of Columbia which had the lowest
prevalence rate of 10%, and West Virginia, Iowa, Maine, Nebraska, and Rhode Island
had the highest prevalence rate of 15%.  The NOF study also estimated that a total of
182,962 women in West Virginia suffered from either osteoporosis (63,683, or 210.2 per
1,000 women) or low bone mass (119,279, or 393.7 per 1,000 women).  That means 210
out of every 1,000 women aged 50 and older in WV already had osteoporosis and 394
women were at risk due to low bone density.  By 2015, the NOF predicts that a total of
227,246 women in the state will have osteoporosis or low bone mass.
Incidence of Osteoporotic Fractures. The state burden of fractures model
developed by Merck and Company, Inc. (Abbott, 1996) predicted the number of fractures
in women aged 45 and older in each of the 50 states and the District of Columbia
annually from 1995 through the year 2015.  It estimated that more than 41,000 women in




would suffer a wrist fracture between 1995 and 2015, while nearly 100,000 women
would experience vertebral fractures.  Also, the model predicted that from 1995-2015
approximately 8,400 West Virginia women aged 50 and older would die within a year
following a hip fracture.  Of these, 5,200 deaths were attributable to the fracture itself.
The prevalence and incidence statistics in WV are alarming.  With the aging of
the population, the situation will worsen if no effective intervention strategy is done.
Prevention and Treatment
Currently, the management of osteoporosis includes both treatment and
prevention.  Patients with osteoporosis or osteoporotic fractures can be treated by HRT,
bisphosphonates, calcitonin, or lifestyle modification (e.g., change in diet, smoking
cessation, and exercise)(Umland et al., 1999).  The primary goal of treatment in
osteoporosis is to prevent fractures.
Although treatment options exist, the most effective method of dealing with
osteoporosis and related fractures is prevention through lifestyle modification, increased
calcium and vitamine D intake, and the use of pharmacotherapy such as estrogen,
alendronate, or raloxifene.  Preventing osteoporosis will ultimately prevent fractures. Too
often the diagnosis of osteoporosis is made only after the occurrence of a fracture. An
early identification and modification of a person’s risk factors are therefore important to
prevent osteoporotic fractures.  Risk factors for osteoporosis include postmenopausal
period, race (being white or Asian), thin body build, cigarette smoking, moderate to
heavy alcohol use, sedentary lifestyle, diet deficient in calcium, and premature




Several clinical guidelines for the prevention, treatment, and management of
osteoporosis have been developed (e.g., Scientific Advisory Board, 1996; Osteoporosis
Task Force, 1996; Kushner, 1998).  All guidelines suggest that osteoporosis is
preventable and treatable.  Prevention and early treatment of osteoporosis are believed to
be a key in limiting the progression of osteoporosis and therefore avoiding the fracture,
which is a major public health problem.  Appropriate treatment strategies, especially
pharmacotherapies, can significantly avert or lessen the morbidity and mortality
associated with fractures associated with the osteoporosis.
Pharmacotherapy in the Treatment and Prevention of Osteoporosis
Major changes in the prevention and treatment of osteoporosis and related
fractures have occurred in the last three years with the approval of new drugs such as
alendronate and raloxifene.  These two new drugs can be used as an alternative to
hormone replacement therapy, which has been used for many years.  All of these
therapies vary in their regimen, benefits, risks, and adverse effects.  As with all
therapeutic decisions, physicians should consider the benefits, risks, and costs of each
treatment when applying it to the individual patient.  The comparative efficacy of these
agents have been discussed in many study reviews, especially for HRT and alendronate
(e.g., Whittington & Faulds, 1994; Meunier et al., 1999; Scientific Advisory Board, 1996;




Hormone Replacement Therapy (HRT)
Regimens
All forms of estrogen (including transdermal, equine and synthetic estrogens) are
effective in preventing bone loss (Scientific Advisory Board, 1996).  Progestins are given
along with estrogen therapy to prevent the development of endometrial hyperplasia and
carcinoma.  Two major hormone replacement schedules are used for women who have a
uterus (Dosh et al., 1997).  Estrogen and progesterone in combination can be taken either
cyclically or continuously.  Cyclical combined schedule more or less copies the natural
menstrual cycle.  Estrogen is taken on days one to twenty-five and progesterone is added
on or about day fourteen.  After day twenty-five, no hormone is taken for five days,
during which time bleeding will probably occur.  This bleeding gradually diminishes over
the years and eventually disappears.  Continuous combined schedule requires women to
take both estrogen and progesterone every day.  The lining of the uterus thins and never
builds up, so there is no bleeding.  However, because taking progesterone does not
duplicate the cyclical biological schedule of the premenopausal woman, some researchers
feel that it is less effective in protecting you against heart disease.
The most common dosage forms for the prevention and treatment of osteoporosis
are: (1) cyclic estrogen 0.625mg/day + cyclic medroxyprogesterone 5mg/day; 2)
continuous estrogen 0.625mg/day + continuous Medroxyprogesterone 2.5mg/day; (3)
cyclic transdermal estradiol 50µg/day + cyclic Medroxyprogesterone 5mg/day; and (4)





Effects on Bone Loss and Fractures
The protective effect of HRT on bone has been widely reported (Whittington &
Faulds, 1994; The Writing Group for the PEPI Trial, 1996; Mizunuma et al., 1997; Eiken
et al., 1997; Schneider 1997; Lufkin et al., 1992).  HRT is effective against osteoporosis
in 85% of users and is the first line pharmacotherapy for prevention and treatment of
osteoporosis in postmenopausal women (Scientific Advisory Board, 1996; Whittington &
Faulds, 1994; Willhite,1998; Meunier et al., 1999;  Isenbarger et al., 1997).  Estrogen
decreases bone resorption by inhibiting osteoclastactivity and increases both cortical (1%
to 3%) and trabecular (2% to 5%) bone density (Osteoporosis Task Force, 1996).  The
total BMD can be increased up to 12.1%.  Estrogen therapy with or without concurrent
progesterone therapy prevents accelerated bone loss that normally occurs with
menopause.  Combined estrogen and progestogen result in similar risk reductions to
unopposed therapy.
Epidemiology studies have shown decreased osteoporotic fractures in HRT users
(Miller, 1996).  The Postmenopausal Estrogen/Progestin Intervention  (PEPI) trial, a 3-
year, multicenter, randomized, double-blind, placebo-controlled study, examined the
effects of ERT on BMD in postmenopausal women (The Writing Group for the PEPI
Trial, 1996).  It found that BMD increased by a mean of 5.1% in the spine and 2.3% in
the hip in the treated group. Long-term therapy reduced the risk of hip fracture by 25%.
A meta-analysis of 47 randomized controlled trials indicated that pooled RR rate
was 0.5 for case-control and 0.84 for cohort studies (Robertson et al., 1993).  Another




hip fractures in ever-users of HRT compared with non-users from 11 epidemiology
studies (Grady et al., 1992).  Results also suggested that the relative risk would further
decrease to 0.5 after >10 years of therapy.  Longer duration of HRT may be associated
with greater effect although the optimal duration is still unknown (Miller, 1996). To
confirm its antiosteoporotic efficacy, BMD test after 2 years of treatment is
recommended (Kushner, 1998).
Given the effects of HRT on bone loss and fracture risk, the purpose of using
HRT in the prevention and treatment of osteoporosis is to provide the lowest and safest
level of ovarian hormone dosage that will protect against osteoporotic fracture (Scientific
Advisory Board, 1996).
Effects on Cardiovascular Disease
Cardiovascular disease is considered the most significant health problem.  It is the
number one cause of death in post-menopausal women (DeGregorio & Taras, 1998).
Many studies show that HRT has a protective effect against coronary heart disease in
addition to its effect on preventing bone loss and fractures (Haines et al., 1996; The
Writing Group for the PEPI Trial, 1995; Koh et al., 1999; Hulley et al., 1998).  Results
showed that HRT reduced low-density lipoprotein (LDL) levels by 15 –19% and
increased high-density lipoprotein (HDL) by 6 – 18%. HRT in postmenopausal women
decreases the risk of coronary heart disease through its effect on lipid profiles.
Approximately 75% of estrogen’s cardiovascular benefits come from vasodilation,




The effect of estrogens on raising triglyceride levels may be offset by adding
progestin.  Although both ERT and HRT provide lipid benefits, concomitant progestin
use may decrease estrogen’s positive effects on serum lipid profiles (Whittington &
Faulds, 1994; Grady, 1992).  However, this mechanism is still unclear and only partly
responsible for the cardioprotective effect and depends on the type of progestogen used
(Whittington & Faulds, 1994).
Some studies also examined the association between ERT/HRT and the endpoint
outcomes such as risk of cardiovascular disease and related morbidity and mortality
(Grodstein et al., 1996; Grodstein et al., 1997).  Nabulsi et al. (1993) used a cross-
sectional analysis and estimated a 42% reduction in the relative risk of coronary heart
disease in HRT users compared with non-users.  A large (n = 59,337), 16-year follow-up
in the Nurses’ Health Study showed an approximately 60% decreased risk of major
coronary artery disease for women on HRT or estrogen alone, compared with non-
hormone users (Grodstein et al., 1996).  However, large, randomized clinical trials are
needed to evaluate the impact of HRT on heart disease risk as well as related morbidity
and mortality.
Other Benefits of HRT
Estrogen can relieve menopause symptoms such as hot flashes, vaginal atrophy,
and vaginal dryness (Miller, 1996). The role of estrogen in memory and Alzheimer’s
disease is not definitive (Henderson et al., 2000; Paganini-Hill, 1997; Paganini-Hill &
Henderson, 1996; Paganini-Hill, 1996). The Leisure World Cohort Study showed a




non-users (Paganini-Hill & Henderson, 1996).  But other studies have shown no benefit
or an increased risk of dementia in estrogen users (Paganini-Hill, 1996).
The association between estrogen/progestogen use and stroke is unclear.
Evidence is controversial in the literature.  For example, Grady et al. (1992) estimated a
relative risk (RR) of 0.96 for stroke among estrogen users.  Another two large cohort
studies estimated the RR of any stroke to be 0.69 and 0.90 for estrogen users, and RR of
stroke mortality as 0.37 (Finucane et al., 1993; Falkeborn et al., 1993).  However,
estrogen use did not shown any protective effect against stroke in the Nurses’
HealthStudy – a large prospective trial (Grodstein et al., 1996).
Risks and Adverse Effects of HRT
Breast Cancer.  The relationship between HRT and breast cancer is complicated
and highly controversial in literature.  Many studies revealed no apparent increased risk
of breast cancer in ever ERT/HRT users (Colditz et al., 1993; Grady et al., 1992).  In
contrast, some studies revealed that there is an increased risk of breast cancer in current
HRT users, especially in long-term users, with relative risks (RR) ranging from 1.2 to
1.63 (Colditz et al., 1993; Sillero-Arenas et al., 1992; Collaborative Group on Hormonal
Factors in Breast Cancer, 1997; Roy et al., 1996).  For example, the Collaborative Group
on Hormonal Factors in Breast Cancer reanalyzed data from 51 epidemiology studies of
52,705 women with breast cancer and 108,411 women without breast cancer
(Collaborative Group on Hormonal Factors in Breast Cancer, 1997).  In women who used
ERT for 5 years or more, the RR of breast cancer was 1.35. In women who had never




that the risk of breast cancer increased with the duration of ERT use.  However, the data
also showed that the risk of breast cancer reverted to normal after 5 years of stopping
ERT.
No relationship was found between the dose of estrogen and RR of breast cancer.
Also, adding progestin to ERT did not reduce the overall relative risk of breast cancer
(Colditz et al., 1993; Sillero-Arenas et al., 1992; Collaborative Group on Hormonal
Factors in Breast Cancer, 1997).  And interestingly, no increase in RR of breast cancer
was seen among women with a family history of the disease, compared with those
without a family history (Colditz et al., 1993).
Results and conclusions from many of those studies regarding the effect of HRT
use on the risk of breast cancer were limited by a strong detection bias, because women
on ERT/HRT tend to receive more thorough breast cancer screening.  Also, many studies
failed to control some key variables such as alcohol intake which may also influence the
risk of breast cancer (Zumoff 1993).  Large, prospective, randomized, and well-
controlled trials are needed to establish any relationship between HRT and breast cancer.
Uterine Cancer.  Unopposed estrogen use is related to endometrial cancer and this
relationship has been well proved by many case-control and cohort studies (Grady et al,
1992).  However, the risk of uterine cancer in women with an intact uterus can be
virtually eliminated when estrogen is combined with progestogen.  The conclusion has
been well accepted by researchers and clinicians that the relative risk of endometrial




women (e.g., Whittington & Faulds, 1994; Willhite, 1998; Meunier et al., 1999; Grady et
al., 1992).
Major Adverse Effects. The major side effect of HRT is irregular vaginal
bleeding.  An increased risk of deep venous thromboembolism and pulmonary embolism
is also associated with HRT. Studies found that the increased risk is only in current users
and past users are not at increased risk for these adverse effects. Short-term current users
appeared to have highest risk (Grodstein et al., 1996; Daly et al., 1996).  The risk of
venous thromboembolism doubled with HRT use, but due to the low baseline risk, HRT
produced only one to two additional cases per 10,000 women per year (Gutthann et al.,
1997).  The risk of pulmonary embolism was also showed as twice as that of non-users
(Grodstein et al., 1996) and had low incidence rate.
Other side effects of HRT are nausea, vomiting, abdominal cramps, mastalgia,
bloating, hair loss, and headaches.  The effects of HRT on blood pressure and glucose
tolerance are not significant enough to prevent women with controlled hypertension or
diabetes from taking HRT (Scientific Advisory Board, 1996).
Contraindications
The absolute contraindications to HRT include: history of unexplained vaginal
bleeding, active liver disease, breast cancer, and active vascular thrombosis.  In addition,
cautions or specific monitoring should be given and low dosages are preferred in the
conditions such as migraine, history of thromboembolism, familial hypertriglyceridemia,
endometriosis, uterine cancer, gall bladder disease, and strong family history of breast




Onset and Duration of Treatment
The optimal time to start HRT and duration of HRT for preventing and treating
osteoporosis are uncertain. Many studies suggest that all postmenopausal women should
consider HRT/ERT (e.g., Whittington & Faulds, 1994; Willhite, 1998; Cauley et al.,
1995; Lindsay, 1987).  Long-term treatment is required to achieve the full protective
effect of HRT.  The greatest benefit may occur if it is used for 10 years or more.
However, some studies argued that since there is a long-time interval between menopause
and the peak incidence of fracture (from the seventh decade onwards), a five to ten year-
therapy initiated at menopause is unlikely to provide optimal protection against fracture
some decades later (Adis International Limited, 1997).  Although for women with
menopausal symptoms, an/or at high risk of heart disease, initiation of HRT at
menopause may be appropriate, starting HRT at menopause seems not cost-effective if
short term intervention at a later stage can also prevent fractures.
Another issue is the rate of bone loss after cessation of therapy. Ettinger & Grady
(1993) stated that rapid bone loss will resume when HRT/ERT is discontinued, similar to
that observed in untreated women at the onset of menopause.  The protective effect of
long term HRT is greatest at the end of treatment and will have decreased to
approximately half after a 10-year period following treatment for 10 years.  Thus, even
10 years of HRT cannot be expected to confer protection over the entire remaining life
span. Several other studies also showed that although women who take estrogen have
fewer fractures than those who do not, previous users of estrogen do not appear to have




estrogen after menopause (e.g., Ettinger et al., 1985; Felson et al., 1993; Kiel et al.,
1987).  Therefore, to significantly reduce fracture risk, HRT must be taken continuously.
However, most postmenopausal use of estrogen is prescribed for treating menopausal
symptoms.  Once these symptoms are subsided, the majority of women discontinue
estrogen use.  The long-term compliance to HRT regimens is suboptimal and becomes a
big concern (Meunier, 1999).
Compliance
Compliance to HRT is low, especially for a long-term use (Meunier, 1999;
Salamone et al., 1996; Ravnikar, 1987).  Therapy discontinuation and noncompliance are
major problems for women taking HRT to prevent and treat osteoporosis.  This is even
true in symptomatic women (Whittington & Faulds, 1994).  Studies have indicated that of
women who do receive a prescription for HRT, 30% never have it filled, 20% stop taking
the medication within nine months (Ravnikar, 1987), and about one-fourth stop treatment
within two years (Kushner, 1998).  The major reasons for non-compliance include
perceived lack of need for HRT and concern for adverse effects such as breast cancer and
intermittent vaginal bleeding.  The addition of cyclic progestin to an estrogen regimen
will cause regular withdrawal bleeding in 50% to 80% of women, but the bleeding
becomes less prevalent as the length of treatment increases.
The low treatment compliance and the risks/adverse effects associated with HRT
make researchers and clinicians seek for more treatment solutions with high safety,
efficacy, and effectiveness.  Treatments other than HRT need to be considered, especially




drug therapies such as alendronate and raloxifene also play an important role in
osteoporosis prevention and treatment.
Alendronate Therapy
Alendronate was approved in November 1995 for the treatment of osteoporosis. It
was approved in the summer of 1996 for the prevention of osteoporosis in
postmenopausal women and recently, for steroid-induced osteoporosis.
Dosage and Duration of the Treatment
Alendronate is prescribed at a continuous dose of 10mg/day for treatment and
5mg/day for prevention (Merck & Co., Inc., 1995; Kushner, 1998).  Currently, it is not
clear on the optimal duration of alendronate therapy (Scientific Advisory Board, 1996).
Effects on Bone Loss and Fractures
Bisphosphonates are powerful inhibitors of osteoclastic bone resorption.
Bisphosphonate drugs bind avidly to bone resorption sites, resist enzymatic degradation,
and have half-lives similar to that of bone (Scientific Advisory Board, 1996).  At present,
etidronic acid, alendronic acid, and resedronic acid are approved by FDA for the
treatment of osteoporosis. Etidronate inhibits bone mineralization at antiresorptive doses.
Concerns regarding osteomalacia and increased fracture rates have diminished its role in
the treatment of osteoporosis (Scientific Advisory Board, 1996).  Residronate is very new
and only few clinical studies have been reported so far.
Alendronate does not impair bone mineralization and it is the only FDA-approved
bisphosphonate for the prevention and treatment of osteoporosis (Willhite, 1998).  Many




lumbar (5% to 10%), remoral neck (1% to 5%), trochanter (7%), and distal forearm
(0.3% to 2.0%) BMD in osteoporotic women aged 44 to 84 years (Karpf et al., 1997;
Chestnut et al., 1995).  Alendronate 5mg/day for two years also produced significant
increases in lumbar (3.5%), femoral neck (1.9%), and trochanter (3%) BMD (Hosking et
al., 1998), but not in distal forearm BMD.  Unlike HRT, accelerated bone loss was not
observed two years after discontinuation of alendronate.  Therefore, the previous gains in
BMD are maintained although bone loss resumes once a patient stops taking alendronate.
The continued therapy is required to obtained progressive increase in BMD (Stock et al.,
1997; Chestnut et al., 1995).
Furthermore, alendronate have been found to significantly decrease the risk of
fractures, especially among high risk women.  Data are available from several large,
randomized, controlled clinical trials of up to 5 years duration in patients with
osteoporosis or low BMD treated with alendronate (Liberman et al., 1995; Chesnut et al.,
1995; Adami et al., 1995; Black et al., 1996; Bone et al., 1997; Karpf et al., 1997;
Cummings et al., 1998).  For example, a study conducted in post-menopausal women
aged 51 to 88 years with at least one vertebral fracture at baseline showed that
alendronae10mg/day decreased new vertebral, hip, and wrist fractures by 47%, 51%, and
48%, respectively (Black et al., 1996).  In another three-year controlled study of
alendronate, the rate of new vertebral fractures was 48% lower in the treatment group
than in the placebo group (Liberman et al., 1995).  A meta-analysis of five placebo-
controlled studies in osteoporotic women aged 42 to 85 without baseline fractures




and forearm/wrist fractures by 61%. Fracture reduction was seen in patients both younger
and older than 65 (Karpf et al., 1997).
Efficacy and safety of bisphosphonates beyond 4 years are still unknown.  The
longest study duration so far is 4.25 year (Cummings et al., 1998).  The research is
continuing and more updated results will be expected.
Other Benefits
There is no extra benefit of alendronate reported.
Adverse Effects
Common adverse effects of alendronate therapy are gastrointestinal: dyspepsia,
dysphagia, nausea, diarrhea, and constipation.  The most serious side effects of
alendronate is esophageal ulceration.  However, apart from periodic monitoring of BMD
to detect the occasional non-responder, more intrusive monitoring is usually unnecessary
(Merck & Co., Inc., 1995).
The adverse experience profile was similar for the patients treated with 5, 10, or
20 mg doses of alendronate (Merck & Co., Inc., 1995).  The side effect rates reported in
clinical trials and population-based studies or from actual clinical practice are diverse. In
clinical trial studies, no significant difference was reported in the adverse experience
rates between alendronate and placebo group (e.g., Merck & Co., Inc., 1995; Black et al.,
1996; Tucci et al., 1996).  However, a frequency much greater than that reported in
clinical trials was found by Ettinger et al. (19981).  About one in three women (32.8%)
taking alendronate for osteoporosis reported gastrointestinal symptoms.  Furthermore,




gastrointestinal disorder in a health plan population, of which 14% prompted hospital
admission and 86% prompted outpatient visits.  The risk of having GI side effects and a
clinical encounter among alendronate users were 1.6 times higher than that among
nonusers.  This risk also increased with age and current use of NSAIDS.
Similarly, another study conducted by researchers at the Kaiser Permanente
Medical Care Program of Northern California (KPNC) also found that alendronate use
results in higher costs due to GI disorders (Levin, 1999).  The direct health care costs of
792 women enrolled in KPNC, a large HMO, and took alendronate therapy were
examined and compared to a population-based sample of the health plan’s membership.
The study showed that outpatient care was the major source of excess costs, which were
$40-$67 per member per month higher than that of the control groups not using the
medication.  In addition, alendronate users were found to incur approximately $3.80 more
in monthly acid-related disorder inpatient expenses compared to the control groups.
Excess pharmacy costs to treat acid-related disorders were also $2.80 per member per
month higher among the study group. Using the same database (KPNC), Ray et al. (2000)
found that the clinic and pharmacy costs for acid-related disorders per patient were $715,
after adjustment for the age, gender, and comorbidities.
The difference in GI adverse event frequency may be due to differences in patient
selection.  Most clinical trials of alendronate excluded women who had active upper GI
disease or who regularly use H2 blockers or NSAIDs (Liberman et al., 1995; Tucci et al.,
1996; Black et al., 1996).  In clinical practice, however, many women with osteoporosis




likely to have received intensive counseling on the dosing instructions or medication
adherence.  The higher adverse event rate can furthermore cause a higher discontinuation
rate of therapy in general practice than that in clinical trials.
Administration Requirements and Contraindications
Bisphosphonates, as a class, are poorly absorbed from the gastrointestinal tract
and as a consequence, there are strict administration requirements.  The drug need to be
taken on an empty stomach, 2 or more hours before the next meal, with a full glass of
plain water (not coffee, juice, tea, or mineral water).  Furthermore, patients should remain
fully upright and fasting for at least 30 minutes after dosing (Willhite, 1998).  Failure to
follow these requirement could result in a reduction in bioavailability and/or esphageal
irritation or ulceration.
Alendronate is contraindicated in patients with esophageal abnormalities or
inability to sit or stand upright for 30 minutes (Merck & Co., Inc., 1995)
Compliance
Patients’ compliance may be hampered by the strict administration requirements
of alendronate.  Patients’ non-compliance is a serious issue due to gastrointestinal
discomforts caused by inappropriate drug administration.  Some clinical trial studies
reported that the discontinuation rates of a 2-3 year therapy due to adverse reactions were
4.1% and 6.0% in the alendronate and placebo groups, respectively, for the dosage of
10mg/day, and 7.5% and 5.7% for the dosage of 5mg/day (Merck & Co., Inc., 1995).




increasing over time and by the end of 10-month follow-up, almost half of the women
(46.1%) had discontinued alendronate treatment.
Raloxifene Therapy
Roloxifene is a selective estrogen receptor modulator (SERM).  SERMs are
“nonsteroidal tissue-selective modulators of estrogen receptor-mediated actions”
(Willhite, 1998).  As alternatives to HRT, SERMs positively affect some tissues such as
bone and the cardiovascular system via estrogenic action, while lack estrogenic effects on
the uterus.   Therefore, SERMs are developed to optimize the positive ERT-like effects
while decreasing or eliminating adverse events and risks of other diseases.  So far,
raloxifene is the only FDA-approved SERM for osteoporosis prevention in
postmenopausal women.
Dosage
The dosage of raloxifene for the prevention and treatment of osteoporosis and
related fractures is 60mg/d orally.   There is no special requirement on the drug
administration (Eli Lilly and Company, 1997).
Effects on Bone Loss and Fractures
Several randomized, double-blind, placebo-controlled, two-year studies have been
conducted to examine the effects of raloxifene  (60mg/d) on BMD in postmenopausal
women aged 40 to 60 years: the North American trial, the European trial, and the
international trial (Eli Lilly and Company, 1997; Delmas et al., 1997).  Results in all
three studies showed that the mean total BMD percentage increased significantly at 12




ranged from 1.3% to 2.4%; the femoral neck, 1.6% to 2.5%; the trochanter, 1.3% to
2.7%; intertrochanteric, 1.3% to 2.3%; and lumbar spine, 1.8% to 2.4%.  Conjugated
estrogens produced increases in total hip BMD approximately twice that produced by
raloxifene.  Another study found that compared to the effects HRT and alendronate on
BMD, raloxifene was slightly less effective at the hip and has approximately half
effectiveness on lumbar vertebra (Delmas et al., 1997).
The effects of raloxifene on fracture risk are not thoroughly known yet.  Research
on the raloxifene in fracture risk reduction is ongoing.  By now the Multiple Outcomes of
Raloxifene Evaluation (MORE), a 3-year randomized clinical trial, is the longest trial for
raloxifene (Ettinger et al., 1999).  It was designed to examine the ability of raloxifene to
treat postmenopausal women with osteoporosis and to prevent fractures in these women.
Meanwhile, some secondary study end points such as the incidence of breast and
endometrial cancer were also examined.  More than 7,700 postmenopausal women
participated in this clinical trial with a mean age of 66.5 years.  Based on MORE study,
reloxifene reduces the risk of first-time vertebral fracture in women with osteoporosis by
55% and reduces the risk of subsequent vertebral fracture by 30%.  Frequency of
vertebral fracture was reduced both in women who did and did not have previous
fracture.  However, risk of nonvertebral fracture for raloxifene vs placebo did not differ
significantly, although raloxifene group had less fractures than placebo group.   
Other Benefits
Like estrogen, raloxifene has been proved to reduce major cardiovascular risk




1999; de Valk-de Roo et al., 1999).  In a double-blind, randomized trial, 390
postmenopausal women aged 45 to 72 years used raloxifene (60mg/d and 120mg/d),
HRT or placebo (Walsh et al., 1998).  It found that raloxifene produced LDL decreases
similar to those of HRT (12% and 14%, respectively) and significantly lowered
lipoprotein by 7% to 8% (HRT 19% decrease).  Raloxifene increased HDL2, a
subfraction of HDL that may be an important cardiovascular risk factor, by 15% to 17%
versus 33% by HRT but did not significantly affect total HDL cholesterol.  Triglycerides
were unaffected and fibrinogen decreased by raloxifene. Another recent double blind,
randomized, and placebo-controlled, 6-month clinical trial showed that raloxifene
significantly lowered serum homocysteine levels which are independent risk factors for
the development of cardiovascular disease by 8%, and similar to the 7% reduction
obtained with HRT (Walsh et al., 2000).
However, raloxifene’s effects on cardiovascular end points such as morbidity and
mortality of coronary heart disease have not been reported.  More research need to be
done to determine whether the beneficial effects produced by raloxifene on
cardiovascular risk factors will translate into a reduction of cardiovascular risk.
Recently, with the release of interim data from the ongoing MORE study, there is
a debate on the preventive effect of raloxifene on breast cancer.  The MORE study
showed that postmenopausal women with osteoporosis receiving raloxifene had a 70%
reduced risk of developing newly diagnosed breast cancer, compared with placebo group
(Ettinger et al., 1999).  Similar results were produced by raloxifene 60 and 120mg/day




of treatment with raloxifene reduced the risk of breast cancer in postmenopausal women
who had osteoporosis and no history of breast or endometrial cancer.  However, the
researchers also mentioned that since the study subjects were osteoporotic women and
osteoporosis itself is associated with a reduced risk of developing breast cancer, caution
must be given in interpreting the results.  The MORE trial is continuing and the long-term
effects of raloxifene on prevention of fractures and breast cancer are being studied.   So
far, there is no definite answer on whether raloxifene could prevent breast cancer or not.
A study called STAR (Study of Tamoxifen and Raloxifene), which is comparing the
efficacy of the two agents in the prevention of breast cancer in postmenopausal women,
is on the way. More than 20,000 postmenopausal women will be recruited in this study.
The results of this study are expected to provide a better explanation to the role of
raloxifene in the prevention of breast cancer (Carlson, 1998).
The protective effects of raloxifene on bone, cardiovascular risk (through total
and LDL-cholesterol reduction), and probably breast cancer risk make raloxifene as a
promising agent with a “do-all” therapeutic profile for the postmenopausal women.
Raloxifene may therefore offer better overall prevention for women than other agents
such as HRT, alendronate and tamoxifen when the risks of endometrial cancer, fracture,
and breast cancer are all taken into account.  However, many researchers believe that it is
too early to recommend this approach, as the clinical studies conducted to date have been
designed to primarily evaluate effects on fracture risk and not breast cancer and
cardiovascular disease prevention (Prestwood et al., 2000; Carlson, 1998).




Compared to HRT and alendronate, adverse effects of raloxifene is minimal.
Raloxifene is well tolerated by most patients.  Studies show that there is no significant
difference in the incidence of adverse events between treatment group and placebo group
(Eli Lilly and Company, 1997; Delmas et al., 1997).  Compared to HRT, hot flashes are
more common with raloxifene.  Unlike estrogen, raloxifene does not relieve menopausal
symptoms, and it may actually cause hot flashes.  However, raloxifene appears to cause
less breast pain, vaginal bleeding, flatulence, and abdominal pain (Eli Lilly and
Company, 1997; Ettinger et al., 1999).  Also, it does not stimulate the postmenopausal
endometrium (Goldstein et al., 2000; Meunier et al., 1999).
Raloxifene’s potential for causing deep venous thrombosis is similar to that of
estrogen (Eli Lilly and Company, 1997; Kushner, 1998; Physicians’ Desk Reference,
1999).  The MORE study showed that the risk of venous thromboembolus in women
receiving raloxifene is three times higher than that in placebo group (Ettinger, 1999).  It
is rare but can cause serious consequences.  Therefore, like HRT, Raloxifene is
contraindicated in women with current or past thromboembolic events.
Compliance
Patients are expected to have relatively high compliance rate due to the good
tolerance, easy administration and dosage form.  Compared to HRT, Raloxifene treatment
was reported to have less dropout rate (Willhite, 1998).  A study conducted by Lilly
Research Laboratories (1999) combined eight randomized clinical trials (6-30 months’
duration) of raloxifene to examine the incidence of adverse events and dropout rate.  It




groups and placebo group.  Vaginal bleeding was responsible for significantly more
discontinuations from the HRT groups compared with the raloxifene group.  Hot flashes
was significantly increased in the raloxifene group.  However, it did not increase the
discontinuation rates.  Also, the incidence of leg cramps was greater in raloxifene group
compared with placebo group, but did not cause any discontinuation of therapy.  The
study concluded that raloxifene can be well tolerated by women and the discontinuation
rates were low compared to HRT.
Pharmacoeconomic Research On The Three Drug Therapies
Based on the clinical trial data, pharmacoeconomic research has been done to
evaluate the cost-effectiveness, cost-utility of HRT, alendronate, and raloxifene in the
treatment/prevention of osteoporosis.  There are numerous pharmacoeconomic studies on
HRT and most of them were published in 1980’s and the early of 1990’s .
Pharmacoeconomic evaluations on alendronate and raloxifene are relatively rare,
especially for raloxifene, due to inadequate clinical trial data.  The following will review
the multiple effects of the three drug therapies and the associated risk rates frequently
used in the literature.
Hormone Replacement Therapy (HRT)
Effects on Fracture Risk
Many studies have been done in assessing the cost effectiveness of HRT for
fracture prevention since 1980’s.  Early pharmacoeconomic studies usually based their




who found a relative risk (RR) of 0.43 for current users of estrogen (Weinstein & Schiff,
1983; Cheung & Wren, 1992; Daly et al., 1992).  Various effectiveness rates (risk
reduction rates) have been applied in the analysis.  For example, Weinstein (1980)
assumed a RR of 0.33 while patients received HRT, and 0.5 for a period after ceasing
therapy equivalent to that of its duration.  Tosteson et al. (1990) utilized a computer
simulation model and used an estimated RR of 0.84 and 0.52 for women aged 50 to 74
years after 5 and 10 years of HRT, respectively.   In general, a RR of 0.5 for all types of
fractures has been used (Tosteson et al., 1990; Weinstein & Tosteson, 1990).
Some pharmacoeconomic analyses examined fracture risk by fracture types. Hip
and vertebral fractures are the two types of fractures most often studied. Researchers used
a relative risk of hip fracture of 0.8 for the first 5 years of treatment and 0.4 thereafter,
with the risk increasing gradually after stopping the treatment (Weinstein & Schiff, 1983;
Cheung & Wren, 1992; Daly et al., 1992; Roche & Vessey, 1990; Weinstein & Tosteson,
1990).  For example, in a cost-effectiveness analysis of HRT conducted by Cheung and
Wren (1992), a hypothetical model of women of age 50 with and without HRT was
established. The RR of hip fracture was assumed between 0.8 to 0.4 depending on
treatment durations (5 - 15 years).  A more recent study conducted by the Swedish hip
fracture study group found that the risk of hip fracture decreased at a rate of 6% per year
of HRT use with an RR of 0.36 (95% CI, 0.24 to 0.53) for women currently taking HRT
(Michaelsson et al., 1998).  Rosner et al. (1998) compared cost-effectiveness of HRT,




postmenopausal women with osteoporosis.  The risk of a vertebral fracture was assumed
to decrease by 55% by HRT for 3 years (RR = 0.45, compared with no therapy).
Unlike other pharmacoeconomic studies, Clark and Schuttinga (1992) calculated
health care cost savings of HRT in preventing osteoporotic fractures based on the fracture
risk levels and possible usage of HRT (compliance).  The study evaluated a hypothetical
cohort of 100,000 American white women who reached 50 years of age during 1988.
Baseline risks for hip fracture, vertebral fracture, and other fractures were estimated in
high, medium, and low risk categories.  Risk reduction rate of 50%  (RR = 0.5) for total
fractures after 5 years of HRT was applied for all three risk groups (i.e., the fracture
incidence for each group was assumed to decrease by 50% with HRT).  The study
showed that the total net savings was $27.6 million (1988 dollars) attributable to
screening and HRT.  Although this study did not state clearly how the three risk
categories were classified (no classification criteria was reported), it is one the few
studies that take into account the baseline risk levels and apply this to the cost-saving
calculation.
Although treatment duration and types of fractures varied in pharmacoeconomic
research, almost all studies concluded that long-term HRT for menopausal women, or at
least for symptomatic women, is cost-effective.  However, few studies have considered
women’s compliance with the treatment and examined how non-compliance affects the
extent of cost-effectiveness of HRT.




Generally, a 50% risk reduction rate was assumed for unopposed HRT after 10
years of treatment (Cummings et al., 19902; Cheung & Wren 1992; Tosteson &
Weinstein, 1991).  When progesterone is added to the estrogen replacement therapy,
some pharmacoeconomic studies assume the effect on the relative risk of heart disease is
the same as that of estrogen therapy (Whittington and Faulds, 1994). On the other hand,
many pharmacoeconomic studies have assumed that the cardioprotective effect of HRT,
compared that of ERT, is halved (Cheung & Wren 1992; Daly et al., 1992; Roche &
Vessey, 1990) or completely negated (Tosteson & Weinstein, 1991; Rosner et al., 1998).
Some researcher argued that although long-term use of HRT could provide significant
cardioprotective effects, there was also evidence that it could increase the risk of breast
cancer (Rosner et al., 1998).  The two effects may countervail to some extent.  Also,
these long-term effects may not be substantial due to the low patient compliance with
HRT.   Uncertainty in the effects of long-term HRT on heart cardiovascular disease and
breast cancer as well as low treatment compliance rate make it disputable whether and
how these extra benefits or risks should be included in pharmacoeconomic research.
Effects of HRT on Breast Cancer
As stated before, a definitive association between HRT use and breast cancer risk
has not been established. Consequently, the relative risk rates used in pharmacoeconomic
research are not consistent.  Most of research did not include the increased risk of breast
cancer, or only included it in a sensitivity analysis (e.g., Rosner et al., 1998; Weinstein,
1980).  Daly et al. (1992) assumed that 5 years of HRT did not increase risk, but that after




1.3) and 50% (RR = 1.5), respectively.  The risk was assumed to remain elevated after
treatment cessation for a period equal to that of treatment.  Other studies applied relative
risk rates of 1.25 (Weinstein & Schiff, 1983; Weinstein & Tosteson, 1990, Cheung &
Wren, 1992) or 1.36 (Tosteson & Weinstein, 1991).  The treatment costs of breast cancer
were assumed to be $4,000 in 1982 dollars (Weinstein & Schiff, 1983).
Risk Rates Used for Other Benefits and Risks
Cerebrovascular disease. In a study conducted by Daly et al. (1992), a cohort of
postmenopausal women were followed with HRT for 10 years after onset of menopause
at age 50 years.  The relative risk of stroke with combined estrogen and progestrogen
therapy was 0.88 to 1.0, depending on duration of therapy. Roche and Vessey (1990)
assumed that the effect of HRT on stroke was the same as that for heart disease: a 50% or
25% risk reduction after 10 years of ERT or HRT, respectively.  The benefits of both
therapies were assumed to be halved at 5 years duration of treatment, and to continue
after HRT cessation for a period equal to the duration of treatment.
Gallbladder disease.  Earlier pharmacoeconomic studies also examined the effect
of HRT on the increased risk of gallbladder disease.  A relative risk of 2.5 after 5 years of
therapy was used (Weinstein, 1980; Weinstein & Schiff, 1983).  However, most
pharmacoeconomic studies later did not include this effect in the analyses.
The use of HRT also increases the risk of vaginal bleeding, breast pain, venous
thrombosis, and other side effects.  Unscheduled uterine bleeding is the most common
adverse events and may lead to a dilatation and curettage (Cheung & Wren, 1992).  The




therapy, developed patients’ tolerance, and/or adjusted dosages.  Therefore, different
adverse event rates were used for the first year and subsequent years of therapy in some
studies (Rosner et al., 1998).  Other studies also used a cumulative rate of the side effect
for the treatment duration (Cheung & Wren, 1992).  Although most adverse events of
HRT will not incur extra health care costs and are not considered by most
pahramcoeconomic studies in their calculation of cost-effectiveness ratios, these side
effects do decrease patients’ quality of life and tolerance of the therapy.  The impact of
adverse events on the potential costs and effectiveness of HRT may be reflected by the
reduced treatment compliance and utility (effectiveness).  For example, in a cost-
effectiveness study conducted by Rosner (1998), only 21.5% of the patients were
believed to be willing to continue HRT for 3 years based on the results from a previous
study (Rosner et al., 1998; Ettinger et al., 19982).  Another study calculating health care
cost-savings of HRT used a WTC (willingness-to-continue) rate of 90% for high-, 70%
for mid-, and 0% for low-risk group (Clark and Schuttinga, 1992).  This study also found
that the savings were sensitive to compliance, especially to the compliance of the high-
risk group.  Each increase of 10% in compliance resulted in increased net savings of $0.4
million.  The breakeven points of cost savings balance could be achieved with a
compliance of approximately 70% and 40%, for the high- and mid-risk groups,
respectively.  Therefore, it is very important to consider patients’ compliance in
pharmacoeconomic studies. Studies that ignore the patients’ compliance or the impact of





There are several large, prospective, randomized, controlled clinical trials that
have provided valuable efficacy and safety data for alendronate in the prevention and
treatment of osteoporosis and fractures (e.g., Cummings et al., 1998; Chesnut et al., 1995;
Liberman et al., 1995).  These trials have demonstrated approximately a 50% reduction in
vertebral, hip, and wrist fractures.  The risk reduction rate was consistent across each of
the studies and at each major site of osteoporotic fracture including the hip and wrist.  For
example, in the Clinical Fracture Study of the Fracture Intervention Trial (FIT), treatment
with alendronate for a mean duration of 4.25 years was associated with a 50% and 56%
reduction in the incidence of first vertebral fracture and hip fracture, respectively, among
postmenopausal and osteoporotic women. (Cummings et al., 1998).  In another study
conducted by Liberman et al., treatment with alendronate overall (both 5mg/day
and10mg/day group) was associated with a 48% risk reduction of new vertebral fractures
among postmenopausal and osteoporotic women, although the 5-mg dose was found less
effective than the 10-mg dose.
On the other hand, only few pharmacoeconomic studies have been done that
consider both the effectiveness and costs as well as compare alendronate with other
alternatives (Rosner et al., 1998).  Most clinical trial studies compared alendronate with
“no therapy”, HRT, etidronate, or calcium, but no economic evaluation was conducted.
However, alendronate is commonly believed as an effective drug in reducing the
likelihood of fractures but at a cost that may be prohibitive to many patients (Ullom-




Rosner (1998) compared four treatment strategies in the prevention of vertebral
fractures in postmenopausal and osteoporotic women: two bisphosphonates (alendronate
or intermittent cyclic etidronate plus calcium), HRT, and calcium therapy for three years.
The baseline vertebral fracture risk (in “no therapy group”) was assumed to be 390.3
vertebral fractures per 1,000 patient years.  The relative risk of a vertebral fracture for
alendronate compared with no therapy over 3 years was assumed to be 0.37 (risk
reduction rate of 63%).
The major adverse event associated with alendronate use is upper gastrointestinal
disorders.  The incidence rates of GI adverse events reported in the literature are
inconsistent.  As mentioned before, the incidence rates widely ranged from non-
significant to as high as 32.8%. The cost-effectiveness study conducted by Rosner (1998)
used a rate of 10.3 and 4.1 for minor GI for the first year and the subsequent second and
third year of treatment, respectively.  A rate of 1.5 and 0 for esophagitis/esophagael ulcer
for the first year and the subsequent second and third year of treatment, respectively.
However, they did not mention whether or how the treatment costs were included in the
calculation of cost-effectiveness ratios.  The compliance rate used in this study was
estimated based on a post-marketing surveillance study of etidronate since no WTC
values outside of clinical trials could be found for alendronate (Procter & Gamble
Pharmaceuticals, 1996).  They assumed that only 24% of women were willing to





To date no pharmacoeconomic studies have been published that evaluate
effectiveness and costs of raloxifene compared with its alternatives such as alendronate
and HRT. Like alendronate, long-term effects of raloxifene are still unclear.  The effects
of raloxifene on other disease conditions such as breast cancer and heart disease are also
unknown.  This makes it difficult to evaluate the cost-effectiveness considering both
short-term and long-term effects, and both benefits and risks on multiple organ systems.
There is a great need of research to explore the clinical, economic, and humanistic effects
of raloxifene in the prevention and treatment of osteoporosis.
Challenges to Assessing Cost-Effectiveness of the Three Drug Therapies
The accuracy and validity of pharmacoeconomic evaluations are markedly
affected by the various assumptions made in the analyses on risks and benefits,
compliance levels, and utility values.  Many of the assumptions concerning risks and
benefits made in the pharmacoeconomic studies have not been supported by current
clinical data.  For example, evidence is still lacking on the optimal duration of therapy,
the change in relative risk after discontinuation of therapy, the risk reduction for
cardiovascular/cerebrovascular diseases, and the risk increase for breast cancer and some
long-term adverse events.  Another challenge is how to estimate patients’ compliance and
utility values.  Compliance levels are usually overestimated and utility values
underestimated in pharmacoeconomic analyses (Whittington & Faulds, 1994).  Future
pharmacoeconomic studies should estimate these values based on the most updated and




Controversial areas surrounding the assessment of treatment effectiveness also
include the choice of appropriate health outcomes or end points for evaluation (i.e., BMD
v.s. fracture averted v.s. quality-adjusted-life years gained), the skeletal sites that should
be evaluated (i.e., vertebral v.s. non-vertebral fractures), and the duration of treatment
effects.  Many agents can maintain and may increase BMD level, but it is not clear
whether such changes always relate to reduced fracture risk.  Therefore, many researchers
have proposed fractures as the preferred end point in both clinical trials and
pharmacoeconomic studies.  However, nonosteoporotic fractures have seldom been
controlled for the evaluation.  Another question is what types of fractures should be
considered. Most published pharmacoeconomic studies are restricted to hip fractures.
Vertebral fractures have rarely been included.  Although hip fractures have deep impact
on economics and patients’ quality of life, risk reduction in all types of fractures risk
should be considered for an accurate assessment of drug therapies.
The clinical and economic evaluation of the three preventive drug therapies is also
related to the baseline fracture risk (i.e., population risk without any study treatment).
The cost-effectiveness of an intervention varies among women at different risk levels
(Seeman eta l., 1995; Clark and Schuttinga, 1992; Kanis, 1984).  For HRT and raloxifene
that may provide benefits on multiple organ systems, the risk of diseases other than
osteoporosis may also affect the effectiveness results.  In most clinical and
pharmacoeconomic studies, however, the subjects are women at the great risk for fracture
(e.g., postmenopausal women with osteoporosis or with a previous fracture).  Therefore,




compare favorably with other uses of health care resources only in selected high-risk
groups.  More pharmacoeconomic studies need to be done associating cost-effectiveness
evaluations of preventive drug therapies with the study population risk levels.  A valid
risk assessment model is needed to evaluate the risk distribution for specific populations.
Assumptions and baseline risk rates varied considerably in pharmacoeconomic
evaluations.  This makes it difficult to compare the results between studies.  However,
despite all of these challenges, literature-based pharmacoeconomic evaluation models are
still useful in helping researchers and clinicians obtain a better understanding of the role
of each competing drug therapy, and in developing health policy before clinical trials are
completed.  With the progress of the ongoing studies, the updated data can be used to
validate and improve the existing evaluation models.
Risk Prediction for Osteoporotic Fractures
Prevention strategies are essential for reducing the incidence of osteoporosis and
related fractures.  Effective prevention requires identification of those at risk prior to
fracture. Three common methods used to predict fracture risk independently or together
are: (1) techniques to measure bone mass; (2) biochemical tests; (3) clinical risk factor
analysis (Council of the National Osteoporosis Foundation, 1996).  Although no single
clinical finding or test result can quantify risk of postmenopausal osteoporosis and





Bone mass (or BMD) and risk of osteoporotic fracture.   Evidence of increased
bone turnover from serum and urine markers and low bone mass as determined by
densitometric techniques are highly predictive for osteoporosis and fracture risk.  The
greater the rate of bone loss or the lower the bone mass (especially the peak bone mass
which usually achieved in the 20s to 30s of age), the greater the risk of osteoporosis and
fracture (Scientific Advisory Board, 1996).  Although osteoporosis may be
heterogeneous, and although bone quality may also contribute to fracture susceptibility,
BMD is usually used as an indicator of fracture risk. Both longitudinal and cross-
sectional studies have shown a strong relationship between low BMD and fracture
occurrence (Ross, 1999; Ross et al., 1990).  With each decline in bone mass of one
standard deviation from the young adult mean fracture risk doubles.  For example,
osteopenia (BMD level between 1 and 2.5 SDs below the mean for young adults) carries
a 2-fold increase in fracture risk compared with normal (BMD greater than 1 SD below
the mean for young adult). And osteoporosis (BMD more than 2.5 SDs below the mean
for young adults) carries a 4- to 5- fold increase in risk for fracture.  The presence of
previous osteoporotic fractures increases the risk of further fractures 20-fold (Scientific
Advisory Board, 1996).
Other Risk factors of osteoporotic fracture. Risk factors other than BMD may
also be used to estimate fracture risk.  Age is one of the most important predictors in
calculations of fracture probability. Risk factors such as Caucasian or Asian descent,
slender body build, family history, smoking, alcohol abuse, low calcium diet, and




falls and/or potential fall-related risk factors (e.g., physical capacity, neuromuscular
function, mobility, visual function, and use of medications) should also be included as
risk predictors for fractures (Lips, 1997; Ross, 1996; Dargent-Molina et al., 1996).
In general, the more risk factors a woman has, the higher the likelihood that she
has or will develop osteoporosis/fracture.  However, the effects of many risk factors have
not been quantified, making it difficult to determine the importance of each risk factor
and design most effective strategy to the target population.
In order to examine the association between various risk factors and the
occurrence of osteoporotic fractures, estimate fracture risk in a population, and develop
effective prevention strategies, a valid risk assessment model is needed.  It will enable
clinician to project an individual’s lifetime fracture risk and therefore conduct preventive
interventions.  A few models have been developed to predict fracture risk through BMD
and age (Ross et al., 19881; Carroll et al., 1997; Hui et al., 1988; Black et al., 1992;
Kroger et al., 1995). Models that directly predict an individual’s future risk of fractures
from other risk factors mentioned above are scarce due to the difficulty of accurately
predicting BMD level and fracture risk from risk factors for bone loss.  BMD obtained
from dual energy X-ray absorptiometry  (DXA) scanning is so far the best predictor of
osteoporosis and osteoporotic fracture. Measuring BMD directly is always recommended
whenever possible (Ross, 1996).
On the other hand, measuring BMD to diagnose osteoporosis and predict future
fracture may not be cost-effective for the whole population (mass screening), and in most




and fracture risk has been considered to be inadequate for precise diagnostic purpose, risk
factors other than low BMD, may be helpful as a population-based screening tool to
estimate the risk prevalence and determine who actually needs BMD assessment. There is
a great need for establishing a population-based screening model using risk indicators for
which data could be easily obtained.
Carroll et al. (1997) proposed a predictor equation for bone loss using BMD, age,
years since menopause, and weight. The population to which this prediction model
applied was normal and osteoporotic women aged 40 - 80 years.  When a spinal BMD
cutoff value of 0.86 gm/cm2 was used, their model had a sensitivity of 90% and a
specificity of 60% for detecting women with vertebral fractures and was therefore
defined as a high-risk BMD.  Then they derived prediction curves using the prediction
model they established to forecast the age at which that individual would reach the
above-defined high-risk BMD.  The person’s expected number of remaining life-years at
high risk for fractures thus could be estimated.  This study provided a conceptual
framework for constructing a risk assessment model for osteoporosis and related fractures
through changes in bone loss rates.  The prediction model they established had high
sensitivity and fair specificity.  However, the model only predicts high risk BMD, no
direct connection between the risk factors (e.g., age, years since menopause, weight,
family history, body mass, and calcium intake) and the clinical endpoint – fracture, was
attempt to be made in this study.
Another study examined the predictive accuracy of objectively measured, self-




et al., 2000). More than one thousand postmenopausal women aged 50-80 were asked for
their present height and their weight at age 20-30 years.  Subsequently their actual
weight, height and BMD of the lumbar spine were measured. Predictive values (PV) and
odds ratios were used to evaluate the prediction accuracies of the three factors. The study
found the objective BMI test detected 50% of the osteoporotic patients.  And
interestingly, the self-reported BMI test and the recalled BMI test had higher detection
rates: 55% and 69%, respectively.  The study presents a possibility that detecting
osteoporotic or low BMD patients by just measuring/asking a woman’s weight and
height.  However, due to the low sensitivity of the prediction model, the authors
suggested that age and BMI are not adequate when used for screening the population for
osteoporosis.
Studies using risk factors to predict fractures are rare and the results are far away
from satisfactory.  Torgerson et al. (1996) conducted a prospective cohort study to build a
fracture risk assessment model from BMD and other risk factors among perimenopausal
women.  Women aged 47-51 years were followed up for two years to assess the incidence
of any self-reported fractures.  The study revealed that the odds ratio (OR) for having at
least one fracture during a 2-year perimenopausal period was 1.6 for every standard
deviation (SD) reduction in BMD at the spine.  The fracture risk of women who were
postmenopausal, or having a hysterectomy or prior history of fracture, was approximately
twice than that of women without corresponding experience.  A family history of fracture
also significantly increased the fracture risk (OR = 3.7).  The researchers concluded that




Furthermore, they found that BMD at the hip and spine could also predict nonhip and
nonspine perimenoausal fractures. However, no more information regarding model
coefficients such as sensitivity and specificity was reported in their study. Another major
limitation of this study is that the participating women were those who underwent a bone
density measurement 2 years previously.  This may cause a selection bias and greatly
influence the interpretation of the results.  The findings of this study may only applicable
among high-risk women.  Finally, the study was limited to a 2-year perimenoausal
period, further follow-up is required to assess the predictive performance of BMD
measurements and other risk factors for the long-term fracture risk.
Margolis et al. (2000) examined how body size influenced the risk of clinical
fractures in older women (age >=65 years).  Weight, weight change since 25 years of age,
body mass index, lean body mass and percent body fat, and nonspine fractures were
measured during an average 6.4 years of follow-up period.  The study found the OR was
from 2-2.4 for each factor when examined separately.  Adjustment for total-hip BMD
eliminated the elevated risk.  Therefore, the study concluded that total body weight, as a
factor can be easily measured, is useful in the risk assessment of clinical nonspine
fractures (hip, pelvis, and rib fractures) when bone density measurements are not
available.  The results of this study also suggest that measurements of other attributes of
body size or composition do not provide clinically relevant information about risk for hip,
pelvis, and rib fracture beyond that provided by weight.  Finally, measurement of body
size or body composition contributes little to the clinical risk assessment for wrist,




calcium intake and family history.  Also, spine fractures, a common type of fracture in
women with osteoporosis were not examined.
Different techniques have been used to build risk assessment model.  Multi-
logistic regression is the most commonly used tool to create the prediction model.
Artificial Neural Network (ANN), a non-linear computational model has also been used
in clinical diagnosis and classification.  A study showed that the two techniques produce
similar sensitivity, specificity, and accuracy in the prediction (Ongphiphadhanakul,
1997).  Therefore, the unsatisfactory performance of the prediction models in the
prediction of low BMD may be due to the lack of adequate association between BMD
and the risk factors selected rather than the nature of the computational models.
In conclusion, osteoporosis may be detected before signs and symptoms occur
through BMD tests and/or risk factor assessment. The challenge in the literature of this
area is to obtain a risk function with high accuracy that predicts fracture risk based on
major risk factors.  Although there are a few such equations available (e.g., Tosteson et
al., 1990; Melton 1988; Ross et al., 19881), questions remain about the validity of these




West Virginia Medicaid Program
Medicaid is the joint federal and state funded health insurance program for the
indigent, disabled, and members of families with dependent children (NPC, 1999).  It is a
federal-state partnership, with state laws and regulations, federally approved state
waivers, and approved state plans.  The federal government provides fiscal assistance and
establishes regulations, guidelines, and policies that provide a framework within which
the state governments operate their individual Medicaid programs.  State governments are
responsible for administration of the Medicaid program such as determination of
eligibility and services provided, claims processing, and monitoring (NPC, 1999).
Demographics of WV Medicaid Women Population
Reflecting the gender, age, and race constitutions of the state, elderly white
women compose a larger proportion of the total Medicaid eligibles population, compared
to Medicaid programs in other states.  The total number of female eligibles is 174,244
(58%) in 2000.  Among these women, more than 92% are white.  Approximately 26% of
white women are with age of 45 years or older.  More specifically, the number of white
female eligibles is 20,422 in the 45-64 age group, 8,180 in the 65-74 age group, 7,526 in
the 75-84 age group, and 5,858 in the 85+ age group (National Pharmaceutical Council,
2000).
West Virginia Medicaid Spending Growth
Medicaid programs nationwide have been plagued by escalating health care costs.
Medicaid program costs have grown from $5.3 billion in 1970 to $193.4 billion by the




pharmaceuticals costs only account for a small proportion of total health care costs
compared to hospital care, physician services, and long-term care services costs, it is the
fastest growing component of the health care budget.   Prescription drug costs in
Medicaid programs have grown from $400 million in 1970 to $19.7 billion in 2000, and
is expected to grow to $44.8 billion by 2007 (Madhavan, 2000).
The national trend in healthcare costs is also evident in WV Medicaid program.
Based on a recent review of WV Medicaid Program utilization and costs, the Medicaid
drug expenditures per recipient increased dramatically, from less than $100 in 1982 to
over $700 in 2000 (Madhavan, 2000).  The percentage of drug expenditures in total
Medicaid expenditures also increased from 7% in 1982 to more than 15% in 1999. The
possible reasons for the significant growth in health care costs, especially pharmaceutical
costs, have been widely discussed.  For WV Medicaid program, a rapid growth in the
number of recipients and introductions of new drugs with high price can contribute
together to the increase in pharmaceutical costs.  WV has high poverty rate and
unemployment rate in its population.  The Medicaid recipient population of prescription
drugs had been doubled from 112,497 in 1982 to 274,214 in 1999 (Madhavan, 2000).
Meanwhile, the R&D costs had increased dramatically from $2 billion in 1980 to about
$24 billion in 1999. New drugs are introduced at much higher prices that they were about
several years ago.
The recent introduction of new chemo-preventive agents brings about a lot of
concerns on the continuously increased drug budgets.  Although most prevention




technologies applied in the preventive treatment may add considerable present dollars
and offset the possible benefits in the future.  Under a cost-sensitive environment, it is
extremely important for WV Medicaid policy maker to decide the most appropriate
treatment compared to available alternatives, especially for preventive treatments, of






The objectives of this study were:  (1) to develop a decision model that compares
the cost-effectiveness of three preventive drug therapies for osteoporotic fractures in
postmenopausal women; (2) to assess the relationship between various risk factors and
the occurrence of first osteoporotic fracture in the study population; (3) to determine the
distribution of women on the basis of their probabilities for osteoporotic fractures in the
study population; and (4) to examine the expected cost-effectiveness of the three drug
therapies based on the fracture risk distribution in the study population.  The study
population consists of postmenopausal women who are enrolled in WV Medicaid and
aged 45 to 85 years.  To accomplish these study objectives, different methods were
required.  Hence, the study was completed in three phases.
Phase I.  Model Development
Phase I constructed a decision model to identify and examine the relevant costs
and consequences of HRT, alendronate, and raloxifene therapies for preventing
osteoporotic fractures. The treatment costs and risk reduction rates of the three alternative
drug interventions were identified. A hypothetical cohort of white women aged 45-85
years, postmenopausal, and without past incidence of osteoporotic fractures was studied
in the model. The women in the cohort were treated with one of three treatment




to coincide with the time period for which relevant clinical data from studies were
available  (Eli Lilly and Company, 1997; Carroll et al., 1997; Meunier et al., 1999;
Rosner et al., 1998).
Data Collection
Extensive literature review was conducted to obtain the relevant information.
Studies that reported the direct relationship between the three drug therapies and the
observed risk of fracture were identified by a MEDLINE search.  Studies that reported
the association between the drug therapies and BMD were not used, because BMD is an
intermediary end point in terms of the primary outcome of interest – osteoporotic
fractures.
 Medicaid claims data (1999) were used to estimate the treatment costs.  A Delphi
panel of experts was also used to assess variables not available in literature or in the
Medicaid database.  The participating experts included a faculty in health services
research from the School of Pharmacy, an internist, an endocrinologist, and a clinical
pharmacist from West Virginia University Hospitals, and an internist from Johns Hopkins
Hospital in Baltimore, MD.  Experts’ suggestions and opinions were collected in an
iterative manners: first by an expert panel survey, then in a panel meeting, and finally by
follow-up telephone calls.  The expert panel questionnaire asked the experts about drug
dosage forms and related patient distributions, drug adverse events’ probability and
recommended treatment, type of monitoring necessary for each therapy, major






Treatment effectiveness was measured in terms of the number of fractures averted
by each drug therapy.  Resource costs included the medication costs (CMedication) of each
treatment strategy, monitoring costs (CMonitoring), and the cost of the adverse effects (CAE).
The expected economic savings associated with the additional benefits (other than
preventing osteoporotic fractures) of each treatment, such as the risk reduction effects on
cardiovascular disease, breast cancer, and hyperlipidemia, were not included in the model
at this time since it is difficult to evaluate these effects from a short-term intervention and
there are many uncertainties in this area.  The cost-effectiveness ratios were thus defined
as:
C/E = (CMedication + CMonitoring + CAE)/(Number of Fractures Averted)
The treatment duration was three years.  No cessation effect was considered for
all of the three therapies since a continuous, long-term therapy (> 3 years) was highly
recommended in the prevention of osteoporotic fractures.  Furthermore, the willingness
of the woman to continue each therapy for three years (i.e., the probability of taking each
drug for three years) was incorporated in the model. A cumulative discontinuation rate





Figure 3-1. The Structure of the Proposed Decision Tree.
*  The subsequent branches will be the same as those for alendronate.
Intervention Strategies and Effectiveness Parameter
The choice of three drug intervention strategies - HRT, alendronate, and
raloxifene, was based on published guidelines and clinical practice.  Doses, formulations,
and patient distributions for the three drug therapies were determined to calculate
appropriate treatment costs.  The effectiveness variable was the number of osteoporotic
fractures averted by each drug therapy.  It was calculated as: (I0 – It) or (I0 * R), in which
I0 was the fracture incidence (risk) of women not on any study treatments; It was the
fracture incidence (risk) of treatment group; R was the risk reduction rate by the
treatment.
Based on the information available from clinical trial data, risk of any type of
clinical fractures (more commonly hip and vertebra fractures, and less frequently wrist
fractures) was considered.  The two major fractures reported in literature are hip fracture

















which is the most costly and serious consequence of osteoporosis, and vertebral fracture
which is the most common osteoporotic fracture.  The clinical trial did not examine the
effects of raloxifene on wrist fracture risk (Ettinger et al., 1999).  The positive effect of
alendronate on the risk of wrist is not definitive either.  However, from the Medicaid
point of view, the direct medical expenditures caused by wrist fracture is minimal. The
effect of including wrist fractures had been shown to be negligible in previous studies
(Johannesson & Jönsson, 1993).  For simplicity, risk reduction rates and treatment
effectiveness (number of fracture averted) were not examined by different types of
fractures.  Nevertheless, the model developed in this study can be always applied to a
specific type of fracture once the data on risk reduction rate for different types of
fractures becomes available.
Fracture risk reduction rate associated with each therapy was obtained from
published literature.  When different published rates exist, the approximately median rate
was chosen and subject to sensitivity analysis.
The incidence of fracture in the untreated women was viewed as the background
risk and estimated from of West Virginia Medicaid women who do not have osteoporotic
fracture experience, and have not taken any of the 3 preventive drug therapies.  The risk
distribution for the first osteoporotic fracture in this population is investigated in Phase II.
Cost Parameters   
The direct costs of interventions included the average drug costs and monitoring




was that of third-party payers. All costs were calculated in 1999 prices (constant dollar
method).
The average annual medication costs were estimated from the 1999 WV
Medicaid reimbursement rates. The brand name drugs were used for extracting average
wholesale price (AWP) information from the database. For estrogen and progesterone,
selected common brand name drugs were used to estimate the drug costs (Appendix A).
The average of the highest and lowest prices was used as the medication AWP. The WV
Medicaid medication reimbursement formula (AWP * 88% + $3.90) per prescription was
then used to calculate the actual monthly and yearly Medicaid drug payments.
The cost of physician visits, endometrial monitoring (biopsy or aspiration
curettage) for HRT and raloxifene and the cost of BMD tests for all three therapies were
also added to the treatment costs. The number of follow-up physician visits was estimated
based on literature (Johannesson & Jönsson, 1993) and expert panel suggestion.
Conservatively, three follow-up physician visits were needed per year for all three drug
therapies. Also, based on the literature (Weinstein and Schiff, 1983; Johannesson &
Jönsson, 1993; Whittington & Faulds, 1994) and experts’ suggestion, we estimated that
HRT would result in 1.5 extra mammography during the three-year study period
compared to the “no therapy” group (increasing from biannual test to yearly test). In
addition, 1.5 extra biopsy (a biannual examination) would be needed for HRT and
raloxifene, and 2 extra BMD tests for all three therapies during the three-year study
period.  The CPT codes were used to extract the procedure cost based on 1999 WV




Finally, the medical costs associated with adverse events of interventions were
included, if there were any.  Both clinical trial data and expert panel suggestions were
used to identify these adverse effects and their probabilities as well as the related
treatment procedures.  Adverse events were grouped into "baskets" of symptoms based
on underlying common body system affected, resource use, and cause.  For example, the
gastrointestinal basket included nausea, diarrhea, heartburn, etc.  This will avoid double-
counting of physician visits that may occur for a group of symptoms rather than for each
individual symptom.  Only the side effects that could incur extra health care costs were
examined in the study.  The costs of OTC drugs that may have been used to treat side
effects were also not included in the analysis.  Since the study period is only three years,
the long-term adverse effects were not considered.
The cumulative rates of the adverse events during the three-year treatment period
were used to determine the probability of the woman experiencing each adverse event
(AE).  Then, the appropriate treatment cost was applied based on the treatment needed.
According to the literature and experts’ opinion, the major adverse events that need
further treatment include unscheduled bleeding and DVT/leg pain for HRT, severe GI
disorders for alendronate, and DVT/leg pain for raloxifene.  Again, the CPT codes of the
corresponding treatment procedures such as vaginal ultrasound, biopsy, and diagnostic
ultrasound were used to obtain the unit cost information from 1999 WV Medicaid data
(Appendix B).  The costs for treating GI disorders were estimated from the literature (see




The monitoring costs and AE related treatment costs during the three-year
treatment period were divided by three to obtain an average annual costs.  Therefore, the
total annual treatment costs would be the annual medication costs plus the annual
monitoring and AE related costs.  These total annual costs (assumed occurred at the end
of each year) were then converted to the present value (the value same as that in the first
year) using a discount rate of 3%.  The range of the discount rate tested in sensitivity
analysis was from 2% to 5%.  The discounting formula was: NPV = U (P/U,i,n), where U
is the annual costs, “(P/U,i,n)” is the discount uniform series factor, i is the discount rate,
n is the number of years (Au & Au, 1992).
Treatment Discontinuation Rate
Hormone Replacement Therapy.  Based on the literature (see Chapter 2: Ettinger
et al., 19982; Clarkand Schuttinga, 1992; Rosner et al., 1998), a cumulative willingness-
to-continue (WTC) rate of 25% for the 3-year treatment was used in the model for HRT
(i.e., an average annual discontinuation rate of 25% and a cumulative discontinuation rate
of 75% were assumed). The range of cumulative WTC rate tested in the sensitivity
analysis was from 20% to 30%.
Alendronate Therapy.  Information regarding patients’ compliance with
alendronate was inconsistent. The discontinuation rate of a 3-year therapy varied greatly
from 7.5% to 76% (see Chapter 2: Merck & Co., Inc., 1995; Rosner et al., 1998; Ettinger
et al., 19981). Since this study was a population-based study, data from general practice
settings rather than clinical trials would be preferred.  Therefore, a discontinuation rate of




hypothetical woman would have 40% chance to complete the 3-year treatment).  Due to
the great inconsistency in the literature, the range of 28% to 52% (base value + 30%)
WTC rate was tested in the sensitivity analysis.
Raloxifene.  Since there are no studies of treatment compliance with raloxifene in
general practice, an assumption was made prudently based on the existing clinical trial
data and recommendations in the literature (see Chapter2).  There are many factors that
may influence women’s compliance with drug therapies such as side effects and
treatment costs.  Compared to HRT, raloxifene is unlikely to increase the risk of breast
cancer, endometrial cancer, and vaginal bleeding.  Thus, it seems safer for many women
with a fear of these diseases and side effects.  Other adverse events of raloxifene are
similar to those of HRT.  Although the extent to which how other factors such as drug
costs affect compliance with raloxifene was not clear, we estimated that the
discontinuation rate of raloxifene was much less than that of HRT, which is one of the
most important advantages of raloxifene over HRT reported in research and practice.
The hypothetical woman in the model will be assumed to have a relatively high WTC
rate of 70%.  Conservatively, the average annual discontinuation rate of raloxifene was
10%.  Due to the lack of knowledge about patients’ compliance with raloxifene, the range
of cumulative WTC rate tested in the sensitivity analysis was from 49% to 91% (base
value + 30%).
How to model the cost and effectiveness for the non-compliant group is always a
question.  Few research studies have incorporated treatment compliance into a decision




effectiveness.   For preventing osteoporosis and related fractures, long-term treatment is
necessary.  It has been suggested that all three drug therapies should be continually used
for several years to demonstrate their positive effects on fracture risk.  In this short-term
study, both treatment effectiveness (risk reduction rate) and costs were assumed to occur
in a linear way over the 3-year study period (Rosner et al., 1998).
Main Assumptions
The key assumptions in the construction of this model are:
• Because of the difficulty in differentiating osteoporotic fractures from fractures
due to other causes, we assumed that women over 45 years of age and having a
vertebral, wrist, or hip fracture, had osteoporosis and their fractures were
osteoporotic fractures.
• Fracture risk reduction rates were obtained from published literature. When
different rates were reported, the median value was chosen given the three-year
study period and subject to sensitivity analysis over its reported range.
• Probabilities of adverse events were the average incidence rate for all major
adverse event baskets. The effects of minor or rare adverse events were assumed
negligible for all three therapies. A woman with adverse events but no additional
treatment costs needed (e.g., breast tenderness, or minor GI with only over the
counter drugs needed) would be included in the “No AE” group.  For HRT, since
the chance of having DVT is very small (< 1%), having both DVT and vaginal
bleeding was assumed to be a very rare situation and not considered in this model.




diagnostic ultrasound due to the leg pain and if the ultrasound results are positive,
further anticoagulant treatment  (heparin + warfarin) may be needed. The costs of
anticoagulant therapy are minimal due to the small probability.  Therefore, only
the ultrasound costs were included and the further anticoagulant treatment costs
were ignored.
• The discontinuation rates were assumed to be same for women with and without
adverse events since the overall cumulative rates for the 3-year treatment period
were used.
• No study has been done in modeling the decreased effects of the three therapies
after the termination of treatment (Jönsson, 1998).  In this study, the treatment
effects (risk reduction rate) and costs were assumed to occur in a linear way over
the 3-year period.  The average treatment discontinuation time was assumed to
occur at the end of each year.  The effect of the medications was assumed to begin
immediately on start of therapy and to cease immediately on discontinuation (i.e.,
no delayed effects).  Therefore, the treatment costs for the dropout women can be
calculated based on the average annual treatment costs and the retention rates by
the end of each year.  The treatment effects (risk reduction rates) for the dropout
women were assumed to be approximately 50% of the full effects (the average of
the best effects and the least effects).
• In practice, women who use each drug therapy may also use vitamin D




HRT, alendronate, and raloxifene on health outcomes are assumed to be same for
all three interventions.
• Treatment and prevention of osteoporosis induced by chronic use of high-dose
corticosteroids are not examined in this study.
• The effectiveness of each therapy is not discounted in this study.  Discounting
health benefits through long-term preventive measures is controversial, because of
the potential to excessively devalue downstream benefits (Fuchs & Zeckhauser,
1987; Lipscomb et al., 1996; Jillman & Kim, 1995).  Whereas some researchers
suggest that the same discount rate should be applied to both healthcare costs and
health benefits, others argue that health benefits should not be discounted.  The
costs are discounted at 3% per year. This relatively low discount rate (comparing
to 5% which is commonly used in the literature) is used because long-term
treatment with three preventive drugs are desired and the low discount rate can
avoid underestimating long-term benefits (Fuchs & Zeckhauser, 1987; Lipscomb
et al., 1996; Jillman & Kim, 1995).  Although in this model, only 3-year treatment
duration is used due to the limited clinical trial information, the model is expected
to incorporate long-term treatment costs and effects whenever it is possible.
Phase II.  Analysis of Background Risk
In the hypothetical model built in Phase I, one key variable - I0, which stands for
the fracture risk in the women without any treatments, needs to be defined to calculate the




background fracture risk which varies in different populations.  To apply the decision
analytic model and calculate cost-effectiveness ratio to the study population, data are
needed on the disease risk without the interventions.  A risk assessment study of
osteoporotic fractures needs to be conducted in the study population. The objective of
Phase II is therefore to build a prediction model and estimate the distribution of women
with different background risks for osteoporotic fractures in the study population.  The
prediction model is based on those widely reported risk factors such as age, family
history, and body mass index (see chapter 2).
Sample Selection
A retrospective, case-control study design was used in Phase II of the study.  The
WV Medicaid data for 1998 and 1999 were used to extract information for women who
were aged 45 - 85 years and had claims with a date of service between January 1, 1998 to
December 31, 1999.  The number of cases in women between 45 and 64 years of age
were expected to be small in the WV Medicaid data.  Also, diagnosis information was not
available for all women over 65 years of age in the Medicaid population since Medicare
is the primary source of coverage for those 65 years or older.  Therefore, two approaches
were utilized for the selection of cases and controls for each age group (Figure 3-2).  The
approximate number of woman recipients in the two age groups was close: 21,000 in 45-
64 age group v.s. 19,000 in 65-85 age group in 1999 (WV Medicaid Internal Report, as of





Figure 3-2. Data extraction for the two age groups.
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Sample selection among women aged 45 to 64: Cases were all women with
diagnosed hip, vertebral, and/or wrist fractures between January 1, 1998 to December 31,
1999, a two-year period deemed sufficient to generate adequate number of cases in this
younger age group.  ICD-9 codes of the relevant diagnoses were used to identify and
select case samples (Appendix D).  The sample size goal was approximately 500 for
cases.  Once the cases had been identified, controls would be randomly selected from the
remaining 45 to 64 age group using a 2:1 ratio of controls to cases.  The sample size goal
was approximately 1,000 for women who would serve as controls.
Sample selection among women aged 65 to 85: The potential cases were identified
on the basis of prescription drugs used for treating osteoporotic fractures such as
raloxifene, alendronate, and calcitonin.  Potential controls for this older group were
women randomly selected from those who were not on any of the above medications.
Note, the eventual number of cases and controls for both age groups might change
later based on self-reported information from the survey.  Women who reported never
having a fracture in the case groups and women who reported having fracture experience
after 45 year-old in the control groups would be excluded from the analysis.
Inclusion and Exclusion Criteria: Generally, women were eligible for this study
only if they were aged 45 to 85 years and experienced menopause. Also, there were some
specific selection criteria for cases and controls. For cases, the screening question was
“Have you ever had an osteoporotic fracture?” Women with an answer of “No” would be
excluded. For control group, there were two screening questions. One was “Have you




from the control group. The second screening question asked the women whether they
had ever taken any of the three drug therapies for bone weakness or for menopausal
symptoms. Women who checked any one of the three treatments would be excluded from
the control group.
Sample Size Estimation
A multiple logistic regression model was used to establish the equation model for
fracture risk assessment.  Under the assumptions that α is 0.05 (i.e., the probability of
type I error is 5%), β is 0.2 (i.e., 80% detection power), an average probability of
exposure in controls is 10%, odds ratio of exposures between cases and controls is 2, and
the ratio of control to case is 2, the estimated case sample size would be 205 for
uncorrected chi-squared test and 223 for Fisher’s exact test or corrected chi-squared tests
(Strom 2000; Schlesselman 1982; Casagrande et al., 1978; Fleiss 1981).
Based on the response rates of previous studies in the WV Medicaid population
(Ambegaonkar et al., 1997; Al-Momani et al., 1999), the response rate for this study was
expected to be about 20% - 30%.   Assuming a response rate of 20%, the 3,000 surveys
would generate approximately 600 responses (200 cases and 400 controls). Therefore, the
sample size of 600, if achieved, would be adequate to run the analysis for the prediction
model.
Data Collection
Data were collected over a two-month period from October to November 2000.
The IRB approved final surveys were accompanied by a cover letter from the Medicaid




the questionnaire took place after 3 weeks to non-respondents of the first mailing.  A
sample of non-respondents to both mailings (cases: 50; controls: 100) was sent an
abbreviated survey to determine critical demographic and study variables and reasons for
nonparticipation to assess non-response bias.
Instrument Construction
A self-administered questionnaire was mailed to the selected sample.  The final versions
of the survey and cover letters are presented in Appendix E.  The questionnaire has three parts:
(1) Demographics, (2) Health Profile, and (3) Risk Assessment.  The first two parts asked
women about their demographic characteristics (e.g., age and education level), general health,
and co-morbidity.  As already mentioned, screening questions with regarding the osteoporotic
fracture and menopause status were also included.   In addition, the use of medications that may
affect bones were assessed by asking women whether they had been taking steroids, thyroid
medications, diuretics, sedatives, and antiseizure drugs.  The commonly used brand names of
these medications were listed to help women answer this question.
The Risk Assessment part measures several well-established risk factors for
osteoporosis and osteoporotic fractures among the sample women.  These factors
included: a) age, b) age at menopause, c) current body mass index (BMI), d) peak BMI,
e) family history, f) calcium and vitamin D intake, g) smoking, h) alcohol consumption, i)
exercise; and j) physical job.  Since more than 96% of WV population including the




The variables of age, age at menopause, current weight and height (which are
used to calculate current BMI), and peak weight and height (which are used to calculate
peak BMI) were examined by an open question directly asking the value of these
variables.  Calcium intake was evaluated by asking women about their daily consumption
of some selected dairy products based on calcium supplements tables (Willhite, 1998;
Sagraves et al., 1993; Calcium Supplements, 1989).   Smoking and alcohol consumption
were investigated by two questions with frequency-categorized responses.  Finally, to
simplify the questionnaire and reduce the respondents’ burden, family history, vitamin D
intake, exercise status, and whether women had a physical job were evaluated by
“Yes”/“No” questions.
While the first two parts of Demographics and Health Profile were common for
both cases and controls, the risk assessment part was different for the two groups.
Women in the control group were surveyed mainly about their current risk factor
information.  Women in the case group and reporting fractures were asked to report their
present age and age at the time of the first osteoporotic fracture.  These women were also
asked about their risk behaviors prior to the first osteoporotic fracture.  Several answers
were listed to help women to recall, and respondents were instructed to check all that
apply.
Data Analysis
Statistical Package for Social Sciences (SPSS-version 8.0) was used for all data
analyses.   Multiple logistic regression analysis was used to investigate the relationship




model.  The dependent variable was thus the fracture status, and the independent
variables were the risk factors discussed above.  Women’s health status and affecting
medication use were also included in the model to control their effects since these
variables may confound the study relationship.  The odds ratio (OR) was calculated for
each predictor.  Important model parameters such as goodness of fit, sensitivity,
specificity, positive predictive value (PPV), negative predictive value (NPV), and overall
percentage accuracy classification (PAC) were determined.
The c statistic, a frequently used measure of the ability of a model to discriminate
between the two groups of cases was also examined.  The c statistic can be interpreted as
the proportion of pairs of cases with different observed outcomes in which the model
results in a higher probability for the cases with the event than for the case without the
event (SPSS Inc., 1999).  The c statistic ranges in value from 0.5 to 1.  A value of 0.5
means that the model is no better than assigning cases to groups by chance.  A value of 1
means that the model always assigns higher probabilities to cases with the event than to
cases without the event (SPSS Inc., 1999).  The c statistic is equal to the area under the
Receiver Operating Characteristic (ROC).   Therefore, ROC analyses was conducted to
obtain the c statistic.
To validate the model generated in logistic regression, the respondent data would
be split into two subsets by randomly selecting 50% of subjects.  One-half of the subjects
(selected subjects) would be used in model building, and the other half (unselected




were generated and compared for both selected and unselected samples. This provided a
mechanism for partitioning the data to perform a sound validation test (Wright, 1995).
Furthermore, the validated model was applied to all the controls to estimate the
fracture probability. The predicted fracture probability for each individual in the control
group calculated based on the model was saved as a new variable. Then the risk
distribution (mean, standard deviation, range) can be estimated. Since the control women
were randomly selected sample from the population, the fracture probability distribution
in this sample can be inferred to the fracture-free women in the study population.
More specifically, the logistic model yielded a constant term (b0) and regression
coefficients for the significant predictor variable (b1,2,3,…). Then the predicted probability
(P) of fracture occurrence in the control group can be calculated by the following steps
(Wright, 1995):
g = b0 +b1(x1) + b2(x2) + b3(x3)…             …..… (1)
Then,
P = eg/(1 + eg)                                            …..… (2)
For example, if the regression analysis shows b0 = 10, b1 = .8, b2 = -.5, b3 = -.1, and x1,
x2, x3 represent age, weight, exercise (yes/no), respectively, for a 65-year-old, 110-pound
woman with no exercise habit, her fracture probability will be:
g =  10 + .8*65 - .5*110 - 2*(0) = 7
P = e7/(1+e7) = 1.95/2.95 = .66






The Medicaid data was only accessible to the principal investigator. After data
cleaning and extraction, the recipients were assigned an identification number and all
traceable personal identifiers (e.g., SSN and name) were removed from the claims data
prior to analysis. Completed anonymous surveys were maintained by the principal
investigator and only aggregate data were used in research reports.  The principal
investigator takes all responsibility for obtaining, organizing, analyzing, and maintaining
the data base used in this study.
Phase III.  Cost-Effectiveness Analysis
Phase III combined the information obtained from Phase I and Phase II to
evaluate the cost-effectiveness of the three preventive drug therapies based on different
levels of osteoporotic fracture risk in the study population. The economic impact of each
drug therapy was examined for the whole WV Medicaid study population, and
suggestions on the coverage policy were made to the WV Medicaid program.
Conventional Cost-Effectiveness Analysis Using Mean Values
A decision-analytic model incorporated all the relevant information from Phase I
and Phase II. The cost-effectiveness (CE) ratio defined by the formula of C/E =
(CMedication + CMonitoring + CAE)/(Number of Fractures Averted) was calculated for each
therapy using a decision tree construction. The software DATATM (version 3.5 for
Healthcare, TreeAge Software Inc.) was used to construct the decision tree and conduct




“Roll Back” method to calculate CE ratios. The mean or base value of the direct medical
costs and risk reduction rate obtained from Phase I, and the mean risk of a woman
without any interventions estimated from Phase II will be used in the “Roll Back”
procedure (actually, in DATATM, during all analyses other than Monte Carlo simulation,
the value taken from a distribution will always be its mean).
Simple sensitivity analyses in which variables were tested individually were
utilized to evaluate key assumptions and test the robustness of the model. The stability of
the results was assessed by varying the assumptions for each critical study variable.  The
highest and lowest possible values for each cost, effectiveness, probability, and
compliance variable were tested in the model. Those values were decided based on the
literature, expert panel survey, or assumptions made by the researchers. Through simple
sensitivity analysis, variables that had significant impact on the results would be
identified.
Probabilistic Analysis and Monte Carlo Simulation
Probabilistic analysis considers all possible cases/situations simultaneously.  It
allows researchers to assign plausible ranges and/or estimated distributions to the input
variables. In other words, for each variable used in the formula, a range of values and
their probabilities of occurrence are used as input instead of a single value. Since inputs
are probabilistic, most of uncertainty or risk inherent in the intervention is reflected in the
range of input variables. A computer program using a method called Monte Carlo
simulation can be run to generate hundreds of variations of input variables' combinations





In this study, a probabilistic analysis (Monte Carlo simulation) was conducted to
calculate the probabilistic CE ratio for each thearpy based on the distributions of
background fracture risk (f (I0)), treatment costs (f (C)), and fracture risk reduction (f (R))
in the treatment group. Then, the expected values (median costs per fracture averted per
woman) were estimated for the three preventive drug therapies among fracture-free
women in the study population. For a better understanding of the value of the three
therapies, incremental effects and costs relative to the next most effective strategy were
also calculated for each treatment strategy.
Specifically, the formula used as the base of Monte Carlo simulations was:
f[costs/(fracture averted)] = f(C)/ [(f(I0) x  f(R)]
in which f(C) was the distribution of treatment costs for the treatment, f(I0) was the
distribution of background fracture risks, and f(R) was the distribution of fracture risk
reduction rates. In this study, the f(I0) was estimated from the actual risk distribution in
the study population obtained from Phase II.  The distributions of treatment costs and
fracture reduction rates were estimated by Triangle distribution using high, basic, and low
values.  Unlike using a fixed mean value in the conventional CE analysis for the
treatment costs, risk reduction rate, and the fracture risk in the non-study group, the
probabilistic CE calculation took into account the distributions of these variables
simultaneously.
In order to evaluate how cost-effectiveness of each drug therapy was affected by




outcomes, a matrix of expected CE ratios by risk levels (e.g., <10%, 10% < Risk < 20%,
etc.) and by preventive drug strategies were created.  It would then be possible to
compare cost-effectiveness of various combinations of the three therapies based on the
fracture risk levels.  The recommendations to the WV Medicaid program on the coverage
policy of the preventive drug therapies were made based on the comparison results.
The advantages of probabilistic CE analysis over the conventional CE analysis are
obvious.  Information obtained from a probabilistic simulation is superior to that obtained
from a single-value sensitivity analysis (Torries, 1997).  It takes into account the
distributions of input values rather than just uses a single mean value or a value that
occurs the most frequently.  Its ability to focus on unknowns in data elements can reduce
major concerns caused by these uncertainties for most decision makers.
Limitations of the Study
The study has several limitations inherent in the data. Those include:
1. The main limitation of this study is that the data currently available makes it difficult
to simulate the cost-effectiveness values precisely. For example, the effects of
raloxifene and HRT on risks and benefits of multi-organ systems are not clear.
However, even minor changes in the relative risks of these conditions may have
profound effect on cost-effectiveness ratios. If HRT proves beneficial in the
prevention of heart disease, the issue about osteoporosis prevention may become




information in the economic assessment model, it should be possible to improve the
accuracy and precision of the analysis as new data become available.
2. When evaluating the outcomes of chronic diseases and treatments, a lifetime horizon
is favored. The model is designed to consider only three-year or less effects of each
therapy and hence ignored long-term effects. Currently, the long-term effects of
alendronate and raloxifene are still unknown. The long-term use of HRT may provide
significant cardioprotective effects but there was also evidence that it could increase
the risk of breast cancer. Additionally, because of the low patient compliance with
HRT, whether these long-term effects would result in a substantial difference is
unknown. Therefore, the long-term effects of all three drug therapies are difficult to
measure and incorporated into the study model at present.
3. Patients’ compliance is an important issue, especially for HRT and alendronate
therapy. The relationship of treatment duration and treatment effects is unknown.
Future research is needed to evaluate the discontinuation effects for each studied drug
therapy.
4. In the risk assessment survey, all disadvantages associated with mail survey,
especially recall bias, will impair the accuracy of the inferences made about the
population. However, we feel that these effects will not significantly alter the results
because the questions were made as simple and clear as possible and several possible
answers were listed to improve the accuracy of responses.  In addition, questions with




Finally, the same background risk distribution was used for all three therapies.
Therefore, the recall bias may not affect the cost-effectiveness conclusion.
5. More information is required to further validate the risk prediction model and
enhance its application. There is a great need for well-designed longitudinal studies to
examine the association between bone density, clinical risk factors, and risk of
fractures.
6. Inconsistency may exist within the literature on treatments' costs and effectiveness.
But the probabilistic analysis used in this study can minimize discrepancies and
identify most likely values.
7. In the literature, although there are a few fracture prediction models developed by
clinical and population-based studies, no recognized cutoff values for categorizing
risk levels, and no fracture incidence rates for each risk group have been reported.
The model developed in this study is based on the WV Medicaid population, the
generalization of study results (e.g., cutoffs for risk classification and CE ratios at
each risk level) to other populations may not be appropriate.
8. A major disadvantage associated with probabilistic analysis is that many decision
makers do not understand probabilistic evaluation and how to interpret the results.
The result distribution itself does not indicate which intervention should be chosen.
Multiple factors such as the decision makers’ attitude toward the risk and the
probability and amount of maximum costs for preventing one fracture should be
considered together to make a decision (Torries, 1997). Although the analysis




makers may feel more comfortable with a single value, even it is less precise or even
misleading. However, as the discipline of pharmacoeconomics expands to include
more disease and prevention/treatment modeling, probabilistic analysis and Monte
Carlo simulations are expected to become more commonly used and will be gradually
familiarized and accepted by decision makers.
9. This study assessed the cost-effectiveness of the three study drugs for the population.
However, the most appropriate therapy for an individual woman may vary from the
recommendation about the population.
10. Some may argue that regardless of fracture risk and treatment cost-effectiveness, drug
therapies should always be considered as long as there is a probability of fracture,
albeit low. Decisions about care are always difficult, especially in case of
osteoporotic fractures with high morbidity and mortality rates. Only descriptive
analyses and suggestions will be made in this study. Decisions on which therapy is
preferred and who should obtain the drug therapies will depend upon individual






PHASE I.  MODEL DEVELOPMENT
Phase I built an economic evaluation model for HRT, alendronate, and raloxifene
therapies in the prevention of osteoporotic fractures.  A hypothetical white woman aged
45 years or older and without past incidence of osteoporotic fractures was treated with
one of the three alternatives: HRT, alendronate, or raloxifene, and was tracked for 3
years.  To calculate the cost-effectiveness ratios, the corresponding costs and risk
reduction rates need to be evaluated.
Decision Tree Structure and Relevant Variables
The software DATATM (version 3.5 for Healthcare, TreeAge Software Inc.) was
used to construct the decision tree and conduct the cost-effectiveness analysis. Figure 4-1




Figure 4-1. The Structure of Decision Tree*



































































Doses, formulations, and patient distributions for the three drug therapies included
in the model were based on clinical guidelines and Delphi panel suggestions (Table 4-1).
Results from expert panel survey revealed that for HRT, most women (90%) were on oral
cyclic or continuous schedules. Only 10% of women were on an expensive trandermal
schedule. This estimation was consistent with the literature (Rosner et al., 1998).
Cost Parameters
The direct cost of interventions included the average costs of drugs, monitoring
costs, and adverse event costs for each drug therapy during the 3-year treatment.  All
costs were calculated in 1999 dollars.
Medication costs: The total costs paid by Medicaid per prescription (for one
month) was calculated as: [(Unit AWP price) * (1 – 0.12) * (Usage/month) + $3.90].
Therefore, the annual costs were calculated by multiplying monthly costs by 12 (Table 4-
2).  Ten representative products were used to calculate the medication costs: Premarin®,
Ortho-Est®, Ogen®, Menest®, Estratab®, Provera® (5mg and 2.5mg), Climara®,
Fosamax®, and Evista® (Appendix A).  The weighted average of the medication





Table 4-1. Therapy Formulations and Patient Distribution for Each Dosage Form
Based on Clinical Guidelines and Delphi Panel Estimates
      Therapy        Therapy Dose and Formulation                   Patient
                                                                                                                  Distribution (%)
        HRT       Cyclic estrogen 0.625 mg/day + cyclic 45%
                              Medroxyprogesterone 5 mg/day
                  Continuous estrogen 0.625 mg/day + 45%
      continuous  Medroxyprogesterone 2.5 mg/day
               Cyclic transdermal estradiol 50 µg/day + cyclic 5%
                              Medroxyprogesterone 5 mg/day
      Continuous transdermal estradiol 50 µg/day + 5%
      continuous  Medroxyprogesterone 2.5mg/day
      Alendronate    5 mg/day 100%
                  














    Cyclic combined schedule (pill)
     Cyclic combined schedule (patch)
     Continuous combined schedule (pill)
     Continuous combined schedule (patch)
















Alendronate 58.50 55.38 664.56
Raloxifene 60.90 57.49 689.88
1. (ii) = (i) * .88 +3.90;
2. (iii) = (ii) * 12;




Monitoring costs: Besides the medication costs, the costs of physician visits,
endometrial monitoring (biopsy or aspiration curettage) for HRT and raloxifene, and the
cost of BMD tests for all three therapies were added to the treatment costs (Table 4-3).
According to the literature (Weinstein and Schiff, 1983; Johannesson & Jönsson, 1993;
Whittington & Faulds, 1994) and experts’ suggestion, HRT would results in 1.5 extra
mammography at the cost of $11/test during the 3-year study period compared to the “no
therapy” group (increasing from biannual test to yearly test). Also, 1.5 extra biopsy (a
biannual examination) would be needed for HRT and raloxifene. The costs were
approximately $106/biopsy.  Furthermore, the expert panel suggested that the BMD test
should be conducted for all the three therapies every 1 to 2 years. Therefore,
approximately 2 extra BMD tests were needed during the 3-year treatment for each
therapy, at a cost of $39/BMD test.  Finally, three follow-up physician visits were needed
per year for all three drug therapies, at a cost of $24/visit, compared to no therapy group.
Thus, the average monitoring costs during the 3-year treatment period was $469.50





Table 4-3. Average Monitoring Costs During the 3-year Treatment Period
HRT Alendronate Raloxifene                Therapy
   Treatment Utilization  Costs ($)   Utilization  Costs ($)   Utilization  Costs ($)
Physician visits 9 216        9 216 9 216
Mammography 1.5 16.5         0 0 0 0
Endometrial biopsy 1.5 159         0 0 1.5 159
BMD test 2 78         2 78 2 78




Costs related to adverse events: Both clinical trial data and expert panel
suggestions were used to identify these adverse effects and their incidence rates as well as
the related treatment/diagnostic procedures.  The cumulative rates of the adverse events
during the three-year treatment period were used to determine the probability of the
woman experiencing each adverse event. The major adverse events that need additional
treatment and incurred costs are listed in Table 4-4.  All costs were examined based on
1999 prices and reported in 1999 dollars.
The major adverse events that may require extra medical care include
unscheduled bleeding and DVT/leg pain for HRT, severe GI disorders for alendronate,
and DVT/leg pain for raloxifene. The extra costs for treating GI disorders were estimated
from the literature (see Chapter 2: Levin, 1999; Ettinger, 1998). The GI disorders
included were peptic ulcer, gastric ulcer, gastroesophageal reflux disease, gastritis,
esophagitis, dyspepsia, nausea, vomiting, and abdominal pain (Ettinger, 1998).  The
average outpatient care costs (clinic and pharmacy costs) were approximately $700 per
person per episode (Ray et al., 2000, Levin, 1999; Ettinger, 1998).  Other reimbursement
rates were obtained from 1999 WV Medicaid database based on CPT codes (Appendix
B).  The extra AE costs for HRT and raloxifene during the 3-year treatment period were




Table 4-4.  Adverse Events and Related Treatment Costs
         Therapy Treatment Related Costs ($)
    & AE needed 
HRT
   Unscheduled     Vaginal ultrasound and  44
   bleeding endometrial biopsy 106
DVT/Leg pain Diagnostic ultrasound 47
Alendronate
   GI disorders Outpatient care 700
(clinic visit & Rx drugs)
                  
Raloxifene
   




The monitoring costs and AE related treatment costs during the three-year
treatment period were divided by three to obtain an average annual costs.  Therefore, the
total annual treatment costs with or without AE can be calculated.  These total annual
costs were assumed to occur at the end of each year and were converted to the present
value (the value same as that in the first year) using a discount rate of 3%.  The range of
the discount rate tested in sensitivity analysis would be from 2% to 5%.  The discounting
formula was: ∑PV = ∑[U*(P/U,i,n)], where U is the annual costs, (P/U,i,n) is the
discount uniform series factor, i is the discount rate, n is the number of years (1 to 3)  (Au
& Au, 1992).  At this time, the treatment costs were calculated for the entire 3-year
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* All costs were calculated in 1999 dollars.





In reality, not all women can complete their treatment. In another word, there is a
probability that the studied hypothetical woman could discontinue her treatment during
the 3-year period. To calculate the costs correctly, treatment continuation rate or
willingness-to-continue (WTC) rate should be considered.  Table 4-6 presents the
cumulative WTC rate for the three-year treatment and WTC rate at the end of each year.
According to the literature, the dropout rate among HRT users is high. The cumulative
probability or percentage of discontinuing the treatment was 75%. That means the
hypothetical woman in this study had only 25% chance to complete the 3-year treatment.
The average annual discontinuation rate was 25% for HRT. For women who took
alendronate, about 40% women remained after 3-year treatment. The average annual
discontinuation rate was 20%.   Women on raloxifene had a relatively high WTC rate.
The cumulative WTC rate was 70% and the average annual dropout rate was 10%.
The treatment costs of the discontinuation group was assumed to occur linearly
over the 3-year period. They were calculated based on the WTC rate by the end of each
year.  The same method used in the calculation of total treatment costs (present value) for




Table 4-6. Treatment Willingness-To-Continue (WTC) Rate (%)
Cumulative
WTC Rate Year 1 Year 2 Year 3
HRT 25 75 50 25
Alendronate 40 80 60 40




Table 4-7. Treatment Costs Summary for Discontinuation Group
Average Annual Costs (Constant $)
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* The costs were assumed to occur in a linear way over the 3-year period.   





The effectiveness variable was the number of osteoporotic fractures averted by
each drug therapy.  It was calculated as: I0 * R, in which I0 was the fracture incidence rate
of “no therapy group”; and R was the risk reduction rate by the treatment.  The risk
reduction rates and the range tested in sensitivity analysis are presented in Table 4-8.  The
estimation was based on literature reports: both previous pharmacoeconomic studies and
the most updated clinical trials (see Chapter 2).  The rates were adjusted for the shorter
study duration compared to most clinical trials.  Therefore, the rates were lower than
those used in some pharmacoeconomic studies.  For women who completed the 3-year
treatment, the risk reduction rates of any clinical fractures were 40% for HRT, 50% for
alendronate, and 55% for raloxifene therapy.  The average risk reduction rates used for
women who stop the therapy were 20%, 25%, and 27.5% for HRT, alendronate, and
raloxifene, respectively.
In summary, the treatment costs, risk reduction rates, and probability variables




Table 4-8. Risk Reduction Rates Used for the Three Preventive Drug Therapies (for
a 3-year treatment).
Therapy Risk Reduction Rate
(any clinical fractures)
Range Tested
HRT 40% 20% - 60%
Alendronate 50% 45% - 65%




Table 4-9. The Value of Costs and Probability Variables
















costs of HRT: have bleeding, continue
costs of HRT: have bleeding, discontinue
costs of HRT: have leg cramps, continue
costs of HRT: have leg cramps, discontinue
costs of HRT: no AE, continue
costs of HRT: no AE, discontinue
costs of alendronate, have GI, continue
costs of alendronate, have GI, discontinue
costs of alendronate, no AE, continue
costs of alendronate, no AE, discontinue
costs of raloxifene, have leg cramps, continue
costs of raloxifene, have leg cramps, discontinue
costs of raloxifene, no AE, continue























risk reduction rate by HRT, continue
risk reduction rate by HRT, discontinue
risk reduction rate by alendronate, continue
risk reduction rate by alendronate, discontinue
risk reduction rate by raloxifene, continue





















probability of having unscheduled bleeding
probability of DVT or leg pain due to HRT
probability of having GI disorders
probability of DVT or leg pain due to raloxifene
probability of completing 3-year HRT
prob. of completing 3-year alendronate treatment


















PHASE II.  ANALYSIS OF BACKGROUND RISK
Phase II cross-sectional study evaluated the fracture risk in “no therapy” group
(I0) by estimating the actual risk distribution of the study population.
Subjects
Results of the data extraction from WV Medicaid claims database are presented in
Figure 4-2.  The total number of enrolled women aged 45 - 85 and having claims in 1998-
1999 was 37,349 (the mean age was 62.9+11.7 years old and 91.3% were white). Among
women aged 45-64 years old (N1 = 24,323), 431 women had claims with a diagnosis code
of hip, vertebral, or wrist fractures (see Appendix D for related ICD-9 Codes) and all of
them were included as sample cases.  The sample base for controls (N10’) was 23,892,
from which 1,000 women were randomly sampled as controls.   For women aged 65-85
(N2 = 13,026), the number of women who had been prescribed raloxifene, alendronate, or
calcitonin (N20’), and women who was not on these drugs (N21’) was 1,295 and 11,731,
respectively (see Appendix G for related NDC Codes).  In order to have 1000 cases from
the two age groups, 569 women were randomly selected from the potential case base.
Again, 1000 women were randomly selected from the potential control base.  In
summary, the overall sample size was 3,000 for the two age groups, including 1,000




Figure 4-2. Results of Data Extraction for the Two Age Groups.
                                                                                                          Potential            Potential

































Three thousand surveys were sent out at the first mailing which was followed by a
second mailing to the non-respondents of the first mailing after 3 weeks.  The total
number of responses from the two mailings was 1,466 (cases: 478, controls: 988).  The
number of surveys returned due to a wrong address or deceased recipients was 273
(cases: 84, controls: 189).  The response rates were quite high for both case and control
groups: 52.18% and 54.56% respectively.  However, the eligibility rate of these returned
responses was much lower after the inclusion and exclusion criteria were applied (Figure
4-3).  Among the 1,466 women who returned the survey, 78 were pre-menopausal (cases:
9; controls: 69); 72 did not answer the question: “Have you ever had an osteoporotic
fracture?” (cases: 55; controls: 17); 154 pre-classified cases reported that they had not
experienced any osteoporotic fracture, and 121 pre-classified controls reported that they
had been diagnosed an osteoporotic fracture; finally, 269 controls indicated that they had
taken at least one medication for preventing osteoporotic fracture. After excluding all the
above women who met the exclusion criteria, 772 (cases: 260, 34%; controls: 512, 66%)
out of 1,466 returned responses were eligible for further analysis. The eligibility rate was
54.39% and 51.82% for cases and controls, respectively.
Seven cases and 16 controls returned the non-respondent survey (after excluding
wrong address or deceased recipients).  The most common reasons for not responding the
survey were “I did not receive it” (2 cases and 5 controls), “I haven’t completed it yet” (2
cases and 3 controls); and “I do not respond to mail surveys” (1 case and 5 controls).
One case and 2 controls indicated that they had already sent the survey back.  The mean




Figure 4-3. Results of Data Screening for Cases and Control Groups.
Screening  Questions
 Yes or Missing
       Excluded
No









Note:  There is a possibility that a woman could meet two or more exclusion criteria and would be
excluded by the first one.
Total returned responses
N = 1466 (Cases: 478; Controls: 988)







any of study drugs?
Cases =  55
Controls = 17
Cases =  154
Controls = 121






Statistical Package for Social Sciences (SPSS-10.0) was used for data analysis.
Comparisons on demographic characteristics and health related risk factors between cases
and controls are presented in Table 4-10.  Overall, the general health status was not good
in the study subjects: nearly 50% of women rated their health as poor, and less than 5%
of women rated their as excellent or very good.  Compared to those having osteoporotic
fractures, women without osteoporotic fractures reported better general health (X2 =
31.03, p < .001).  Women who had female first-degree relative(s) with osteoporosis or
osteoporotic fractures accounted for 57% in cases, compared to 19% in controls (X2 =
106.66, p < .001).  Furthermore, more cases (47%) reported their job involved intensive
physical activities than controls (35%).  More cases than controls smoked occasionally or
everyday (43% vs. 18%, X2 = 42.46, p < .001) and drank alcohol (21% vs. 8.0%, X2 =
25.73, p < .001).
There were no statistically significant differences between cases and controls on
calcium and multivitamin intake, calcium supplement, exercise, and education.  Reported
calcium contents of the selected dietary products were used for calculating an average
calcium intake (Willhite, 1998; Sagraves et al., 1993; Calcium Supplements, 1989).   The
majority of all subjects (60%) had inadequate calcium intake (<1200mg).  Only a small
number of subjects took a calcium supplement (26%), vitamin D (10%), or did exercises
regularly (34%).  The education level of both cases and controls was uniformly low.
Overall, almost 50% of all subjects had 8th or less than 8th grade education, and 95% of




  Table 11 presents the range and number of valid responses for the cases and
controls for the continuous variables.  Table 12 provides the means and standard
deviations of these continuous variables.  The mean age of the study subjects was about
66.5 (SD = 10.5) years, with 66.3 (SD = 10.8) years for cases and 66.7 (SD = 10.3) years
for controls.  The mean age at menopause was 41.9 (SD = 7.8) for cases and 46.9  (6.4)
for controls (F = 82.23, p < .001).  The mean current weight for cases and controls were
145.9 (SD = 41.4) pounds and 169.3 (SD = 45.7) pounds, respectively (F = 48.18, p <
.001).  The mean current height for cases and controls were 158.8 (SD = 8.3) cm and
160.3 (SD = 7.3) cm, respectively (F = 6.85, p < .001).  The current body mass index
(BMI) was calculated based on current weight and height.  The mean current BMI was
significantly lower in cases (26.1 + 6.7 kg/m2) than that in controls (29.8 + 7.7 kg/m2) (F
= 42.20, p < .001).   The mean weight for cases and controls at age of 20-30 years were
129.9 (SD = 27.9) pounds and 136.4 (SD = 30.9) pounds, respectively (F = 7.48, p =
.006).  Regarding the height at age of 20-30 years, although the mean current height was
significantly higher in controls than that in cases, there was no significant difference in
the mean peak height between cases and controls.  The mean peak height for cases and
controls were 161.9 (SD = 6.7) cm and 161.2 (SD = 7.2) cm, respectively.  The peak BMI
was also significantly lower in cases (22.4 + 4.9 kg/m2) than that in controls (23.8 + 5.6




Table 4-10. General Comparisons of Cases and Controls on Categorical Variables.

























0mg < CI < 800mg
800mg < CI < 1000mg
1000mg < CI < 1200mg






























































































Every day (<1 pack)










































8th or less than 8th grade
9th to 12th grade or GED
College 1 year to 3 years


















Table 4-11. Valid N and Value Range for Continuous Variables
Overall Cases Controls
Variables
Valid N Range Valid N Range Valid N Range
Age (years) 771 45.0-85.0 260 45.0-85.0 511 45.0-85.0
Age at menopause 678 20.0-61.0 235 20.0-57.0 443 26.0-61.0
Current Weight (pounds) 765 66.0-340.0 260 66.0-294.0 505 76.0-340.0
Current Height (cm) 752 121.9-182.9 255 121.9-176.5 497 121.9-182.9
Current BMI (kg/m2) 746 13.3-54.9 255 13.7-51.3 491 13.3-54.9
Peak Weight (pounds) 679 80.0-310.0 242 89.0-261.0 437 80.0-310.0
Peak Height (cm) 653 129.5-182.9 232 142.2-182.9 421 129.5-182.9












Age (years) 66.54 + 10.47 66.27 + 10.83 66.68 + 10.28 0.26
Age at Menopause 45.17 + 7.34 41.85 + 7.81 46.92 + 6.42 82.23*
Current Weight (pounds) 161.34 + 45.61 145.86 + 41.41 169.31 + 45.66 48.18*
Current Height (cm) 159.82 + 7.72 158.79 + 8.34 160.34 + 7.33 6.85*
Current BMI (kg/m2) 28.57 + 7.60 26.12 + 6.74 29.84 + 7.72 42.20*
Peak Weight (pounds) 134.10 + 30.02 129.89 + 27.89 136.43 + 30.93 7.48*
Peak Height (cm) 161.42 + 7.03 161.88 + 6.73 161.16 + 7.18 1.56
Peak BMI (kg/m2) 23.30 + 5.37 22.43 + 4.92 23.79 + 5.55 9.25*




Table 4-13 showed the comorbidities reported by the study subjects.  Arthritis
was the most prevalent disease, especially in the cases: approximately 79% of cases and
68% of controls had arthritis (X2 = 10.04, p = .001). Hypertension and diabetes were also
quite common, especially in the controls: approximately 50% of cases and 60% of
controls had hypertension (X2 = 6.67, p = .006), and 20% of cases and 38% of controls
had diabetes (X2 = 25.28, p < .001).  In addition, 36% and 23% of all subjects indicated
having heart disease and asthma respectively and there was no significant difference in
their reporting between cases and controls.  Other diseases reported included allergies,
digestive system diseases, chronic obstructive pulmonary disease (COPD), and cancer.
The use of medications that have been reported to affect bone mineral density and
the incidence of fractures were also evaluated although the findings on the relationship
are still controversial in the literature.  The use of steroid and sedatives were significantly
higher in cases than that in controls (steroid: 18% v.s. 11%, X2 = 7.81, p = .001;
sedatives: 22% v.s. 10%, X2 = 19.69, p < .001).  In contrast, diuretics were used less
frequently in cases (17% v.s. 28%, X2 = 10.56, p < .001).  There was no significant
difference in thyroid and antiseizure drugs use between cases and controls.  The overall




Table 4-13.  Comorbidity and the Use of Drugs that May Affect Osteoporotic
Fracture Incidence among Cases and Controls.

























































Building and Validating a Risk Prediction Model
A multiple logistic regression model was used to investigate the influence of age,
age at menopause, family history, physical job, smoking, alcohol use, and current BMI,
while controlling for their general health and some medications use.  Other possible
factors such as calcium intake and exercise were not included in the model based on the
results of general comparison between cases and controls.  Additionally, due to a large
number of missing data and relatively higher recall bias, the peak BMI calculated from
peak weight and peak height (weight and height at age of 20 – 30 years) was excluded
from the regression model. Comparison of the data in a bivariate correlation matrix
revealed no evidence of a problematic level of multicolinearity among predictors.  All
Pearson correlation coefficients among predictors were < 0.50 (Licht, 1994).
Results of the multiple regression analysis including model coefficients, odds
ratios (ORs), and related statistics are presented in Table 4-14.  The analysis revealed that
family history, current BMI, age at menopause, self-rated health, and diuretics use were
significantly related to the occurrence of predictors of osteoporotic fracture.  Family
history was the most powerful predictor of osteoporotic fracture (OR = 8.49, p < .001).
Poor self-rated health was also associated with having a fracture (OR = 1.56, p = 0.016).
The probability of fracture was negatively related to the current BMI (OR = 0.93, p =
.002), age at menopause (OR = 0.89, p < .001), and the use of diuretics (OR = 0.44, p =
.045). Age, the use of steroid and sedatives, alcohol consumption, smoking, and physical
job did not show a significant relationship with fractures. The goodness of fit X2 test was




Table 4-14.  The Relationship of Osteoporotic Fractures and Selected Risk Factors
Risk Factors &
Controlled Variables
B S.E. Wald p OR 95% CI
Family history 2.13 .34 39.73 < .001 8.49 (4.37, 16.51)
Current BMI -.08 .02 9.92 .002 .93 (.89, .97)
Age at menopause -.12 .02 23.97 < .001 .89 (.85, .93)
Self-rated health .45 .19 5.79 .016 1.56 (1.09, 2.24)
Diuretics -.82 .41 4.01 .045 .44 (.20, .98)
Steroid .79 .46 2.91 .088 2.21 (.89, 5.47)
Sedatives .46 .41 1.31 .252 1.59 (.72, 3.52)
Alcohol use .27 .20 1.93 .165 1.31 (.89, 1.92)
Smoking .19 .126 2.70 .101 1.21 (.96, 1.52)
Physical job -.13 .31 .17 .681 .88 (.47, 1.63)
Age .03 .02 2.63 .105 1.03 (1.00, 1.06)
* For all scales, higher scores represent greater amounts of the construct or the presence of the
disease.




The predicted probability of having an osteoporotic fracture was saved as a new
variable.  Since the case-to-control ratio was 1:2, a cutoff value of 0.66 (66% probability
or chance) was applied to predict the group membership which was also saved as a new
variable with a value of 0 or 1 (0 = non-fracture group; 1 = fracture group).  Table 4-15
shows that the sensitivity of the prediction model was 44% and the specificity was 95%.
The positive predictive value (PPV) and negative predictive value (NPV) were
approximately 81% and 77%, respectively.  The false positive rate (FPR) and false
negative rate (FNR) were approximately 19% and 23%, respectively.   The overall
percentage accuracy classification (PAC) was 78%.  Area under the ROC curve  = 0.85
(p < .001, 95% CI: .81 - .88)  (Figure 4-4 & Table 4-16).
To validate the model generated in logistic regression above, the data set were
split as two subsets by randomly selecting 50% of cases.  Half of the subjects (selected
cases) were used in model estimation, and the other half (unselected cases) was used for
the model validation.  Model validation results are presented in Table 4-17.  The results
showed that the key statistics were fairly consistent or repeatable in the unselected cases.
The specificity and the overall prediction accuracy in the selected cases kept relatively
high.  The sensitivity and the PPV, NPV, FPR, and FNR were also confirmed in the








Positive Predictive Value (PPV) 81.0%
Negative Predictive Value (NPV) 77.0%
False Positive Rate 19.0%






















Table 4-16.  Area Under the Curve (Test Result Variable: Predicted Probability)
Area Std. Error Asymptotic Sig. 95% CI*
.
846 .016 .000 .814 - .878




Table 4-17.  Results of Model Validation with the 50% Hold-Out Sample.
Predicted















204 11 94.9 161 14 92.0
Fracture
group




a.  Nselected cases = 323 (41.8%); Nunselected cases = 354 (45.9%); Nmissing = 95 (12.3%).
b.  Some cases are not classified due to missing values in the independent variables.








Positive Predictive Value (PPV) 77.4%
Negative Predictive Value (NPV) 78.2%
False Positive Rate 22.6%





Estimating Risk Distributions in the Study Control Sample
The distribution of predicted risk in the study sample was evaluated.  The study
control sample referred to the WV Medicaid white women, aged 45 – 85 years,
postmenopausal, without past incidence of osteoporotic fractures, and not taking any of
the study drugs.  Necessary information of 122 women on their predicted risk or
probability and group membership was missing due to missing value(s) in the risk
factor(s).  Therefore, the final valid study sample size is 390.  The estimated risk
distribution in the study sample is presented in Figure 4-5.
The mean risk was 22.0% (SD = 22%).  The lowest probability of fracture was
0.37% and the highest probability was 98% in the study sample.  One quarter of the
sample had fracture risk less than 5.3%, half of the sample had risk less than 13%, and
the majority (75%) of the sample had risk less than 31%.
The risk or probability of osteoporotic fracture was further categorized into three
levels: low (risk<0.1), medium (0.1<risk<0.3), and high (risk>0.3).  Statistics for the
overall risk distribution and the distribution in each risk category are shown in Table 4-
19.   One hundred and sixty-six women (42.6% of the total sample) were classified into
low risk group, with a mean risk of 5% (SD = 2.7%).  Most women in this low risk group
had a fracture risk less than 7%.  One hundred and twenty-three women (31.5% of the
total sample) were classified into medium risk group, with a mean risk of 19% (SD =
5.9%).  Seventy-five percent of women in this group had a fracture risk less than 24%.
The rest of the women in the study sample (101, 25.9%) fell in the high risk group with a




probability greater than 50% (who would be classified into fracture group by the
prediction model based on the predicted probability).
Since the study control sample was randomly selected from the study population,
the fracture probability distribution in this sample was inferred to all the fracture-free



































Table 4-19.  Overall and Categorized Risk Distributions in the Study Control Sample.
All Risk Levels Low Risk
(0 < risk < 0.1)
Medium Risk
(0.1 < risk < 0.3)
High Risk
(0.3 < risk < 1)
Valid N (%) 390 (100) 166 (42.56) 123 (31.54) 101 (25.90)
Mean + SD 0.22 + 0.22 0.050 + 0.027 0.19 + 0.059 0.53 + 0.18




















Phase III.  Cost-Effectiveness Analysis
In order to evaluate the risk-based cost-effectiveness of HRT, alendronate, and
raloxifene, Phase III study applied the background risk distribution estimated in Phase II
to the decision model built in Phase I.
Cost-Effectiveness Analysis Using Mean Values
First, an analysis was conducted using the “Roll Back” method to calculate CE
ratios.  The base value of the direct medical costs and risk reduction rate obtained from
Phase I, and the mean risk of a woman without any interventions estimated from Phase II
were used in the “Roll Back” procedure.  The results are presented in Table 4-20.
The results showed that HRT had the lowest costs ($885), while the raloxifene
treatment had the highest effectiveness (0.12).  The cost-effectiveness (CE) of HRT,
alendronate, and raloxifene were $12,401, $16,082, and $18,685 per fracture avoided,
respectively.  The marginal or incremental cost-effectiveness was $23,799 for
alendronate relative to HRT, and $37,782 for raloxifene relative to alendronate.
Simple sensitivity analyses in which variables were tested individually were
utilized to evaluate the robustness of the model.  The highest and lowest possible values
for each cost, effectiveness, probability, and compliance variable were tested in the











    C/E Marginal
C/E
HRT 884.70 0.0713 12,401.11
Alendronate 1,694.70 810.00 0.1054 0.0341 16,082.36 23,798.71




Results from a sensitivity analysis on costs revealed that even when HRT costs
were increased by 10%, it still was the most cost-effective treatment (Figure 4-6).  When
the costs of alendronate therapy changed from $1,525 to $1,864 (+10% on the base
value), the CE increased from $14,471 to $17,687.  Raloxifene CE ranged from $16,823
to $20,561 with the 10% variation in costs.  Raloxifene therapy was more cost-effective
than alendronate when its costs were reduced by at least 10%.
The CE of HRT, alendronate, and raloxifene was sensitive to the risk reduction
rate (RR) of each therapy (Figure 4-7).  CE ratios varied greatly with the change of risk
reduction rates: the CE of HRT was tripled (from $8,267 to $24,802) when the RR
decreased from 0.6 to 0.2, and the CE of raloxifene was doubled (from $15,373 to
$30,747) when the RR decreased from 0.6 to 0.3.  The change in alendronate CE was
relatively moderate compared to the other two alternatives: the CE increased from
$13,052 to $18,853 when the RR decreased from 0.65 to 0.45.
Table 4-21 shows that the CE of HRT, alendronate, raloxifene was not sensitive
to those AE probabilities.  Women’s willingness-to-continue rate (WTC) did not





































Table 4-21.  Sensitivity Analysis on AE probability and WTC Rate.
Treatment Probability Cost Effectiveness C/E
HRT PBleeding
   0.02 882.95 12,376.18
   0.0275 883.61 12,385.53
   0.035 884.28 0.07134 12,394.87
   0.0425 884.95 12,404.22
   0.05 885.62 12,413.57
PDVT1
   0.001 884.61 12,399.54
   0.00325 884.68 12,400.42
   0.0055 884.74 0.07134 12,401.30
   0.00775 884.80 12,402.18
   0.01 884.87 12,403.06
Alendronate PGI
   0.05 1,669.57 15,843.62
   0.075 1,682.15 15,962.99
   0.1 1,694.73 0.10538 16,082.36
   0.125 1,707.30 16,201.73
   0.15 1,719.88 16,321.10
Raloxifene PDVT2
   0.001 2,237.26 18,684.00
   0.00325 2,237.35 18,684.79
   0.0055 2,237.44 0.11974 18,685.57
   0.00775 2,237.54 18,686.36



















Probabilistic Analysis and Monte Carlo Simulation
In probabilistic analysis, distribution variables, instead of single values, are used.
Based on the results of simple sensitivity analyses, new distribution variables were
created for treatment costs, risk reduction rate, and background risk. The distributions of
treatment costs and fracture reduction rates were estimated by Triangle distribution using
high, basic, and low values.  The distribution of background risk was estimated from the
actual risk distribution in the study sample obtained from Phase II.  The raw data table
was used in the simulation since no preset distributions in Treeage program fits the actual
distribution.
Monte Carlo simulation was conducted incorporating all the randomly generated
values from the distributions of input variables.  The number of simulations (i.e., the
number of values randomly sampled from each distribution) was set to 500.  The new
decision tree structure using distribution variables for Monte Carlo simulations is
demonstrated in Figure 4-9.






























































Results of Monte Carlo simulations in the overall study sample showed that
compared to no therapy, the expected CE was $29,119 per fracture averted for HRT,
$35,101 for alendronate, and $39,760 for raloxifene (Table 4-22).  The incremental or
marginal CE was $42,181 for alendronate relative to HRT and more than doubled
($85,509) for raloxifene relative to alendronate.
In order to evaluate how cost-effectiveness of each drug therapy was affected by
the fracture risks in the study population, CE ratios were also calculated among women
with different risk levels.  The overall risk distribution variable was replaced by 3
distribution variables reflecting 3 risk levels (see Table 4-19): low (risk<0.1), medium
(0.1<risk<0.3), and high (risk>0.3).  The same Monte Carlo simulation procedure was
run for each stratified risk distribution variable.  The results are presented in a matrix of
expected CE ratios by risk levels (Table 4-23).   For all three therapies, CE declined
rapidly with increased fracture risk.  For women with low fracture risk, the cost of
preventing one fracture was $79,130, $105,911, and $140,675 for HRT, alendronate, and
raloxifene, respectively.  For women with medium and high fracture risks, the costs for
preventing one fracture significantly decreased for all three therapies, especially for
alendronate and raloxifene.  The CE was $19,569, $25,937, and $30,505 for HRT,
alendronate, and raloxifene, respectively in women with medium risk, compared to
$7,232, $9,690, and $11,536 respectively in women with high risk.  The incremental CE
of alendronate (relative to HRT) and raloxifene (relative to alendronate) were $151,981
and $697,270 among women with low risk, compared to only $11,099 and $34,017












    C/E Marginal
C/E
HRT 717.34 0.0296 29,118.55
Alendronate 1392.65 675.31 0.0456 0.0160 35,101.03 42,180.51
Raloxifene 2335.81 943.16 0.0567 0.0111 39,760.47 85,508.61




Table 4-23. Cost-Effectiveness Ratios of the Three Drug Therapies in Women with
Different Risk Levels*
Low Risk Medium Risk High Risk
           Risk
           Levels






HRT 79,130.02 19.569.40 7,232.48
Alendronate 105,910.69 151,981.2 25,937.43 35,256.7 9,690.24 11,098.7
Raloxifene 140,675.34 697,270.1 30,505.01 75,714. 11,535.96 34,016.8






This chapter presents a review of the study and discusses its major findings.
Where applicable, conclusions are drawn regarding those findings.  In addition, the
implications of this study are stated.  Finally, the major study limitations are discussed
and recommendations for the future research are made.
Study Review
Osteoporosis is an important health problem in the United States affecting
approximately 15 to 20 million women over 45 years of age (Iqbal, 2000).  Bone
fractures are the major cause of morbidity and mortality associated with osteoporosis.
Osteoporotic fractures result in complications leading to prolonged hospitalization,
decreased independence, increased morbidity and mortality, and reduced quality of life.
The disease takes an enormous personal and economic toll, with estimated costs in excess
of $13.8 billion annually for direct medical treatment alone.  The incidence of
osteoporosis-related fractures is increasing and constitutes a major public health problem
in the United States.   Although several drug therapies are available for preventing
osteoporotic fractures, the escalating drug costs bring about a heavy economic burden to
consumers and third-party payers, and make it difficult for them to make decisions purely




drug therapies HRT, alendronate, and raloxifene evaluated in this study were the most
competitive and commonly used preventive drug therapies for osteoporotic fractures at
the current time. The study population was WV Medicaid women with age of 45 to 85
years.  The goal of this study was to provide information to WV Medicaid decision
makers regarding the relative cost effectiveness of these three preventive drug therapies
based on the risk distribution of their population.
The study was conducted in three phases.  Phase I identified the direct medical
costs and major adverse events associated with each therapy.  Treatment compliance
patterns with the three drug therapies were also ascertained.  Phase II estimated
osteoporotic fracture risk distribution in the study population based on well-recognized
risk factors.  Phase III utilized the data from Phase I and Phase II to establish a decision
model incorporating women's risk of osteoporotic fractures in the study population.  The
cost-effectiveness ratios by risk levels were calculated for each drug therapy.
Discussion of Results
Cost-Effectiveness of the Three Drug Therapies
Results from the first analysis using mean values of direct treatment costs, risk
reduction rate, and background risk revealed that $12,401 were needed for HRT to
prevent a fracture, and $16,082 and $18,685 were needed for alendronate and raloxifene,
respectively.  In addition, compared to HRT, to prevent one more fracture, an extra cost
of $23,799 was needed for alendronate therapy.  An extra cost of $37,782 was needed for




analysis was conducted to identify the key variables and evaluate the robustness of the
model.  It showed that the CE ratios were sensitive to treatment costs and risk reduction
rate, but not much sensitive to AE probability and willingness-to-continue rate.  The
preference for alendronate or raloxifene could be altered depending upon treatment costs
and risk reduction rates.  However, HRT always had lowest costs per fracture averted
compared to the other two treatments in the sensitivity analysis, even though its CE was
also sensitive to treatment costs and risk reduction rates.  Therefore, HRT seemed to be
the most cost effective therapy.
Since the above CEs were calculated based on the mean values of key variables,
they did not reflect the variety of key variables and the uncertainty risk in data.  Although
simple sensitivity analysis can be helpful in identifying factors that significantly affect
CE ratios and collecting information in a more efficient manner, single-value analysis
and even scenario analysis can be extremely misleading (Torries, 1997).  In reality,
within the possible range of each variable, there are thousands of different value
combinations exist.  It is unlikely that a single variable changes while others keep
constant (i.e., single value sensitivity analysis) or several variables change to certain
values at the same time (i.e., scenario analysis).   In this study, a probabilistic analysis
using Monte Carlo simulation method was conducted to overcome the disadvantages of
simple sensitivity analysis.  The probabilistic CE analysis takes into account all possible
situations/scenarios simultaneously.  The study applied the distribution of each key
variable.  Values were randomly sampled from these distributions (input variables).  In




were probabilistic, most of uncertainty or risk inherent in the intervention was reflected in
the range of input variables.  The result or output variable was also probabilistic and the
expected value (median value) was used in the report to make comparisons.
Results from Monte Carlo simulation showed that $29,119, instead of $12,401 in
the analysis using mean values, were expected for HRT to prevent a fracture, and
$35,101 (instead of $16,082) and $39,760 (instead of $18,685) were expected for
alendronate and raloxifene, respectively.  Furthermore, compared to HRT, to prevent one
more fracture, an extra cost of $42,181 was needed for alendronate therapy.  The extra
cost for raloxifene to prevent one more fracture was more than doubled comparing to
alendronate marginal costs and reached as high as $85,509.
The expected values of the three treatment strategies from Monte Carlo
simulation was much higher than that from the analyses using single mean values.  This
is because the uncertainty in data or the risk has been taken into account and reflected in
the expected value.  Additionally, in some project evaluations, risk preference theory is
used to determine the actual value of an intervention or a project (certainty equivalence)
based upon investors’ risk attitudes.  Theoretically, what the investor would eventually
accept/pay should be lower (for costs) or higher (for benefits) than the expected value of
an intervention from Monte Carlo simulation because the risk preferences of the investor
have not yet been considered in the later.
Findings from both conventional CE analysis and probabilistic analysis revealed
that HRT was the most cost-effective therapy to prevent osteoporotic fractures.  The




findings on long-term, multi-system effects, most pharmacoeconomic studies concluded
that HRT was both medically and economically beneficial in postmenopausal women,
especially for those who have undergone hysterectomy and/or with high treatment
compliance rate. For women with prior hysterectomy, estrogen therapy should always be
the first choice, and the CE is better because of the absence of risk of endometrial cancer
or uterine bleeding and the lack of need for biopsies (Willhite, 1998; Johannesson and
Jönsson, 1993).  Although there lacks formal data from pharmacoeconomic evaluations,
most researchers believe that alendronate and raloxifene are unlikely to replace HRT in
the prevention of osteoporosis and fractures and should be used as a second-line
alternative for women intolerant to HRT or not willing to take HRT (Willhite, 1998;
DeGregorio and Taras, 1998).  No study has been done to compare the cost-effectiveness
of alendronate and raloxifene.  This is partly because their long-term effects are still not
available.
Some people argue that ethically, treatments with higher effectiveness, regardless
of their costs, should be favored.  Although HRT is the cheapest therapy and have
showed cost-effective in most studies (including this study), it does not mean that
alendronate and raloxifene will be out of consideration.  Even in a cost-sensitive managed
care environment, the treatment with lowest CE ratio may not always be the first choice.
The definition of a “cost effective therapy” should be based on the comparisons to the CE
ratios of treatments for various diseases.  Cost-effectiveness ratios (cost/life-year gained)
for some commonly reimbursed medical interventions include $237,000 for liver




younger than age 50, $45,000 (1995 dollars) for screening mammography for women
older than age 50, and $82,000 to $88,500 (1992 dollars) for zidovudine for human
immunodeficiency virus infections (Noe et al., 1999).  Although the threshold for
determining whether an intervention is cost effective is hard to define and generalize, less
than $50,000 per life-year gained has been sited as acceptable for therapeutic
interventions, and more than $100,000 per life-year gained is generally considered
excessive (Mark et al., 1995).   Nevertheless, many interventions that cost as much as
$100,000 per year-of-life saved have been accepted (Hillman and Kim, 1995).
The available data do not allow direct comparisons of the CE ratios obtained in
this study to those using life-year gained as effectiveness measures in the literature.  Also,
some studies use quality-adjusted life year (QALY) gained and some use non-quality
adjusted life year gained (which is solely based on mortality rate).   Even among studies
using QALY, different utility values have been applied.  If an average value of 0.1 life-
year gained for one vertebral or hip fracture prevented, the expected CE ratios obtained in
this study appear to be moderate in relation to the CE of breast cancer, hypertension and
hypercholesterolemia prevention (Noe et al, 1999; Smith & Hillner, 1993; Whittington &
Faulds, 1994).
It should be emphasized that the acceptable level of CE or incremental costs may
vary greatly by different perspectives taken (e.g., patients’ perspective vs. third party
payers’ perspective).   The interpretation of satisfactory CE ratios highly depends on




high costs such as alendronate and raloxifene in this study may also be favored in certain
circumstances.
Applying Background Risk Distribution to the Economic Assessment
Cost-effectiveness of a preventive intervention is affected by the background risk
of the disease and varies in different populations (Jönsson, 1998).   To evaluate the
influence of background fracture risk in the study population on the cost-effectiveness of
each drug therapy, the background risk distribution was applied to the CE analysis.
Furthermore, the background risk was stratified as three levels: low, medium, and high.
CE ratios were calculated for women in each risk category.
Results showed that the average fracture risk was 0.22 in the study population.
Using a risk level of 0.1 and 0.3 as cutoff values, 42.6% women in the study sample had
less than 10% chance to develop osteoporotic fracture (low risk group); 31.5% women
had less than 30% but greater than 10% chance to develop osteoporotic fracture (medium
risk group); and 25.9% women had a fracture risk greater than 30% (high risk group).
Since there is no information on categorizing risk levels based on risk distribution data in
the literature, these cutoff values were arbitrary.  However, in a report of WV Bureau for
Public Health (“The Burden of Osteoporosis in West Virginia”, 1999), the estimated
1996 osteoporosis rate in West Virginia women aged over 50 years was 21%, the rate of
women with low bone mass was 39%.  If we assume that the rate of women with high
fracture risk could be reflected by the rate of osteoporosis, and women with low bone




study are similar to those from the WV report.  Thus the projected risk cutoff values may
be reasonable to the study population.
To illustrate whether and how the cost-effectiveness of each drug therapy was
affected by the background risk levels, CE ratios were calculated in women with different
risk categories.  Monte Carlo simulation procedure was conducted for each risk group.
Results showed that the cost effectiveness ratios decreased dramatically with increased
fracture risk for all three therapies.  For HRT, the expected costs for preventing one
fracture compared to no therapy were $79,130, $19,569, and $7,232 for the low, medium,
and high risk group, respectively.  For alendronate and raloxifene therapy, although the
expected costs for preventing one fracture were as high as $105,911 and $140,675 for
low risk women – almost doubled than the corresponding HRT costs, the expected costs
reduced dramatically to $9,690 for alendronate and $11,536 for raloxifene in high risk
women.  This indicates that with the increase of fracture risk, alendronate and raloxifene
become more cost-effective choices and competitive with HRT.
A same trend was observed in the incremental CE ratios.  Among low risk
women, $151,981 were estimated for alendronate to prevent one extra fracture compare
to HRT, and $697,270 were estimated for raloxifene to prevent one extra fracture than
alendronate; while among high risk women, the marginal costs were down to $11,099
and $34,017 for alendronate and raloxifene, respectively.   Therefore, background risk
plays a critical role in determining cost-effectiveness and marginal costs of preventive
treatments, especially for treatments with high costs and high benefits.  Non-risk




some more effective but expensive treatments, and provide a negative impression to
decision-makers.
In the context of cost-effectiveness analysis, one alternative is defined to be
dominated by another if the first both costs more and is less effective (Treeage software,
Inc., 1999). The dominated alternative will usually be removed from consideration in
decision making.  In this study, no treatment was dominated by any of the other two
treatments.  Also, no “willingness-to-pay” of decision makers on minimum effectiveness
and/or maximum costs were considered.  Therefore, it is not an easy decision on which
therapy should be taken or covered and which therapy should not.  In such circumstances,
applying background risk to the cost-effectiveness analysis and obtaining risk-stratified
CE ratios would be more relevant and meaningful.
Background Risk Evaluation
As discussed above, the CE ratio of a preventive intervention is sensitive to
changes in the background risk.  Measuring background risk also helps to estimate the
preventable fraction of the events (fracture), by obtaining the relative risk which is the
comparison of risks among women with and without treatment.  However, consensus on
background fracture risk is difficult to achieve since fracture risk, in both general and
osteoporotic populations, can vary widely because of measurement methods, and
geographical variations.  The major problem for estimating background fracture risk is to
obtain a risk function that predicts fracture risk for a specific population.  Many
researchers have estimated fracture risk by predicting low bone mineral density (BMD) -




Consensus Development Conference, 1993; Carroll et al., 1997).  However, uncertainty
still exists in estimating the association of BMD and other explanatory variables (factors)
such as age, weight, and family history.  Moreover, no quantitative relationship has been
established between fracture risk and BMD level.  The prediction model gets more
complicated when different types of fracture and bone mineral density at different sites
are considered.
In order to obtain a best estimation on the fracture risk among WV Medicaid
postmenopausal women who had not experienced osteoporotic fracture and not received
any preventive drugs, a risk assessment model was built for this specific population using
those widely reported risk factors.  The risk factors included in this study were age, age at
menopause, current body mass index (BMI), family history, physical job, smoking, and
alcohol consumption, while controlling for general health and some medications use.
Race was not included in the model since more than 96% of WV population are white.
For peak BMD, 25% data were missing (153 out of 772 women).  Also, the current BMD
and peak BMD were significantly correlated (r = 0.43, p < .001).  Therefore, only current
BMD was included in the model.  Other risk factors such as exercise and intake of
calcium/calcium supplement, vitamin D, and multivitamin pills were excluded from the
final study model due to the lack of variety between case and control groups.  Finally,
there was significant difference in women’s general health and the use of diuretics,
steroid, and sedatives between two groups.  Thus, these variables were included to




When general health and the use of some influential medications were controlled,
family history was the most powerful determinant.  The fracture risk of a woman with
family history of osteoporosis and/or osteoporotic fracture was more than 8 times higher
than that of a woman without such family history.  Women with lower BMI score were
also more likely to develop a fracture.   In addition, the risk of fracture risk significantly
associated with the age at menopause.  The younger when a woman had her menopause,
the greater risk she has to have an osteoporotic fracture.  These findings are consistent
with the literature (e.g., Carroll et al., 1997; Ribot et al., 1992; Turner et al., 1998).
However, unlike many studies, this study did not detect a relationship between age and
fracture risk.  The lack of heterogeneity in age distributions between the two groups may
be due to a sample selection bias.  In the sample selection, to ensure enough cases were
obtained in the younger group (women with age of 45-64), all fracture women had been
included as cases, comparing to that in the 65-85 age group, only 500 women were
randomly selected from all the women with fractures.  Another explanation is that the
effect of age on fracture risk was overwhelmed by that of other risk factors such as family
history and BMI.
As reported in some studies (Reid et al., 2000; Sebastian, 2000; LaCroix et al.,
2000), the use of diuretic medications were found to lower fracture risk by 56% (OR =
.44) in this study.  Thiazide diuretics reduce urine calcium excretion and might therefore
reduce postmenopausal bone loss.  In some, but not all, case-control studies, their use has
been associated with a reduced incidence of hip fractures (Reid et al., 2000).  Since




most commonly prescribed medications for this health condition, the protective effect of
diuretics on osteoporotic fracture should be well recognized.  Alcohol use, smoking, and
physical activity were found not significantly related to fracture risk in this study.  The
relationship between these risk factors and fracture risks is also indefinite in the literature.
For example, alcohol use has been associated with low bone density and fractures in
some studies due to poor nutrition, impaired calcium and vitamin D metabolism, and risk
of falls (Moniz, 1994), but some studies did not find this relationship (Turner et al.,
1998).  Cigarette smoking is also found to decrease estrogen concentrations, lower body
weight, and cause early menopause and thus increase the risk of fracture (Hollenbach et
al., 1993).   However, some studies did not find cigarette smoking related to a increased
fracture risk in postmenopausal women (Franceschi et al., 1996; Turner et al., 1998).
Vitamin D in combination with calcium increased bone density and decrease fracture rate
in some studies (Dawson-Hughes et al., 1997; Willhite, 1998) but not in others (Lips et
al., 1996; Turner et al., 1998; Franceschi et al., 1996), depending on the population
studied and doses used.  Finally, exercise such as running, walking, or weight lifting may
maintain or increase bone density in combination with calcium and vitamin D (Reid,
1996; Cumming & Nevitt, 1997).  However, another study indicated that excessive
exercise many increase bone loss and fracture risk (Cumming, 1996).
The risk assessment model (-2LL=275.81, R2=0.48) had a low sensitivity (44%)
and high specificity (95%).  A hold-out sampling analysis for model validation provides a
quick way to demonstrate a consistency or reliability of the sensitivity/specificity.  The




the model, and approximately 95% of the women without fracture could be predicted as
negative by the model.  Also, approximately 81% of the women with a positive
prediction result actually had fracture (PPV) and 77% of the women with a negative
prediction result actually did not have fracture (NPV).  The False Positive Rate and False
Negative Rate revealed that 19% of the women who predicted as positive but actually did
not have fracture and 23% of the women who predicted as negative but actually had
fracture.  An overall accuracy rate of 78% was relatively high, meaning that 78% of the
women tested could be classified as positive or negative correctly.  A high c statistic of
0.85 was also obtained for the study model, which means in almost 85% of all possible
pairs of subjects in which one subject had fracture and the other did not, the projected
model assigned a higher probability of having fracture to the subject with fracture.
The model had a relatively low sensitivity but very high specificity.  Since the
study goal was to develop a risk assessment model for women without fracture rather
than a diagnostic tool, the high specificity and overall prediction accuracy may be more
important.  The low sensitivity of the model was unlikely to affect the estimation on risk
distributions. Compared to the risk assessment models developed by other studies (e.g.,
Lydick et al., 1998; Carroll et al., 1997; Blalock et al., 1996; Franceschi et al., 1996;
Elliot et al., 1993; Robit et al., 1992), the model established in this study had a relatively
strong capability of predicting women’s osteoporotic risk among disease free women.
For example, a risk assessment model for postmenopausal osteoporosis using clinical
factors showed a sensitivity of 73% and a specificity of 66%.  Elliot et al. (1993) used




and a low specificity of 25%.  Another low BMD prediction model also had a relatively
high sensitivity (89%) but low specificity (50%).
Implications of the Study Results
As stated in the previous chapter, the health care system nationwide has been
concerned by escalating drug product costs.  The introduction of new chemo-preventive
agents with high effectiveness but also high costs may further increase drug treatment
costs.   Managed care providers or third-party payers have been challenged by the
question of whether all preventive drug therapies with well-demonstrated efficacy should
be covered.  Due to limited health care resources, the decision should be based on both
effectiveness and costs of a drug therapy.  There is a great need to measure and compare
value of pharmaceutical products/services.   This study evaluated cost-effectiveness ratios
of three comparable preventive drug therapies.  The information could help decision
makers understand the overall value or benefit of drug therapies and determine the most
appropriate intervention(s) that should be covered to achieve their outcome goals.
Additionally, the study provides a framework to make risk-appropriate coverage
decisions for competitive drug therapies.  The study illustrated the relationship between
varying risk levels and the range of economic and clinical impact.  Few studies have been
done to evaluate risk-stratified CE ratios of preventive interventions (Jönsson, 1998).
Findings from this study revealed that targeting high-risk populations is very important to
achieve optimal cost- effectiveness for interventions, especially for those with high cost




stratified preventive intervention approach.  Previous studies have shown that women at
the greatest risk of fracture are only slightly more likely to receive treatment that reduces
fracture risk than women who are at low risk (Cummings, 1998).   A non-stratified
population-based prevention strategy may undertreat high-risk women and overtreat low-
risk women, and thus could not achieve an optimal cost-effectiveness or overall
outcomes.  The study illustrated significant variance in the cost-effectiveness ratios
among women with different risk levels for all three drug therapies.  This could increase
the awareness and knowledge of payers or decision makers on the different economic
scenarios for each therapy, and help them determine the most cost-effective therapy
based on their specific target population.
Since the economic assessment model developed in this study is particularly
based on WV Medicaid population, the economic impact of different coverage decisions
on WV Medicaid program could be further evaluated.  The possible costs for the WV
Medicaid program to prevent one fracture could be estimated based on the therapy
choices and related CE ratios, as well as an average total number of women recipients
with age of 45 to 85 years in each risk category.  It will also make it possible to compare
cost-effectiveness of various combinations of the three therapies based on the fracture
risk levels.  These results may be instructive for WV Medicaid program policy makers in
guideline constructing, budget planning, and coverage decision making.   
Finally, the risk assessment model developed in this study could be used as a
simple risk assessment tool.  Clinicians could use it to quickly identify women with high




expensive drug therapy (e.g., instead of calcium supplement only).   A valid and
economical risk assessment tool is critical to achieve high effectiveness for a risk-
stratified prevention strategy.  If the cost of detecting high-risk population is too high, the
savings of a risk stratified approach over a mass approach will be offset by the high
detection or screening costs.  This will make it hard to achieve a cost-effectiveness goal,
even for a well- targeted intervention.  It should always be aware that the costs of
evaluating women’s fracture risk are included in the total intervention costs for a risk-
stratified intervention.   However, the cost of a simple assessment based on some medical
and lifestyle risk factors may be neglected.  This study presented such simple self-
reported risk assessment questionnaire and validated it in the study population.
In summary, although there are many uncertainties existing in the literature, and
the results from the cost effectiveness analysis were sensitive toward different
assumptions, the economic decision model developed in this study can still contribute
many important insights to the evaluation of competitive drug therapies.  This study
provides a good way to structure the problems inherent in the methodology and identify
the areas where more accurate information is needed.  As new results and data become
available, the model could be improved by incorporating them into the model.
Recommendations for Future Research
There are several major limitations of this study.  First of all, the study only




type of fractures.   Whenever the data becomes available for alendronate and raloxifene
on risk reduction rates of different types of fractures, the economic evaluation model
should be updated and CE analysis should be done for each major type of fractures.
Future studies should also enhance the control for the non-osteoporotic causes of
fractures. 
In addition, the model is sensitive to the risk reduction rates.  There is
considerable uncertainty concerning the effects of preventive treatments, especially long-
term and multi-system effects.  This makes it difficult to simulate the effectiveness values
precisely.  Moreover, the relationship of risk reduction rates (or treatment effects) and
treatment duration is also still unknown.  Research is needed to evaluate the
discontinuation effects for each studied drug therapy.  Further studies should be
conducted to obtain more accurate information based on updated findings from clinical
trials and/or long-term epidemiology studies.
Unlike many pharmacoeconomic studies, quality adjusted life-year-gained were
not used in this study as a measure of treatment effects.  This makes a comparison
difficult among diverse treatment strategies.  However, there is little data on the effects of
treatment strategies on health related quality-of-life (HRQL) (Taylor et al., 1997;
Tosteson et al., 2000).  Validated HRQL instruments are needed for proper evaluation.
Appropriate assessment of utility is also critical to obtain a valid utility value, rather than
an arbitrary value as used by many studies.
Patients’ adherence is another important issue, especially for HRT and




prescribed.  Studies on exploring factors that affect patients’ adherence behaviors are
highly recommended, especially for alendronate and raloxifene therapy.  As withdrawal
and irregular bleeding are a well-recognized major reasons for non-adherence to HRT,
(Scientific Advisory Board, 1996), the determinants for alendronate and raloxifene non-
adherence need to be examined.  The way to improve women’s long-term medication
adherence should also be stressed.   There is little information on women’s decision or
preference when they are fully informed of risks, benefits, and alternative strategies.  It
will be interesting to find out how women’s preference affects their adherence and even
physicians’ prescribing behaviors.
Finally, the risk assessment model developed in this study is only applied and
validated in WV Medicaid population. The results obtained from this study must be
interpreted with great care due to the assumptions used in the model.  One of the
important limitations in estimating the background risk is recall bias.  However, if only
women who had their first osteoporotic fracture in recent years (e.g., within the last 3)
were included as cases in order to decrease the recall bias, many women with advanced
age and/or having fracture at their early stage of menopause would be excluded.  The
sample would still be biased and unrepresentative, which makes it difficult to obtain the
risk determinants and estimate fracture risk in the study population correctly.  More






The study results suggest that the use of HRT to prevent osteoporostic fracture is
most cost effective, even though it may have relatively high monitoring and AE costs,
and low WTC rate.  The greater number of fracture averted by alendronate and raloxifene
were not sufficient to offset the higher treatment costs.  It indicates that HRT may remain
as the first-line therapy for preventing osteoporotic fracture.  For women who are
unwilling to take HRT or are contraindicated for HRT, alendronate or raloxifene will be
another option.  In addition, the cost-effectiveness ratios are influenced by the
background risk.  The significant decrease in marginal costs of alendronate and
raloxifene in high-risk women indicates an economic condition to use these two drugs.
Among women with high fracture risk, alendronate and raloxifene may be within the
acceptable threshold of cost effectiveness for therapeutic interventions.
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0.625 mg Ogen 0.68
Package: 30 Menest 0.60
Estratab 0.48
Medroxyprogesterone Provera (5mg) 0.71
5 mg, 2.5 mg Provera (2.5mg) 0.51
Package: 30
Transdermal Estradiol Climara 6.58











List of CPT Codes Used in the Study
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BMD Test
76075  Dual energy x-ray absorptiometry (DEXA), bone density study, one or more sites;
axial skeleton (e.g., hips, pelvis, spine).
76076  Appendicular skeleton (peripheral) (e.g., radius, wrist, heel).
Endometrial biopsy  
56351  Hysteroscopy, surgical; with sampling (biopsy) of endometrium and/or
polypectomy, with or without D & C.
58100  Endometrial sampling (biopsy) with or without endocervical sampling (biopsy),
without cervical dilation any method (separate procedure).
Intravascular Ultrasound
93965  Diagnostic ultrasound (non-invasive)
Mammography
76092  Screening mammography, bilateral
Physician Office Visits
99271-99275  Office Consultations
99211-99215  Established patients
99201-99205  New patients
Vaginal Ultrasound
76830  Echography, transvaginal






On The Use Of HRT, Alendronate (Fosamax®), And Raloxifene (Evista®)
In Preventing Osteoporotic Fractures Among Postmenopausal Women
Question I. Drug Dosage/Formulation and Patient Distribution (%)
Based on your practice, please estimate the proportion of patients on each therapy formulation
for PREVENTING FRACTURES in women with or without diagnosed osteoporosis.
Ø HRT
       Cyclic estrogen 0.625mg/day + cyclic medroxyprogesterone 5mg/day _____%
       Continuous estrogen 0.625mg/day + continuous medroxyprogesterone 2.5mg/day _____%
Cyclic transdermal estradiol 50mg/day + cyclic medroxyprogesterone 5mg/day _____%
Continuous transdermal estradiol 50mg/d + continuous medroxyprogesterone 2.5mg/d _____%
Ø Alendronate
10 mg/day  _____% 5 mg/day  _____%
Ø Raloxifene
60 mg/day  _____% 30 mg/day  _____%
Question II. Adverse Events & Costs
Ø HRT
Major AEs Frequency (%) Treatment Needed        Procedures of the Treatment
Vaginal bleeding ______ q Yes     q No ________________________
GI complaints ______ q Yes     q No ________________________
Leg pain/DVT ______ q Yes     q No ________________________
Other_____________ ______ q Yes     q No ________________________
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Ø Alendronate
Major AEs Frequency (%) Treatment Needed        Procedures of the Treatment
Upper GI effects ______ q Yes     q No ________________________
Esophagitis/esophagael ulcer ______ q Yes     q No ________________________
Other_____________ ______ q Yes     q No ________________________
Ø Raloxifene
Major AEs Frequency (%) Treatment Needed        Procedures of the Treatment
Leg cramps/DVT ______ q Yes     q No ________________________
Other_____________ ______ q Yes     q No ________________________
Question II. What are the major considerations for choosing one therapy of the three?
Question III.  Are there certain tests (e.g., biopsy, blood work, BMD, etc.) needed for
follow-up or to maintain HRT, Raloxifene, or Alendronate therapies? Please specify name
and average frequency of the tests.
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Question IV.  How do the oral contraceptives affect women’s risk of osteoporosis and
fractures? Does the protective effect diminish rapidly after women stop taking them?
Question V. How do the hysterectomy and ovariectomy (before or after menopause) influence
the risk of osteoporosis/osteoporotic fractures and preventive treatment decisions?
Comments/Suggestions about the Fracture Risk Survey:
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Appendix D.
List of ICD-9 Codes Used in the Study
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ICD-9 Codes

















Source:  International Classification of Diseases 9th Edition. 1999-2000.
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Osteoporosis is a disorder in which the bones become increasingly porous, brittle,
and are likely to fracture. It is especially prevalent in postmenopausal women.  In West
Virginia (WV), there were a total of 183,962 women who suffered from either low bone
mass or osteoporosis in 1996. Over one half of all women aged 50 and older in WV are at
risk for osteoporosis or osteoporotic fractures (WV Bureau for Public Health, 1998).
To address this problem, researchers at West Virginia University School of
Pharmacy are conducting a study to find out what factors are related to osteoporosis in
WV Medicaid women. This study is part of a doctoral research project. Information
obtained from this study could be useful in helping the Medicaid program understand the
needs of those with osteoporosis and develop appropriate strategies to help them better.
Please find the attached questionnaire that asks you about your health and lifestyle
factors related to the risk of osteoporotic fractures. Your participation in this study is
voluntary and your response will not influence your Medicaid services. Although we
hope that you could answer all of the questions, you do not have to answer any question
that makes you uncomfortable. Your responses will be coded and your name will not
appear in any data analysis or study reports.  Therefore, we assure you of as much
confidentiality as legally possible.
Your response will provide valuable information and is critical to the results of
the study. We would appreciate it if you could kindly take a few minutes to complete the
survey and return it in the postage-paid envelope. If you have any questions, please do
not hesitate to contact us at (304) 293-6991 or 293-1652.
Thank You.
Sincerely,
Xin Gao, M.S. Suresh Madhavan, M.B.A, Ph.D.
Outcomes Research Fellow Associate Professor and Chairperson of
Department of Pharmaceutical Department of Pharmaceutical




About 2 weeks ago, we sent you a survey asking about your health and lifestyle
factors related to the risk of osteoporosis and fractures. We have not yet received your
completed survey.
We understand that you are busy or may not have received the survey. However,
your views are extremely important to us, and the information obtained from this study
would be very useful in helping the West Virginia Medicaid program understand the
needs of women with osteoporosis, or who are at high risk of osteoporosis, to better help
them. Therefore, we are again sending you this survey and would appreciate it very much
if you could kindly take a few minutes to complete and return it in the postage-paid
envelope.
Your participation in this study is voluntary and your response will not influence
your Medicaid services in any way. Although we hope that you will answer all of the
questions, you do not have to answer any question that makes you uncomfortable. Your
responses will be coded, and your name will not appear in any data analysis or study
reports.  Therefore, we assure you of as much confidentiality as legally possible.
If you have any questions or concerns, please do not hesitate to contact Xin Gao







Instruction: This questionnaire asks you about your health, as well as risk factors
related to bone weakness and fractures. Please answer each question by checking
the box that best represents your situation.  If you are not sure how to answer,
please give the best answer that you can.
SECTION A.  HEALTH PROFILE
1. In general, would you say your health is
q Excellent     q Very Good     q Good     q Fair     q Poor     q Don't Know
2. Have you ever had an osteoporotic fracture? (Osteoporotic fracture  is a broken
bone due to weakened bones. It usually occurs after 45 years of age. The most
common broken bones are back bone, wrist, and hip.)
q Yes          q No
If "Yes", at what age did you experience your first osteoporotic fracture? _____
If "Yes", did a doctor tell you that the fracture was related to osteoporosis?  qYes  qNo
3. Have you ever been told by a doctor that you have osteoporosis or osteopenia?
q Yes          q No
If "Yes", approximately how long has it been since the diagnosis?   ____ year(s)
4. Do you suffer from any of the following illnesses?
q Arthritis q Asthma
q Diabetes q High Blood Pressure
q Heart Disease q Others, please specify _______________
5. a) About how much do you weigh now without shoes?   ______ pounds
    b) About how much did you weigh without shoes at age of 20-30 years? ______pounds
6. a) What is your height now without shoes?  ____feet ____inches
    b) What was your height without shoes at age of 20-30 years? ___feet ___inches
7.   Bone mineral density (BMD) screening is a test for measuring bone mass in the spine,
wrist, hip, or in the heel or hand. Have you ever had a BMD test?
q Yes          q No
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8.   Have you ever taken any of the following medications for menopausal symptoms such as
hot flashes, or for bone weakness? (Please check all that apply)
q estrogens (such as Premarin® or Estrace®) q Evista® q Fosamax®
q calcitonin (such as Cibacalcin® or Miacalcin®) q other: ____________
q I have NOT received any treatment for menopausal symptoms or bone weakness
9.  Since you were 45 years of age, have you ever taken the following medications for
more than 3 months? (Please check all that apply)
q Steroid pills such as Celestone®, Cortisone, Deltasone®, Prednisone, or Prelone®
q Thyroid medications such as Levothroid®, Levoxyl, or Synthroid®
q Diuretics (water pills) such as Aquatensen®, HydroDiuril®, HCTZ, or Oretic®
q Sedatives such as Doriden®, Miltown®, Nembutal®, Seconal®, or Valium®.
q Antiseizure drugs such as Dilantin®, Klonopin®, Phenobarb, Mysoline®, Tegretol®, or Zarontin®
q I have NOT taken any of the above medications
SECTION B.  FAMILY AND REPRODUCTIVE HISTORY
10.   Do you have any female first-degree relatives (such as grandmother, mother or
sisters) who have been diagnosed with osteoporosis, or have experienced height loss
or fractures after 45 years of age?
q Yes          q No
11.   Have you ever taken oral contraceptives (birth control pills) for more than 1 year?
q Yes          q No
If “Yes”, how long have you been taking them or did you take them:  ____ year(s)
and if you are not using them now, how long ago did you stop taking them: ____ year(s)
12.   Have you reached menopause?
q Yes          q No
If "Yes", What was your age at menopause? ______ years
13.   Have you had an operation to remove the uterus (womb)?
q Yes          q No
If "Yes", at what age? ______ years
14.   Have you had an operation to remove an ovary/ovaries before  natural menopause?
q Yes          q No
If "Yes", at what age? ______ years
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SECTION C.  GENERAL LIFESTYLE DATA
15.   On average, about how many servings of the following dairy products do you have
per day? (Each serving is approximately equal to an 8 oz cup or 240 gms in weight)
                       Number of Servings per day
a. lowfat milk, skim milk, butter milk or dry milk _____________/day
b. whole milk or evaporated milk _____________/day
c. any kind of yogurt _____________/day
d. cottage cheese _____________/day
e. hard or soft cheese including cheese dishes
such as macaroni and cheese  _____________/day
f. ice cream _____________/day
g. cream, half and half, or sour cream _____________/day
h. orange juice containing calcium _____________/day
16.   Do you take any calcium supplement (e.g., Caltrate, Os-Cal 500, or Tums) regularly*?
q Yes          q No
If "Yes", for how long have you been taking these products regularly?  ____ year(s)
17.   Do you take Vitamin D or cod liver oil or other fish oils regularly*?
q Yes          q No
If "Yes", for how long have you been taking them regularly?  ____ year(s)
18.   Do you take any multivitamin pills including therapeutic and geriatric multivitamins
regularly*?
q Yes          q No
If "Yes", for how long have you been taking them regularly?  ____ year(s)
19.   Do you exercise regularly* (such as running, walking, weight-bearing exercise, etc.)?
q Yes          q No
If "Yes", for how long have you exercised regularly?  ____ year(s)
20.   Does/Did your job involve intensive physical activities (such as lifting, lots of
walking, or carrying heavy objects)?
q Yes          q No
*  “Regularly” means daily, or at least 3 times a week.
(PLEASE GO TO THE NEXT PAGE)
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21.   Do you smoke cigarettes?
q Never q I smoke occasionally
q I did, but I quit q I smoke every day (less than a pack)
q I smoke every day (more than a pack)
22.   Do you drink alcoholic beverage such as beer, wine/wine coolers, or liquor?
q Never q I drink occasionally
q I did, but I quit q I drink about 2-3 times a week 
q I drink daily/almost daily
SECTION D.  DEMOGRAPHICS AND RISK PERCEPTION
23.   How old were you at your last birthday? _______ years.
24.   What is the highest level of education that you have completed?
q 8th or less than 8th grade
q 9th to 12th grade or GED (high school graduate)
q College 1 year to 3 years (some college or technical school)
q College 4 years or more (college graduate)
25.   How would you rate your chance of having a fracture due to brittle bones in your
future life time? (Please mark on the scale, where 0% means “I will definitely not
develop a fracture”, and 100% means “I will definitely have a fracture”.)
     0%                        25%                       50%                      75%                       100%
If you have any comments about osteoporosis/fractures, please write them below.
Please return the survey in the self-addressed envelope.  No postage is required.
THANK YOU VERY MUCH FOR YOUR TIME AND EFFORT!
WE WISH YOU A LONG, HAPPY, AND HEALTHY LIFE!
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Questionnaire for Cases
Instruction: This questionnaire asks you about your health, as well as risk factors
related to bone weakness and fractures. Please answer each question by checking the
box that best represents your situation.  If you are not sure how to answer, please give
the best answer that you can.
SECTION A.  HEALTH PROFILE
1. In general, would you say your health is
q Excellent     q Very Good     q Good     q Fair     q Poor     q Don't Know
2. Have you ever had an osteoporotic fracture? (Osteoporotic fracture  is a broken
bone due to weakened bones. It usually occurs after 45 years of age. The most
common broken bones are back bone, wrist, and hip.)
q Yes          q No
If "Yes", at what age did you experience your first osteoporotic fracture? _____
If "Yes", did a doctor tell you that the fracture was related to osteoporosis?  qYes  qNo
3. Have you ever been told by a doctor that you have osteoporosis or osteopenia?
q Yes          q No
If "Yes", approximately how long has it been since the diagnosis?   ____ year(s)
4. Do you suffer from any of the following illnesses?
q Arthritis q Asthma
q Diabetes q High Blood Pressure
q Heart Disease q Others, please specify _______________
5. a) About how much do you weigh now without shoes?   ______ pounds
    b) About how much did you weigh without shoes at age of 20-30 years? ______pounds
6. a) What is your height now without shoes?  ____feet ____inches
    b) What was your height without shoes at age of 20-30 years? ___feet ___inches
7.   Bone mineral density (BMD) screening is a test for measuring bone mass in the spine,
wrist, hip, or in the heel or hand. Did you have a BMD test before your first
osteoporotic fracture?
q Yes      q No
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8.   Did you take any of the following medications for menopausal symptoms such as hot
flashes, or for bone weakness before your first osteoporotic fracture? (Please check
all that apply)
q estrogens (such as Premarin® or Estrace®) q Evista® q Fosamax®
q calcitonin (such as Cibacalcin® or Miacalcin®) q other: ______________
q I did NOT received any treatment for menopausal symptoms or bone weakness
before my first osteoporotic fracture
9.   Had you ever taken the following medications for more than 3 months before your
first osteoporotic fracture (but after 45 years of age)? (Please check all that apply)
q Steroid pills such as Celestone®, Cortisone, Deltasone®, Prednisone, or Prelone®
q Thyroid medications such as Levothroid®, Levoxyl, or Synthroid®
q Diuretics (water pills) such as Aquatensen®, HydroDiuril®, HCTZ, or Oretic®
q Sedatives such as Doriden®, Miltown®, Nembutal®, Seconal®, or Valium®.
q Antiseizure drugs such as Dilantin®, Klonopin®, Phenobarb, Mysoline®, Tegretol®, or Zarontin®
q I have NOT taken any of the above medications
SECTION B.  FAMILY AND REPRODUCTIVE HISTORY
10.   Do you have any female first-degree relatives (such as grandmother, mother or
sisters) who have been diagnosed with osteoporosis, or have experienced height loss
or fractures after 45 years of age?
q Yes          q No
11.   Have you ever taken oral contraceptives (birth control pills) for more than 1 year?
q Yes          q No
If “Yes”, how long have you been taking them or did you take them:  ____ year(s)
and if you are not using them now, how long ago did you stop taking them: ____ year(s)
12.   Have you reached menopause?
q Yes      q No      If "Yes", What was your age at menopause? ______ years
13.   Have you had an operation to remove the uterus (womb)?
q Yes      q No      If "Yes", at what age? ______ years
14. Have you had an operation to remove an ovary/ovaries before  natural menopause?
q Yes      q No      If "Yes", at what age? ______ years
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SECTION C.  GENERAL LIFESTYLE DATA
15.   On average, about how many servings of the following dairy products did you have
per day before your first osteoporotic fracture?
(Each serving is approximately equal to an 8 oz cup or 240 gms in weight)
                       Number of Servings per day
a. lowfat milk, skim milk, butter milk or dry milk _____________/day
b. whole milk or evaporated milk _____________/day
c. any kind of yogurt _____________/day
d. cottage cheese _____________/day
e. hard or soft cheese including cheese dishes
such as macaroni and cheese _____________/day
f. ice cream _____________/day
g. cream, half and half, or sour cream _____________/day
h. orange juice containing calcium _____________/day
16.   Did you take any calcium supplement (e.g., Caltrate, Os-Cal 500, or Tums) regularly*
before your first osteoporotic fracture?
q Yes          q No
If "Yes", for how long had you been taking these products regularly?  ____ year(s)
17.   Did you take Vitamin D or cod liver oil or other fish oils regularly* before your first
osteoporotic fracture?
q Yes          q No
If "Yes", for how long had you been taking them regularly?  ____ year(s)
18.   Did you take any multivitamin pills including therapeutic and geriatric multivitamins
regularly* before your first osteoporotic fracture?
q Yes          q No
If "Yes", for how long had you been taking them regularly?  ____ year(s)
19.   Did you exercise (such as running, walking, weight-bearing exercise, etc) regularly*
before your first osteoporotic fracture?
q Yes          q No
If "Yes", for how long had you exercised regularly?  ____ year(s)
*  “Regularly” means daily, or at least 3 times a week.
(PLEASE GO TO THE NEXT PAGE)
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20.   Did your job involve intensive physical activities (such as lifting, lots of walking, or
carrying heavy objects) before your first osteoporotic fracture?
q Yes          q No
21.   Did you smoke cigarettes before your first osteoporotic fracture?
q Never smoked q I smoked occasionally
q I did, but I quit q I smoked every day (less than a pack)
q I smoked every day (more than a pack)
22.   Did you drink alcoholic beverage such as beer, wine/wine coolers, or liquor before
your first osteoporotic fracture?
q Never drank alcohol q I drank occasionally
q I did, but I quit q I drank about 2-3 times a week 
q I drank daily/almost daily
SECTION D. DEMOGRAPHICS
23.   How old were you at your last birthday? _______ years.
24.   What is the highest level of education that you have completed?
q 8th or less than 8th grade
q 9th to 12th grade or GED (high school graduate)
q College 1 year to 3 years (some college or technical school)
q College 4 years or more (college graduate)
25.   How would you rate your chance of having a fracture due to brittle bones in your
future life time? (Please mark on the scale, where 0% means “I will definitely not
develop another fracture”, and 100% means “I will definitely have another fracture”.)
     0%                        25%                       50%                      75%                       100%
If you have any comment about osteoporosis/fractures, please write them below.
Please return the survey in the self-addressed envelope.  No postage is required.
THANK YOU VERY MUCH FOR YOUR TIME AND EFFORT!






About 2 weeks ago, we sent you a survey about your health and lifestyle factors
related to the risk of osteoporosis and fractures. We have not yet received your completed
survey. Since your views are extremely important to us, we would like to know your
reason for not responding and some key information for the study.  Please answer the few
questions below and mail it to us in the business reply envelope provided. If you have
any questions please call us at (304) 293-6991 or 293-1652.
Sincerely,
Cindy (Xin) Gao, M.S. Suresh Madhavan, M.B.A, Ph.D.
Outcomes Research Fellow Associate Professor and Chairperson
************************************************************************
1. I did not respond to the survey because:
q I did not receive it q I do not respond to mail surveys
q I was not at home q The survey was too long
q I did not have time to complete it q The survey was confusing
q Lost the survey q I am not interested in this issue
q I haven’t finished it yet q Other reasons (Please specify): _________
2. In general, your health is:  qExcellent    qVery Good    qGood    qFair    qPoor
3. Have you ever been told by your physician that you have osteoporosis?   qYes   qNo
4. Have you ever had a fracture since you were 45 years old?  qYes   qNo
5. Have you reached menopause?  qYes   qNo    If “Yes”, age at menopause ____ years
6. Your current age: ____ years
7. About how much do you weigh?  ______ pounds (or ______ kgms)
8. What is your height?  ____feet ____inches (or   ______ cm)
9. How would you rate your chance of having a fracture due to brittle bones in your
life time? (Please mark on the ruler, 0% means “I will definitely not develop a
fracture, 100% means “I will definitely have a fracture”.)
      0%                        25%                      50%                       75%                      100%
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PPD DEVELOPMENT, MORRISVILLE, NC
Pharmacoeconomist
November 2000 - Present
Study design, project development/completion, data analysis, and result summary/report
(or assists in these tasks) in the research related to pharmacoeconomics, quality of life,
and other outcomes and/or marketing studies.
PFIZER INC., NY
Summer Intern
May 2000 – August 2000
• A wellness evaluation project to measure the indirect costs due to lost productivity
for 11 common health conditions.
• A large retrospective study aimed to examine the relationship of various risk factors
and erectile dysfunction (ED) status, and to establish a risk assessment model for ED.
• A Community Acquired Pneumonia (CAP) project to examine the effects of different
regimens on hospital length-of-stay (LOS).
• Business booklet for the Coronary Heart Disease Risk Assessment Model.
WEST VIRGINIA UNIVERSITY, DEPARTMENT OF PHARMACEUTICAL SYSTEMS
& POLICY, SCHOOL OF PHARMACY, MORGANTOWN, WV
Pfizer Health Outcomes Research Fellow
August 1999 – October 2000
• Dissertation project: Economic evaluation of three preventive drug therapies for
osteoporotic fractures among women with different risk levels.  A cost-effectiveness
analysis is conducted using a decision model and Monte Carlo simulations.
• Dissertation study on a risk assessment model for osteoporotic fracture among WV
Medicaid postmenopausal women.
• Using the Health Plan claims data to examine the effect of co-payments on medical
care utilization and expenditures among diabetic patients.
• Using the Health Plan claims data to examine the relationship between health care
expenditures and compliance, endocrinologist visit, and care received among type-II
diabetic patients.
Revised: 03/14/01
• Lecturing on topics such as decision analysis (using Treeage), risk assessment, and
sensitivity analysis in Pharmacoeconomics class in spring semester, 2000.
WEST VIRGINIA UNIVERSITY, PERVENTION RESEARCH CENTER,
MORGANTOWN, WV
Research Assistant
August 1997 – July 1999
Summer Intern
May 1997 – July 1997
• Developing and evaluating smoking cessation interventions.
• Developing instruments for various study designs.
• Literature review, data analysis, and manuscript writing.
• Thesis study examining the relationship between disease severity, health beliefs, and
treatment adherence among HIV patients.
• Using time series analysis to evaluate trends in Medicare and Medicaid payments on
nursing home care and home health care: 1975 – 1995.
• A cost-benefit analysis and quality-of-life assessment for the use of filgrastim (G-
CSF) in HIV/AIDS patients with antiretrovirals-induced neutropenia.
WEST VIRGINIA UNIVERSITY, DEPARTMENT OF PHARMACEUTICAL SYSTEMS
& POLICY, SCHOOL OF PHARMACY, MORGANTOWN, WV
Teaching Assistant
August 1996 - April 1997
• Assisting faculties in teaching pharmaceutical care and disease management, and
pharmacy law.
CHINESE ACADEMY OF MEDICAL SCIENCES, CARDIOVASCULAR INSTITUTE
AND FUWAI HOSPITAL, DEPARTMENT OF PHARMACY, BEIJING, CHINA
Pharmacist
August 1994 - July 1996
• Completing the rotation in out-patient pharmacy, in-patient pharmacy, emergency
pharmacy, and clinical pharmaceutics and pharmcokinetic laboratory.
• Distributing medications and providing basic pharmaceutical care.
Revised: 03/14/01
EDUCATION
• 2001  Ph.D. in Department of Pharmaceutical Systems and Policy, School of
Pharmacy, Morgantown, West Virginia University.
• 1999 M.S. in Department of Pharmaceutical Systems and Policy, Morgantown,
West Virginia University.
• 1994 B.S. in Pharmaceutical Sciences, China Pharmaceutical University,
Nanjing, China.
PROFESSIONAL DEVELOPMENT
Training received while employed at PPD is available upon request.
Prior to PPD:
Managed Care Training (8/2000) given by Pfizer, Inc.
Health Outcomes Research 1-day seminar (7/2000) given by the Outcome Research Group
(Marketing Department) of Pfizer, Inc.
Risk Management workshop (7/2000) provided by Pfizer, Inc.
Applied Pharmacoeconomics workshop (5/2000) workshop conducted by the International
Society for Pharmacoeconomics.
Osteoporosis Management workshop (1/2000) conducted by school of nursing, West Virginia
University, Morgantown, WV.
Reference Manager workshop (12/1999) conducted by the Computer Based Learning Center
(CBLC), West Virginia University, Morgantown, WV.
Access and HTML summer workshops (6/99-7/99) offered by the Computer Based Learning
Center (CBLC), West Virginia University, Morgantown, WV.
SAS summer workshops (6/98-7/98) on offered by the Computer Based Learning Center
(CBLC), West Virginia University, Morgantown, WV.
PROFESSIONAL AFFILIATIONS
International Society for Pharmacoeconimics and Outcomes Research, January 1999 - Present




• Graduate Research Award 1999
• Graduate Student Representative of School of Pharmacy
• Vice-President of WVU-ISPOR Student Chapter
• Member of Rho Chi Honor Society
COMPUTER SKILLS
SPSS, JUMP, SAS, LISREL; Analysis Package for Economics: EVIEWS, GAMS; Decision Analysis:
Tree-Age, @Risk; Other: SurveyPro, Excel, Access, Word, Power Point, Word Perfect.
PUBLICATIONS
Horn K, Gao X, Williams J. Conjoint alcohol and tobacco use: A case for dual substance
intervention. Academic Emergency Medicine. 2001; (in press).
Gao X, Nau D. The congruence of three self-report measures of medication adherence among
HIV patients. The Annals of Pharmacotherapy. 2000;34(10):1117-22.
Gao X, Nau D, Rosenbluth S. The relationship of disease severity, health beliefs, and medication
adherence among HIV patients. AIDS Care. 2000;12(4):387-98.
Horn K, Gao X, Dino G. Determinants of youth tobacco use in West Virginia: A comparison of
smoking and smokeless tobacco use.  American Journal of Drug and Alcohol Abuse.
2000;26(1):125-38.
Horn K, Maniar S, Dino G, Gao X, Sayers K. Coaches attitudes toward smokeless tobacco &
intentions to intervene with athletes. Journal of School Health. 2000;70(3):89-94.
Horn K, Dino G, Gao X, Momani A. Feasibility evaluation of Not-On-Tobacco: The American
Lung Association’s new stop smoking cessation program for adolescents. Health Education.
1999; Sep(5):192-206.
Gao X, Chen J. Strategies for transnational management in pharmaceutical enterprises. Journal
of Pharmaceutical Economics. 1995,2:27-30.
Chen J, Gao X. Suggestion to national policies about improving the transnational management
in pharmaceutical enterprises.  Journal of Pharmacy in China. 1994;1:15-6.
Revised: 03/14/01
PRESENTATIONS
Gao X, Madhavan S, Nau D, Ambegaonkar A, Islam S, Rosenbluth S, Amonkar M. Applying
background risk distribution to evaluate the Cost-effectiveness of Three Preventive Drug
Therapies for Osteoporotic Fractures.  Poster presentation at the 6th International Society of
Pharmacoeconomics and Outcomes Research (ISPOR) Annual Meeting. Arlington, Virginia.
May 2001.
Gao X, Madhavan S, Nau D, Ambegaonkar A, Islam S, Rosenbluth S, Amonkar M. A Risk
Assessment Model for Osteoporotic Fracture in Postmenopausal Women.  Oral presentation at the
Drug Information Association “Pharmaceutical Outcomes Research” Meeting. Savannah, GA. April
2001.
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